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Models describing glucose homeostasis were developed.  A pharmacokinetic 
model describing the kinetic rates of appearance and disappearance of glucose, amino 
acids, fatty acids, insulin, glucagon, epinephrine, and glucagon-like peptide-1 was 
developed, and a physiologically-based model describing the dynamics of these species 
in the brain, liver, kidneys, muscle tissue, adipose tissue, gut, pancreas, and adrenal 
medullae was developed.  Because sufficient data was not readily available, parameter 
estimation for the models was not performed. 
 Parameter estimation was investigated by using one- and two-compartment 
insulin models to generate test data with known parameter values and investigating the 
effectiveness of a nonlinear least squares algorithm with respect to estimating the actual 
parameter values.  Parameter estimation was strongly dependent on the initial guess of 
the parameter set, and confidence intervals were found to be ±100% of the estimated 
parameter value.  The use of dynamic sensitivity equations in conjunction with a stiff 
  vi 
differential equation solver resulted in the parameters of the one-compartment model 
being accurately estimated with confidence intervals less than 10%.  The two-
compartment parameters were not able to be accurately estimated within confidence 
limits, but all parameter sets from the estimation fit the test data very strongly.  
 Explicit closed-loop control was simulated by incorporating feedback control, 
feedforward control, combined feedforward/feedback control, and model predictive 
control into three patient models describing glucose and insulin kinetics.  No controller 
was able to keep the minimal model glucose below 14 mmol/L in response to a 50 g oral 
glucose disturbance without also resulting in hypoglycemia.  Sorensen model and 
Hovorka model simulations predicted that proportional control is able to mimic the 
healthy pancreas response to a 50 g oral glucose disturbance and 30 minutes of moderate 
exercise. 
 A model describing swelling and release dynamics for a pH-responsive cationic 
hydrogel was developed using the quasi steady-state assumption for particle swelling.  
The response of implicit closed-loop control system was simulated using the minimal 
model.  Physical constraints imposed on diffusion coefficients and the collapsed particle 
radius results in complete insulin depletion in less than 1 minute, rendering the hydrogel 
system infeasible for intravenous implicit closed-loop glucose control. 
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As the field of bioengineering continues to grow, chemical engineers face 
significant challenges and have the potential to make great contributions.  The ability to 
understand and quantify the behavior of materials in a chemical process, as well as the 
ability to optimize, design, and control these processes gives the chemical engineer a 
unique set of tools that can be applied to numerous areas associated with bioengineering.  
In the biological/biomedical field, chemical engineers are heavily involved in protein 
engineering, tissue engineering, and metabolic engineering, as well as biosensor 
development, the development of devices for therapeutics, and controlled drug delivery 
systems.  The broad range of skills required to be successful in chemical engineering 
have proven to be equally powerful when applied to cutting edge biological and 
biomedical problems. 
One particularly interesting area of chemical engineering that can be applied 
toward bioengineering is systems engineering.  Because the body is constantly working 
to maintain homeostasis (steady state), systems engineering can be uniquely applied 
toward not only gaining an understanding of how the body achieves homeostasis, but also 
toward the development of therapeutic methods that can assist in achieving homeostasis 
when individuals are unable to do so themselves.  Although the body is quite complex, it 
is highly analogous to a chemical plant, complete with multiple chemical processes 
working together.  It is a dynamic system, consisting of multiple organ, tissue, and 
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cellular sites at which many chemical species are being transported, generated, and 
consumed.  
To the systems engineer, maintaining homeostasis is analogous to controlling a 
chemical process.  The dynamic system, in this case the body, is modeled based on the 
dynamics of all controlled, manipulated, and state variables.  Often this modeling is based 
on kinetic equations for appearance (either by absorption or production) or elimination.  
Once these pharmacokinetic models have been developed, control systems can be 
developed that allow homeostasis to be maintained by controlling certain species in the 
body through the delivery of another species. 
One of the most important new areas where systems engineering has been 
particularly helpful is the development of improved therapies for patients afflicted with 
diabetes mellitus.   
Diabetes mellitus is a metabolic disease in which the body is unable to either 
sufficiently produce or sufficiently respond to insulin in the plasma.  Insulin is the 
primary hormone that controls the uptake of glucose from the blood into the liver and 
muscle cells.  Without the proper insulin response, the body will have abnormally high 
levels of glucose.  This condition, known as hyperglycemia, can result in long-term 
complications including kidney failure, heart failure, and can often lead to arms and legs 
needing to be amputated.   
Although there are two distinct types of diabetes mellitus (Type I, in which the 
pancreas either does not secrete insulin or produces it in insufficient amounts, and Type 
II, in which the pancreas has diminished insulin secretion and the response to insulin is 
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diminished), patients with both types are often prescribed to receive insulin therapy.  In 
fact, while all Type I diabetic patients require insulin therapy compared to only some of 
the Type II patients, there are more Type II patients requiring insulin therapy than Type I 
patients.  Insulin must be administered to the diabetic patient in order to ensure glucose 
levels are maintained at homeostatic levels.  Thus, to the systems engineer, this is a 
process in which insulin is used to control glucose levels. 
To provide this control for the process, three primary solutions have been 
proposed [1, 2].   First is the open-loop control method, in which the patient, usually with 
the guidance of a doctor, provides insulin for his or herself.  Examples of this method 
include the insulin injection or externally worn insulin pump.  Other possibilities include 
the recently approved inhaled insulin, as well as the oral insulin formulations that are the 
focus of a great deal of research [3, 4].  While relatively easy to administer, the potential 
to accidentally provide more insulin than necessary is a primary disadvantage in open-
loop therapies.  Too much insulin can result in glucose levels that are too low, potentially 
resulting in death.   
Of greater interest to systems engineers is the idea of closed-loop glucose control.  
With closed-loop control, patient intervention is eliminated, allowing the individual to 
live a high quality life similar to that of a healthy individual.  Within the closed-loop 
control realm there are two subtypes.  The first type, explicit closed-loop control, 
involves a glucose sensor, a control algorithm describing insulin infusion as a function of 
the plasma glucose levels, and an insulin pump that administers insulin based on the 
control algorithm.  The second type, implicit closed-loop control, does not require any 
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type of mechanical equipment.  One example of implicit control is the pancreas 
transplant.  Another is the implantation of pancreatic islets that are able to secrete insulin.  
The third type and the type investigated in this work is the system based on pH-
responsive cationic hydrogels.  These devices are able to reversibly swell and de-swell in 
response to a change in the pH of the environment.  Because the swelling directly affects 
the ability of insulin to be infused from the device, the hydrogel system has the potential 
to act as a pH-controlled insulin release system.  By tying the environmental pH to the 
glucose concentration, a glucose-responsive insulin release system can be developed that 
is able to act as the sensor and the pump. 
The development of a closed-loop glucose control system requires two 
approaches.  First, models of the dynamics of insulin, glucose, and all other relevant 
species in glucose control must be available in order to fully understand the glucose 
homeostatic process.  Second, a description of the control algorithm governing insulin 
release must be developed and used with the model in order to simulate the controller’s 
ability to maintain glucose homeostasis for a number of different conditions.  For the 
implicit system, the control will be developed by the development of models describing 
the dynamics associated with the device behavior and then optimally designing the 
system in order to meet specified control requirements. 
The purpose of this research was to develop in vivo simulations of closed-loop 
glucose control systems. This goal was achieved in three ways.  First, different dynamic 
models of diabetic patients were investigated, and a new patient model was proposed.  
Second, control algorithms were developed to simulate the explicit closed-loop control 
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system in vivo.  Finally, a model was developed describing the dynamics of the implicit 
closed-loop system, and simulations were performed to demonstrate the in vivo response 
in a diabetic patient. 
As discussed by Heller [5], the training of chemical engineers in design, process 
control, and materials prepares them very well for the development of novel medical 
devices, including integrated medical systems and polymeric-based infusion devices. The 
use of modeling and simulation in the design step allows the chemical engineer to assess 
the feasibility of proposed methods, saving money that may have been used on 
experiments and patients and also potentially saving lives of test subjects.  As such, the 
use of modeling and simulation toward the development of closed-loop glucose control 
systems is an important contribution toward medical device development. 
Chapter two provides the background information necessary to understand 
glucose control problem, including the physiology of glucose control in healthy and 
diabetic patients as well as a review of the works of others providing closed-loop control 
solutions for the system.  Chapter three will discuss the specific objectives of the 
research.  Chapter four will describe the efforts to develop improved models for the 
glucose control system in diabetic patients, including physiological considerations. 
Chapter five will focus on system identification for patient models.  Chapter six will 
discuss the application of explicit closed-loop control toward glucose control.  Finally, 
chapter seven will focus on the development of a model describing the proposed implicit 
closed-loop control system.  The dissertation will then conclude with a general discussion 
of the proposed methods and their efficacy. 
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In order to provide homeostatic control with respect to the body’s plasma glucose 
levels, several things must first be understood.  First among them is how a healthy patient 
is able to regulate his or her glucose levels, both throughout the day and in response to 
non steady-state conditions.  Second, the differences between the diabetic patient and the 
healthy patient must be understood in order to establish which system elements need to 
be controlled, what constraints exist, and which manipulated variables can be used in 
developing a control scheme.  Finally, it is important to understand the previous work 
performed in the area of glucose control, with respect to modeling, explicit closed-loop 
control, and implicit closed-loop devices.  This chapter will review all of these areas in 
order to provide the necessary background before discussing the research completed in 
this dissertation. 
 
2.2 Glucose Metabolism 
In-depth discussions of glucose metabolism and complications associated with 
glucose control can be found in medical physiology textbooks such as [[1], 
endocrinology textbooks such as [2] or [3], or in clinical textbooks for diabetes mellitus 
such as [4].  The material is summarized here in order to provide a basic understanding of 
the systems and species involved in glucose control.  Puckett [5] provides a more 
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thorough summary of glucose metabolism for a number of different conditions for both 
healthy and diabetic patients. 
 
2.2.1 Glucose 
Nearly every process in the body requires adenosine triphosphate (ATP) as an 
energy source.  In order for ATP to be synthesized, the body uses glucose as its primary 
fuel.  Therefore, glucose is the primary metabolite required for the body to function 
properly.   
In a healthy individual, the glucose concentration is maintained at approximately 
80-90 mg/dL throughout the day.  This is known as the basal level.  The primary source 
of glucose is food consumption.  Although there is usually a spike associated with 
ingesting a meal, especially one high in carbohydrates, the plasma glucose levels of a 
healthy individual seldom go over about 120-140 mg/dL.  If the plasma levels are higher 
than homeostatic levels, the excess glucose is taken into liver and muscle cells and stored 
as glycogen.  However, there is an upper limit on the amount of glycogen that can be 
stored, and additional glucose is usually converted to fat.   
When the glucose concentration is below the basal level, the liver will produce 
glucose endogenously through one of two methods.  The first is glycogenolysis, in which 
the stored glycogen of the liver is catabolized to form glucose.  The second is 
gluconeogenesis, in which amino acids and fatty acids stored in the liver are converted to 
glucose.   
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2.2.2 Hormones 
 Hormones play a major role in nearly every significant glucose metabolic process.  
The primary hormones, including insulin, glucagon, epinephrine, and glucagon-like 
peptide-1 (GLP-1) all play significant roles in allowing the healthy individual to maintain 
glucose at basal levels. 
 The primary hormone associated with glucose control is insulin.  Insulin is 
primarily responsible for two effects.  First, insulin binding to muscle and liver cells 
results in an order of magnitude increase in glucose uptake into those cells.  Second, 
insulin is primarily responsible for the conversion of glucose in excess of that required 
for maximum glycogen storage into fat.  Furthermore, insulin is responsible for the 
uptake of amino acids and fatty acids into the liver cells, which allows the liver cells to 
have enough starting materials to produce glucose via gluconeogenesis. 
Insulin is produced in the beta cells of the pancreas.  A basal level is secreted 
throughout the day in order for the body to maintain basal glucose levels.  The basal 
insulin secretion is approximately 25 ng/min/kg body weight.  A more common way to 
describe insulin levels is through the use of Insulin Units (U).  A Unit of insulin is 
defined such that a milligram of pure insulin contains 22 U of biological activity [2].  As 
glucose ingestion causes the plasma glucose concentration to increase, the secretion rate 
of insulin is increased.  The secretion rate usually is increased by an order magnitude 
with 3-5 minutes of glucose elevation. 
While insulin is primarily responsible for the prevention of hyperglycemia, the 
hormone glucagon is primarily responsible for providing the counter-regulatory response 
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in glucose control.  As glucose levels descend to below the basal level, usually a result of 
either fasting or exercise, glucagon binds to liver cells to stimulate glycogenolysis and 
gluconeogenesis.  Furthermore, the binding of glucagon to the liver cells also increases 
the uptake of amino acids and fatty acids, resulting in increased glucose production via 
gluconeogensis.  Finally, glucagon binding to adipose cells results in the endogenous 
production of fatty acids to be used in glucose production.  Like insulin, glucagon is 
produced in the pancreas.  Glucagon is released during exercise and during episodes of 
hypoglycemia [1]. 
Another hormone responsible for the counter-regulation of glucose is epinephrine.  
Like glucagon, the secretion of epinephrine results in increased gluconeogenesis.  It also 
results in the increased mobilization of fatty acids for use in gluconeogenesis.  However, 
unlike glucagon, epinephrine, combined with norepinephrine, constricts the size of blood 
vessels and dramatically decreases the flow of blood to other tissues.  This results in 
decreasing the uptake of glucose into the other cells.  The secretion of both glucagon and 
epinephrine/norepinephrine is increased in response to exercise.  Epinephrine and 
norepinephrine are also secreted in high stress situations and when the plasma glucose 
concentration decreases well below the threshold level for glucagon release. 
The final hormone that plays a relatively significant role in glucose regulation is 
GLP-1, the most significant hormone among the gastrointestinal hormones produced in 
the intestines.  For reasons not completely understood, GLP-1 is released in response to a 
meal.  The release of GLP-1 causes an increase in both pancreatic insulin production and 
secretion.  This results in an increase in plasma insulin even before hyperglycemia is 
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observed.  In addition, GLP-1 also plays a direct role in regulating plasma glucose levels, 
independent of any role it has in increasing insulin levels.   
 
2.3 Diabetes Mellitus 
As previously mentioned, diabetes mellitus is characterized by a breakdown in the 
glucose metabolic process.  With Type I diabetes, the pancreas is unable to produce the 
necessary insulin to control glucose levels, while Type II diabetes is characterized by 
either insulin insufficiency or insufficient insulin sensitivity of the muscle and liver cells.  
Type II diabetes is often caused by increased intra-abdominal fat, which decreases the 
signal strength associated with insulin binding to liver and muscle cells.  Because the 
secreted insulin is less effective at regulating glucose levels, the pancreas eventually 
begins to produce less insulin, resulting in diminished production.  The current 
therapeutic methods for treating Type II diabetes include placing patients on a strict diet 
and exercise regimen, as well as the prescription of various drugs that can increase 
insulin sensitivity or stimulate pancreatic insulin production.   
Of more interest to this research is Type I diabetes, in which the pancreas is 
unable to provide the necessary level of insulin to control plasma glucose levels.  Type I 
diabetes is an autoimmune disease in which the body destroys its pancreatic beta cells.  
This autoimmune process normally occurs early in a person’s life, with later cases 
normally occurring when a person is in his or her early to mid 20’s.  For Type I diabetic 
patients and a large number of Type II diabetic patients, insulin must be provided from a 
source other than the pancreas. 
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To understand the differences in glucose metabolism for a Type I diabetic patient, 
three scenarios will be considered, comparing the healthy patient and diabetic patient 
response for each.  A more thorough description of the differences can be found in [1]-
[5]. 
 
2.3.1 Basal Conditions 
At basal conditions, glucose levels are maintained by the various hormones.  It is 
more important to ensure that enough glucose exists in order to allow each cell in the 
body to perform its key metabolic processes.  Of particular importance is the brain, which 
requires a certain amount of glucose in order to function properly.  Insulin is secreted at a 
relatively low rate as glucose absorption is not important.  Glucagon levels are relatively 
high to ensure that enough glucose is in circulation.  Amino acids and fatty acids are 
readily available for gluconeogenesis. 
For a Type I diabetic patient, the insulin levels will be based entirely on the 
quality of control that is being provided.  If the amount of insulin provided is not enough, 
more glucose will be produced in the liver than what can be taken up into cells, resulting 
in hyperglycemia.  If the hyperglycemic state is maintained for an extended period of 
time, the diabetic patient will suffer many consequences [1].  First, the increased level of 
glucose in the blood changes the osmotic balance of the body, resulting in the loss of 
water from and ultimately the dehydration of many of the body’s cells.  Second, as the 
glucose levels increase in the body beyond a threshold of approximately 200 mg/dL, 
glucose is no longer able to be reabsorbed in the kidneys and begins to be passed in urine.  
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The high levels of glucose in urine result in changes in the osmotic balance of urinary 
fluid, resulting in the passing of other fluids and electrolytes not normally passed.  The 
presence of high glucose itself in the body can actually destroy tissue walls, including the 
walls of blood vessels, kidneys, eyes, and limbs.  Diabetic patients are at higher risk for 
heart failure and kidney failure.  In addition, it is not uncommon for diabetic patients to 
suffer blindness, and they often must have limbs removed because of the development of 
gangrene.  As a final effect of frequent hyperglycemia, the inability of the body to use 
glucose as fuel results in the body’s switching to fat metabolism and protein metabolism.  
This can result in the body’s pH dropping to dangerous levels that can result in death 
from acidosis, or in the body’s consuming the proteins of its tissues, also resulting in 
death. 
While hyperglycemia could perhaps be prevented by purposely providing more 
insulin than required for glucose utilization, hypoglycemia would result from providing 
too much insulin.  The amount of insulin available in the blood has a direct effect on the 
amount of glucose being taken into the cells of the liver and muscle cells.  As the insulin 
availability increases, so does the uptake of glucose into the liver and muscle cells, 
regardless of the needs of other cells.  This is problematic because glucose is the only 
nutrient that can be used by certain cells in sufficient quantity to allow them to 
sufficiently perform their metabolic processes.   
The most important of these include the brain and the retina.  If the brain is unable 
to get the necessary glucose to perform its metabolic functions, death will result.  Adding 
to the severity of the problem is that if the pancreas is regularly increasing its glucagon 
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output to increase the glucose levels in response to hypoglycemia, it will eventually 
become insensitive to the low glucose levels, and eventually hypoglycemia will not result 
in the production of glucagon.  Because the central nervous system is responsible for the 
production of epinephrine, this low level of hypoglycemia will result in the secretion of 
epinephrine as well.  Therefore, to maintain healthy basal conditions, it is very important 
that a diabetic patient be able to exercise tight glucose control by using carefully 
determined insulin dosages. 
 
2.3.2 Meals 
 When a healthy patient eats a meal, the carbohydrates are broken down into 
glucose, fructose, and galactose, with the fructose and galactose quickly converted into 
glucose.  Fats are converted to triglycerides, phospholipids, and cholesterol, and proteins 
are converted to amino acids.  During this period the body naturally increases its insulin 
levels to facilitate glucose uptake.  This increase in insulin results in a decrease in 
glucagon levels and increased glucose uptake into the liver and peripheral cells.  As 
previously mentioned, the release of insulin is in conjunction with GI hormones released, 
allowing the body to maintain near normal levels of plasma glucose.  A healthy patient 
will rarely go over 140 mg/dL, even during a meal. 
 When a diabetic patient eats a meal, the outcome again strongly depends on the 
quality of insulin therapy.  Specifically, the patient’s glucose levels will depend on both 
the amount of insulin administered and the time of administration.  If insulin levels are 
too low, two dramatic effects will result in extreme hyperglycemia.  First, there will not 
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be enough insulin to allow the glucose to be taken into the liver and peripheral cells.  
Second, the low insulin levels will result in relatively high glucagon levels, which will 
actually result in even higher levels of glucose in the blood. 
 In addition to the amount of insulin administered for a meal, the time of 
administration plays a major role in maintaining normoglycemic conditions.  This time 
usually corresponds with the production of the GI hormones associated with the meal.  If 
the administration is too early, the result will be the onset of hypoglycemia before the 
meal is absorbed and hyperglycemia near the end of the meal, as there will not be 
sufficient insulin to allow the glucose infusion from the end of the meal to be utilized.  If 
the insulin is administered too late, hyperglycemia will result at the beginning of the meal 
and hypoglycemia will result at the end of the meal or shortly after.   
 
2.3.3 Exercise 
 The primary hormone influenced during exercise is epinephrine.  Even before a 
person is actually exercising, his or her epinephrine levels will increase in preparation for 
the exercise that is about to take place.  This epinephrine increase results in the 
metabolism of most cells increasing by an order of magnitude.  To provide this energy, 
the increased epinephrine levels act to increase glucose and fatty acid production while 
simultaneously decreasing glucose uptake into liver or muscle cells.  Insulin levels 
naturally decrease in response to higher levels of epinephrine, decreasing the uptake.  
While glucagon is mainly unaffected during exercise shorter than 90 minutes in duration, 
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an increase in the hormone occurs after approximately 90 minutes, further increasing the 
level of glucose available for utilization.   
 As with both meal consumption and in maintaining basal conditions, glucose 
metabolism for a diabetic patient is strongly dependent on the quality of insulin therapy 
received.  If too much insulin is present in the body prior to exercise, the result will be an 
increase in glucose uptake in the liver and periphery and the inhibition of both glucose 
and fatty acid production.  Because fatty acid levels do not increase, the glucose 
utilization by the cells increases.  The consequence of all of these effects is the onset of 
hypoglycemia, a common occurrence during exercise for diabetic patients.  
When too little insulin is present during exercise, the result will be 
hyperglycemia.  This is not a problem during exercise, as the increased glucose levels 
provide additional fuel that can be used.  However, once exercise has been completed, the 
patient now has higher glucose levels than normal, and there is no effort by the body to 
restore the levels to normal. 
 As the previous sections showed, diabetes can result in very serious consequences 
for both hyper- and hypoglycemia.  The ability to live a life of nearly the same quality as 
a healthy patient largely depends on the ability of the patient to provide the right amount 
of insulin at the right time.  In order to achieve this optimal type of administration, 
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2.4 Review of Insulin Delivery Techniques 
 To effectively control glucose in Type I and some Type II diabetic patients, 
insulin must be administered in such a way that neither hyper- nor hypoglycemic 
episodes are regularly experienced.  Several different insulin administration techniques 
have been studied.  Several other methods have been proposed and are the focus of 
current research.  Each method can be classified by the type of control provided and by 
the site at which insulin is delivered.  Each will be discussed below. 
 
2.4.1 Open Loop Methods 
Open loop methods of insulin delivery focus on a patient administering insulin to 
his or herself at different times of the day.  The purpose here is to briefly describe open 
loop methods of control.  Any interested reader is directed to reference [6] for a more 
thorough review of the open loop route.   
The most common method of open loop insulin delivery is the subcutaneous 
insulin injection.  Patients will often inject a slow acting insulin formulation in the 
morning to provide the basal insulin requirement throughout the day.  This analog, 
known as insulin glargine, is developed by modifying certain amino acids on the different 
insulin chains [6].  Once altered, it is able to provide a steady release of insulin all day.  
In addition to the basal requirement, patients will inject insulin into subcutaneous tissue 
prior to meals.  The amount of insulin to inject will depend on both a measurement of 
glucose and on an estimate of the amount of food that is about to be eaten.  To provide 
rapid insulin during this situation, a fast acting insulin formulation such as insulin aspart 
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or insulin lispro is used.  This method suffers from the requirement of three or more daily 
injections into a layer of subcutaneous tissue.  In addition, because the injected insulin 
must diffuse through the subcutaneous tissue in order to be absorbed into the 
bloodstream, and because some of this insulin may be degraded in the subcutaneous 
tissue during this diffusion, not all of the injected insulin will be available for in the body.  
Also, the diffusion across the subcutaneous layer will create an additional time delay in 
addition to the delay associated with insulin binding to mediate glucose uptake.  Finally, 
because the insulin will go straight from the subcutaneous layer to the bloodstream, the 
first pass effect, in which approximately 40% of insulin secreted from the pancreas is 
degraded in the liver before reaching the bloodstream, will not occur.  This will result in 
increased uptake into the muscle cells and decreased uptake into the liver relative to a 
healthy patient. 
An improvement to the insulin injection is the externally worn insulin pump.  The 
pump is always attached to the diabetic patient, and a basal amount of insulin is provided 
throughout the day.  When the patient is going to modify his or her insulin delivery 
because of a meal or exercise, the insulin infusion rate can be modified.  Pumps have 
recently been developed to determine the bolus size for a given situation [7].  The patient 
must input his or her blood glucose levels and an estimate of the size of the load (meal 
size or exercise load) and the change in infusion will be determined.  This type of 
administration has two primary advantages over injections.  First, because the pump has a 
catheter that is always in contact with the patient, multiple insertions will not be required, 
increasing the quality of life for the patient.  The exception for this is when the catheter is 
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periodically changed, but his is still a significant improvement to the three or more 
injections usually required.  The second advantage is ease in which a change in the 
insulin infusion can be made.  If a patient is was to eat a different amount of food than 
projected, or were to exercise for a different duration, the insulin rate can be adjusted to 
account for this.  However, the disadvantages associated with subcutaneous delivery still 
exist.  Furthermore, the patient is required to wear a bulky device at the abdominal area.  
Such a device would definitely be noticeable and would have a definite impact on the 
quality of life for the patient.  
In addition to subcutaneous delivery, other open loop methods have been 
proposed that take advantage of other administration sites.  Recently, the Food and Drug 
Administration has approved the use of Exubera, an inhaled form of insulin, to be used 
by insulin dependent diabetic patients [8].  The biggest advantage of such a technique is 
the increase in patient compliance, as a result of no longer having to receive injections or 
having to wear an external pump.  However, several disadvantages exist.  First, the 
bioavailability of inhaled insulin is less than that of a subcutaneous infusion.  In addition, 
a slow releasing insulin analog has not been developed in an inhaled form, so basal 
administration is still necessary.  Finally, because the absorption rate of insulin via the 
lungs can vary significantly for circumstances such as if a patient smokes or develops a 
cold, the dose must be carefully determined.  Over-absorption of insulin can easily result 
in severe hypoglycemia [6].  
 In addition to inhalation, NIH funding is currently being applied toward the 
development of oral insulin delivery.  Like the inhalation route, the oral route would in 
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theory prevent the patient from having to receive multiple daily injections.  However, 
there do exist a few drawbacks to oral delivery.  The first disadvantage of the oral route is 
the difficulty in maintaining the integrity of insulin in the harsh environment of the 
stomach.  Insulin must be able to pass through the stomach and into the intestines for 
absorption into the bloodstream.  However, the acidic gastric environment will degrade 
insulin, requiring a protective vehicle to allow the insulin to pass safely to the small 
intestine.  Peppas [9] has developed a biomaterial for oral delivery of proteins that 
protects them in the harsh stomach environment and releases them in the higher pH 
environment of the small intestine.  While protein degradation is one main cause of low 
bioavailability for protein delivery, another disadvantage of oral delivery is the low 
bioavailability associated with poor absorption from the intestine into bloodstream [10].  
Ongoing research in many labs, including the Peppas laboratory, is currently focused on 
improving the transport of insulin across the intestinal epithelium. 
 In addition to oral and inhaled insulin delivery, other proposed methods include 
delivery via the eyes, skin, and nasal passages [6].  All open loop delivery systems 
require some level of patient or doctor involvement in the insulin administration.  This 
will require a blood glucose measurement, an estimate of the meal to be consumed, and a 
calculation in order determine an empirical estimate of the insulin requirement.  With the 
exception of the insulin pump, the open loop method requires a patient to live a 
predictable lifestyle, one in which his or her meal is prepared specifically for the given 
insulin bolus and exercise must be performed only in accordance with the insulin 
received.  
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2.4.2 Closed-Loop Delivery 
 An effective alternative to open loop insulin delivery is closed-loop delivery, in 
which the involvement of the patient in maintaining glucose control is minimal.  Such a 
system would be able to determine the insulin requirement in real time, regardless of the 
situation, and deliver the proper insulin dosage.  It would be able to change the infusion 
as the patient’s activity changes and, ideally, would exist internally, eliminating the 
requirement of wearing external equipment.  Such a system would also aim to 
significantly reduce the number of injections required or to eliminate them altogether.   
 The ideal method of closed loop delivery would be to repair the body’s natural 
ability to infuse insulin.  One method to achieve this would be the pancreas transplant.  
Ideally, the transplantation of a healthy pancreas would enable a diabetic patient to 
produce insulin as a healthy patient.  However, there are many shortcomings associated 
with this approach.  First, this method depends strongly on the availability of a healthy 
pancreas for transplantation.  Second, the body of a pancreas recipient often undergoes an 
immune response that ultimately rejects the foreign organ [6].   
Another natural method would be to restore to the patient’s pancreas the ability to 
naturally secrete insulin as a healthy patient [11].  While such a method has promise, a 
great deal of research must be performed before this type of therapy can be useful to 
humans.  A third method involves implanting encapsulated islet cells from a healthy 
pancreas, in the hopes that the immune response associated with the foreign pancreas can 
be avoided.  At the same time, the islet beta cells will be able to produce insulin as a 
healthy pancreas would.  This method is the subject of much ongoing research [6]. 
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 While natural pancreatic restoration methods are ideal, research must still be 
completed in order to determine the feasibility of these methods becoming reality.  
Perhaps a more realistic method of closed-loop control involves engineered solutions.  
First is the idea of explicit closed-loop control, in which a glucose sensor, an insulin 
infusion algorithm, and an insulin pump are used to form an artificial pancreas.  Second 
is the idea of implicit-closed loop control, in which polymeric material is able to act as 
the sensor, control algorithm, and infusion system.  To test the validity of such methods, 
simulations are performed by first developing a model of the infusion and then 
implementing the infusion model with a model of glucose dynamics within a diabetic 
patient.  Patient modeling, explicit closed-loop control, and implicit closed-loop control 
will now be discussed. 
  
2.4.3 Diabetic Patient Models 
 Models describing the important metabolite and hormone dynamics in diabetic 
patients have been developed since 1960 in order to gain understanding of the glucose 
homeostasis system and to simulate what effect certain therapies would have on the 
patient.  This review covers different models developed during the last few decades.  
Others have written reviews on the models and described their various advantages and 
shortcomings.  The interested reader is directed to Sorensen [12], Puckett [5], Parker and 
Doyle [13], and Steil [14] for more insight. 
 Patient models can be broken down into two main groups.  On one side is the 
pharmacokinetic model, in which elimination and absorption kinetics are described for 
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each species, and a theoretical number of compartments is determined based on 
elimination and absorption data [15].  The second type is the physiologically explanatory 
model, in which organ system is considered to be a compartment, and mass balances are 
written for each organ system by considering convection resulting from blood flow, 
diffusion from blood to within organ cells, and metabolic processes [16, 17].  Both types 
have been developed in the past.  While the pharmacokinetic (PK) models have the 
advantage of being easier to identify from experimental data, Doyle [18] has shown that 
more complex models may be needed to provide the necessary accuracy for effective 
control studies.   
 The first known PK model for glucose regulation was developed by Bolie [19].  
The model consisted of one linear equation for insulin and one for glucose.  Elimination 
and absorption kinetics were described by first order rate equations.  While developed for 
a healthy patient, assuming that insulin secretion was simply proportional to glucose, the 
diabetic patient can be described by setting the first order insulin secretion rate constant 
to zero.  Ackerman et al. [20] modified the model by tying insulin and all other hormones 
involved in glucose regulation together as a single variable.  The model form remained 
the same however.  The main criticisms of these models are that they represent a clear 
oversimplification of the glucose regulatory system.  Besides the fact that insulin or 
hormone secretion is more complex than a simple first order process, the use of a single 
insulin or hormone compartment has been criticized by multiple reviewers, including 
Sorensen [12], and Parker and Doyle [13]. 
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 Frost et al. [21] developed a two-compartment PK model for insulin in healthy 
and diabetic patients.  For healthy patients, the insulin secretion rate is given as an 
exponential function of glucose.  For diabetics the secretion is taken to zero.  Insulin 
elimination was taken to be a nonlinear saturation function of insulin for healthy patients 
and a first order process for diabetic patients.  Frost himself admits that this also is an 
oversimplification, but notes a strong fit to patient data.  His two compartment model 
with nonlinear sinks is also an improvement over the earlier developed models.   
Sherwin et al. [22] and Cerasi et al. [23] simultaneously developed a three-
compartment PK model in which a central compartment is continuously exchanging 
insulin with two side compartments.  While more complex with respect to the number of 
insulin compartments, insulin appearance and elimination from each compartment is 
modeled as first order elimination kinetics.  The model of Cerasi also has six linear 
ordinary differential equations (ODE’s) to describe physiological insulin secretion.  
While the three insulin compartments are said to provide more physiological accuracy 
than the one compartment models previously used, the one compartment glucose model 
of Cerasi is likely inaccurate. Insel et al. [24] developed a three-compartment glucose 
model that included nonlinear terms to account for insulin effects on glucose uptake.  
However, the nonlinear term is effectively zero order with respect to insulin, and thus 
does not really effectively show accurate insulin effects in glucose consumption.   
 The majority of PK models developed since then have been modifications of the 
original PK models previously developed.  Tranberg and Dencker [25] developed a two-
compartment insulin model very much like that of Frost.  Home et al. [26] and Kobayashi 
  25 
et al. [27] both used a one-compartment model to fit kinetic parameters from patient data.  
Hipszer et al. [28] recently used the one-, two-, and three-compartment insulin models to 
fit insulin data from diabetic patients, concluding that a single insulin compartment is all 
that is needed to describe insulin kinetics.  Salszieder et al. [29] developed a one-
compartment model for both insulin and glucose, but increased model complexity in two 
ways.  First, they assumed that glucose production and uptake were best expressed as 
differential equations.  Second, they assumed that insulin accumulation was a function 
both of the glucose concentration and the derivative of the glucose concentration, an 
assumption which, as discussed later, forms the basis of many of the control systems 
designed for glucose control.  Parker and Doyle [13] indicated that this model was not 
able to accurately describe faster dynamic processes associated with glucose regulation.  
Perhaps the most widely used PK model to describe glucose and insulin kinetics 
is the minimal model developed by Bergman and Cobelli [30].  The authors chose from 
seven different PK model structures, including some of the previously developed models, 
to select the model structure displaying both a strong representation of intravenous 
glucose tolerance test (IVGTT) data and physiological relevance.  The minimal model, 
which is derived in Appendix A, consists of a single glucose department and two insulin 
compartments.  The pharmacokinetic diagram is given in Figure 2-1.  Glucose 
elimination is considered to be a nonlinear function of both glucose and a term 
representing insulin that is bound to liver and peripheral cells.  While originally 
developed based on animal studies, the model was later applied to human studies [31,32], 
to an oral glucose tolerance test (OGTT) [33], and to a mixed meal test [34].   
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 There have been several published studies displaying the shortcomings of the 
minimal model, including the work of Quon et al. [35] and Finegood and Tzur [36].  Both 
groups found that the minimal model does not accurately quantify the relative 
contributions of insulin and glucose with respect to glucose uptake.  Quon et al., 
including Cobelli [37] later determined that the problem stemmed from the use of a single 
glucose compartment.  This lead to efforts to develop an improved minimal model, 
beginning with a two-compartment glucose model by Cobelli et al. [38,39], and 
ultimately leading to the recently developed hot IVGTT two-compartment minimal 
model [40].  The model continues to be improved today [41]. 
 More recently, control engineers have gained an interest in the PK model 
developed by Hovorka et al. [42, 43].  In a similar manner to Bergman and Cobelli with 
the minimal model, Hovorka et al. proposed a number of different models before 
deciding on the one that both best fit the data as well as corresponded to physiology.  The 
model diagram is given in Figure 2-2, and the model equations and parameter values are 
given in Appendix B.  It uses two glucose compartments and three insulin-action 
compartments, describing the appearance and elimination of each species as a first order 
process.  While there is only a single actual insulin compartment, three different types of 
insulin action are described and assumed to different with respect to their ability to affect 
glucose metabolism.  This coincides well with the original claims of minimal model 
critics, which may have a lot to do with its rapid acceptance among control engineers.  
Hovorka et al. [44] recently improved upon the model to more accurately describe the 
kinetics associated with subcutaneous insulin delivery. 
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 The second major type of patient model are those that describe biochemical 
species dynamics at each significant organ site.  These models are developed by selecting 
as the main compartments only those organs in which significant species appearance or 
disappearance occur, and writing mass balances accordingly [16].  The first model of this 
type was developed by Foster et al. [45] in 1973.  This model assumed a glucose 
compartment for blood, muscle, and the liver, while assuming a single compartment each 
for insulin, glucagon, and fatty acids.  Guyton et al., including Foster [46] increased the 
complexity of Foster’s model.  A central organs compartment was added to the glucose 
model, insulin secretion from the pancreas was made more complex, and diffusion was 
included in the transport equations.  Sorensen [12] improved Guyton’s work by dividing 
the central organs compartment into the brain and gut compartments and by including the 
counter-regulatory effects of glucagon.  A model diagram of Sorensen’s glucose model is 
given in Figure 2-3, and the full model equations are given in Appendix C.  The model of 
Foster et al. is the only one to include fatty acid metabolism.  
Other physiologically relevant models include the models of glucose [47] and 
insulin [48] of Tiran et al., the model of Cobelli et al. [49], and the model of Puckett [5].  
The many parameters of Tiran’s models were estimated using dog data.  The models also 
did not include the affects of glucagon.  The models are also given in transfer function 
form, meaning that they represent linear representations of the systems.  The model of 
Cobelli considers glucose to be a single subsystem, and contradicts his own minimal 
model improvements made years later.  Puckett developed a model very similar to 
Sorensen’s, but did not include glucagon effects, and removed all transport terms besides 
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the metabolic sources and sinks.  In this way, her model represents a multi-compartment 
PK model.  As such, any dynamics associated with other transport will not be captured by 
this model. 
While Sorensen’s model has been the most widely used physiological model with 
respect to glucose control, it has been criticized for not accurately representing observed 
glucose behaviors in diabetic patients.  Steil [14] has pointed out that the model 
underpredicts the threshold glucose concentration at which insulin action becomes 
saturated.  He also mentions that the model poorly represents the glucose concentration of 
a patient with zero insulin and that the sharp drop in glucose that is experienced by 
patients whose insulin levels rise quickly is also not predicted.  However, despite these 
shortcomings, it remains the most accurate physiologically accurate model developed to 
date. 
In addition to the development of a model, the model parameters must be 
accurately estimated in order to ensure reasonable simulation results.  While the assumed 
accuracy of physiological models relative to PK models makes them enticing for control 
simulations, they suffer from the drawback of having tens to hundreds of parameters that 
must be identified.  Because specific patient metabolic rates cannot usually be measured, 
many different techniques have had to be used in order to estimate model parameters.  
Some authors, such as Bolie [19], Guyton et al. [46], Tiran [47, 48], and Sorensen [12], 
used average reported parameters, such as compartment volumes and blood flows.  
Sorensen and Bolie chose to extrapolate human parameters from reported dog and rat 
parameters, assuming a linear relationship based only on bodyweight.  In other instances, 
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specific data were acquired that allowed specific model parameters to be determined, 
such as most of the kinetic parameters of Sorensen’s mode and the diffusion terms of 
Tiran’s models.  Most often, however, the model parameters were estimated by 
comparing model responses to glucose and insulin data, and selecting the parameter set 
that minimizing the sum of the squared residuals.  It would appear that the lower order 
models have an advantage in that they can be estimated with a single set of glucose or 
insulin data, whereas the larger models will have to either assume average parameters 
values from literature or be able to use experimental data for a specific biochemical 
species in a specific tissue compartment.  Finally, it should be noted that most average 
patient parameter values are given for a 70 kg adult male, independent of age, and that 
values for a human not matching this description would still have to be determined, either 
through experiment or approximation. 
 
2.4.4 Explicit Closed-Loop Control 
 By utilizing the principles of process control, the body can be treated as a 
chemical process.  Glucose metabolism can be simplified to the control of a single 
variable, glucose, through the use of a single manipulated variable, insulin.  The 
effectiveness of such methods depends on the effective development of glucose sensors, 
insulin pumps, and control algorithms relating the insulin infusion to past, present, and 
predicted glucose values.   
 The development of improved glucose sensing methods is probably the most 
active component of research being applied toward the development of an explicit closed-
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loop system.  Even without the pump and algorithm, the use of a glucose sensor that is 
able to give frequent blood glucose measurements in real time is a dramatic improvement 
to drawing blood via a fingerstick and measuring glucose directly.  Joseph and Torjman 
[50] summarized the different types of sensors being developed, including sensor design 
and biological issues associated with each.  Among the sensors discussed are those 
implanted in either the subcutaneous tissue or the bloodstream.  Most invasive sensors are 
based on enzyme catalyzed glucose oxidation.  One issue associated with implanted 
sensors is the immune response of the body to foreign species.  This can reduce the life of 
the sensor and can also interfere with its ability to give accurate readings.  Another issue 
is the frequency of measurements.  Medtronic-Minimed (Minnapolis, MN) has developed 
external sensors capable of giving measurements less than five minutes apart [51].  
However, the device is not implantable.  Devices implanted in the subcutaneous tissue 
also have the issue of not reading the actual glucose values of blood.  The diffusion of 
glucose from blood to the subcutaneous tissue can result in time delays of around 30 
minutes.  Schmidtke et al. [52] and Freeland and Bonnecaze [53] have worked on 
developing dynamic models so that blood glucose values can be inferred from 
subcutaneous values.  Much research is still needed, however, in order to develop 
implantable devices that can frequently report accurate glucose values for long periods of 
time [54, 55].  In addition, the lack of developed sensor technology for the other 
biochemical species to be determined in real time severely limits the possibilities of 
control to be based on glucose measurements only. 
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 The second mechanical component of the system is the insulin infusion pump.  
Insulin pumps currently developed by Medtronic-Minimed are able to provide rapid-
acting insulin throughout the day either as a basal pulse or as a bolus for a meal [56].  
With the patented “Bolus Wizard” the insulin bolus will be calculated based on the size 
of the meal and the current glucose measurement.  However, implantation of such a 
device is still a work in progress.  Many issues must be resolved, including the immune 
response of the body, the location of the device, and how often the pump’s insulin must 
be replaced.  While Renard [57] argues that the pump should be placed within the 
peritoneum, a device planted under the skin may be easier to refill.  However, such a 
device would likely be supplying insulin to the subcutaneous tissue, and delivery would 
not be like that of a healthy patient.   
 Parker and co-workers [58] reviewed many of the algorithms developed for 
glucose control prior to 2000.  Bequette [59] also reviewed many of the older 
developments while also reviewing algorithms developed through 2005.  The aim of this 
work is to summarize those reviews and to review algorithms developed since 2005.   
 The first algorithm of real significance with respect to the development of the 
artificial pancreas was proposed by Albisser [60].  This algorithm provided insulin when 
glucose was higher than the desired level and dextrose when glucose was lower than 
desired.  The dextrose infusion rate was proportional to glucose infusion, and the insulin 
infusion rate was based on a nonlinear proportional plus derivative (PD) algorithm.  The 
“Biostator” algorithms [61] improved upon Albisser’s work to try to improve the 
response of blood glucose to a meal.  This algorithm suffered from many problems.  First, 
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the control algorithm consisted of many patient-dependent parameters, meaning the 
algorithm would have to be developed for a specific patient [58].  If patient parameters 
changed over time, the algorithm may also have to be reprogrammed.  The second major 
problem is that the derivative was calculated using finite difference for the previous four 
measurements [59].  Because each measurement was one minute apart, the rate 
immediately after the beginning or end of a meal will inevitably suffer from a time lag 
before it is properly adjusted.  In addition, measurement noise associated with any of the 
four points could also dramatically affect the infusion rate.  Many authors [58] tried to 
create improvements to the Albisser’s algorithm, but no controllers were found to 
outperform the original nonlinear PD algorithm. 
 As validation that the PD algorithm is indeed the best representation, Nomura et 
al. [62] studied the response of beta cells of healthy rats to a step disturbance of glucose.  
Glucose was infused at a constant rate, and the insulin concentration was noted with time.  
A biphasic response was observed, and the time constants associated with each phase 
were estimated.  The biphasic response of the pancreas is shown in Figure 2-4.  Steil et al. 
[63] investigated Albisser’s algorithm and the algorithms of “Biostator” while also 
proposing a PID algorithm for insulin infusion.  Controller effectiveness was studied by 
performing simulations using the model of Cobelli et al. [49].  For the simulation, the 
model was initially in the hyperglycemic state, and the ability of the controller to return 
glucose levels to normal was investigated.  The algorithm has been implemented in the 
implantable pumps of Medtronic Minimed, and the ability to return glucose levels to 
normal in hyperglycemic diabetic dogs was observed.  The pump was also implanted into 
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human subjects, and the control algorithm was demonstrated to result both hyperglycemia 
after the consumption of a meal and hypoglycemia after the meal.  An argument against 
the use of PID controllers to mimic the biphasic insulin profile is provided in reference 
[59].  The author argues that such a response can be the result of any control system in 
which integral action is present, and that internal model controllers can also have the 
same response.  He also argues that integral control can result in hypoglycemia as a result 
of infusing too much insulin. 
 Many authors have studied control algorithms by performing simulations using 
the well known patient models.  Furler et al. [64] investigated the use of a semiclosed-
loop algorithm based only on current glucose levels by performing simulations with the 
minimal model.  The ability to return glucose levels from hyperglycemia to normal was 
observed, but no attempt was made to prevent glucose levels from approaching 
hyperglycemia after consumption of a meal.  Sorensen [12] developed on internal model 
controller, and simulations were performed using his developed patient model.  The 
controller is able to keep glucose levels under 140 mg/dL during a 100 g oral glucose 
tolerance test (OGTT).  Parker et al. argue in reference [58] that the effectiveness of the 
controller is highly parameter dependent and that changing the model parameters results 
in the controller no longer being able to reject the disturbance.   
 Recent efforts in algorithm development have focused on advanced control 
methods.  Among the first advanced control systems were the optimal controllers 
developed by Ollerton [65] and Fisher [65].  Ollerton used optimal control to minimize 
the integral of the squares of the differences between a glucose measurement and the 
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glucose set point.  The minimal model was discretized with a 10 minute sampling 
interval, and the insulin infusion profile minimizing the objective function was chosen as 
the optimal profile.  A 180 minute sampling time is also used, but such a long sampling 
time would be unable to correct for a meal disturbance that was present in between the 
samples.  The author shows that the algorithm is able to return an initially hyperglycemic 
patient to normal levels, even in the present of a 100 g/day infusion of glucose.  
However, the algorithm is unconstrained with respect to the states, inputs, and outputs, 
and the optimal solution results in insulin levels below zero mU/L, which are not 
physically attainable.  Even with negative insulin levels, the control system is unable to 
prevent the onset of hypoglycemia.  Fisher also used the integral squared error objective 
function to apply optimal control to the minimal model, but chose three different 
semiclosed-loop insulin delivery systems to investigate.  The first system was comprised 
of a basal infusion and injections when necessary, the second consisted of an infusion 
pump only that was optimized every hour, and the third system consisted of the optimal 
hourly infusion and the injection when needed.  The optimal injection and pump infusion, 
where applicable, were determined using the objective function.  Fisher shows that the 
best controllers consist of the optimal insulin injection, and that the optimal infusion 
alone will not be able to reject a meal disturbance without the onset of hypoglycemia.   
 Other methods of advanced control that have been applied include the application 
of H∞ control by Parker et al. [67].  The authors applied H∞ control to a modified version 
of Sorensen’s model in which model parameter uncertainty is considered.  The control 
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was applied after the model was reduced.  Simulations showed that neither hyper- nor 
hypoglycemia are approached.   
 The most recent developments in closed-loop control focus on model predictive 
control (MPC) to provide the optimal control profile while considering constraints.  
Given measured outputs, model parameters are estimated using state estimation, and an 
objective function is solved based on the model prediction of the future glucose trajectory 
resulting from that particular insulin profile.  Parker et al. [68] developed a model-based 
algorithm employing a linearized version of the Sorensen model, a Kalman filter, and a 
linear quadratic objective function.  Like other methods applied to Sorensen’s model, 
neither hyper- nor hypoglycemia were approached.  Bequette and Lynch [69] applied 
linear MPC to the Sorensen model by using the minimal model to determine the insulin 
infusion profile.  The authors later applied MPC directly to the minimal model, showing 
that neither hyper- nor hypoglycemia are approached during a meal [70].  Hovorka et al. 
[43] applied nonlinear MPC to Hovorka’s original model.  While the authors were able to 
show that NMPC used along with an injection at mealtime is able to reduce 
hyperglycemia and prevent hypoglycemia, no work was presented in which only the 
MPC controller was used.   
Diaz et al. [71] applied predictive functional control Carson’s model.  While able 
to simulate the reduction of hyperglycemia during a meal and the prevention of 
hypoglycemia, the results were achieved by utilizing insulin infusion rates that lead to 
hyperinsulinism [1].  Finally, Cinar et al. [72] developed an online simulation tool 
employing MPC to control a patient using Puckett’s model as both model and patient.   
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2.4.5 Implicit Closed-Loop Control 
The development of an effective explicit closed-loop control system depends on 
the ability of engineers to develop an effective sensor for each output, an effect control 
algorithm that allows the controlled variables to be maintained at normal levels during 
many different conditions, and an effective infusion pump.  The pump and the sensor 
must be able to be implanted and they must be able to respond quickly to the changing 
environment.   
An alternative that removes the necessity of developed equipment is the implicit-
closed loop control system, in which a chemical system is acting as all three components 
of the control system.  The system, which contains insulin, is able to modify its insulin 
release profile in response to a change in the local environment.  By mechanically 
changing in response to its environment, the system acts as a sensor.  By releasing insulin 
through natural transport processes, the device acts as the infusion system.  By being 
optimally designed to release the right amount of insulin for each condition, the device 
development is the control algorithm. 
Because the required stimulus is the state of the local environment, a logical 
candidate to serve as such a device is the environmentally responsive hydrogel.  
Hydrogels are cross-linked hydrophilic polymer networks that are able to absorb large 
amounts of water [73].  The functional groups of the polymer backbone can be modified 
to allow the hydrogel to swell or deswell in response to many different stimuli, including 
pH and temperature.   
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To be used as glucose sensors, Albin et al. [74], as well as Peppas et al. [75-77], 
have incorporated enzyme-catalyzed glucose oxidation into the hydrogels by 
immobilizing glucose oxidase into the gel network.  Because one of the reaction products 
is gluconic acid, it is logical to develop the gels to be pH-responsive.  Because the release 
of insulin should increase in response to increased glucose, it is also natural that the 
hydrogel system be designed to swell in response to an increase in acid concentration, or 
a pH decrease.   
Hydrogel systems that are responsive to pH changes can be divided into two 
groups.  The first are the anionic hydrogels the swell in response to a high pH.  These 
gels contain acid groups that deprotonate at a high pH.  This ionization results in 
repulsions among functional groups within the chains.  Examples of anionic hydrogels 
include the poly(methacrylic acid-graft-ethylene glycol) gels developed by Peppas et al. 
[9] for oral delivery, and the poly(N-isopropylacrylamide-co-methacrylic acid) gels 
developed Siegel et al. to serve as a chemomechanical oscillator [78, 79]. 
Cationic hydrogels are hydrogels that swell in response to a decrease in pH.  
These gels contain basic functional groups, such as methacrylates.  Below the pK of the 
functional group, the functional groups become protonated, which results in a change in 
hydrophilicity of the network, causing an increase in water uptake into the gel [76].  This 
results in increased swelling at the pH below the pK of the functional groups. 
Many people have studied the swelling and release characteristics of pH-sensitive 
cationic hydrogels.  Firestone and Siegel [80] investigated the swelling kinetics of 
copolymer gels of methacrylic acid and dimethylaminoethyl methacrylate, poly(MMA-
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co-DMAEM) as a function of pH, ionic strength, and temperature, showing that these 
systems can take in as much as 8 times their collapsed weight in water.  Siegel et al. [81] 
showed that the pK of the buffer solution has a strong effect on the swelling of these gel 
systems.  Firestone and Siegel [82] showed that these systems are able to demonstrate 
oscillatory swelling and deswelling and that successive pH increases with time resulted in 
successive deswelling to a specific swelling ratio.  Cornejo-Bravo and Siegel [83] studied 
water sorption for copolymers of diethylaminoethyl methacrylate and methyl 
methacrylate (poly(DEAEM-co-MMA)), but no dynamic swelling or release results were 
given.  Finally, Siegel et al. [84] investigated the release of caffeine from a hydrogel disk 
approximately 13 mm in diameter and 0.33 mm thick, and the effects of buffers on 
release [85].  At a pH of 3, the loaded disk no longer released caffeine at approximately 
100 minutes from the start of the experiment.  The completion time had increased to 200 
minutes for pHs of 5 and 7.  All of Siegel’s swelling studies showed the gels reaching 
their equilibrium swelling ratios on the order of hours.   
Many people in the Peppas laboratory at UT-Austin have investigated the 
swelling and release of pH-sensitive cationic hydrogels as well.  Peppas and Hariharan 
[86] studied both dynamic and equilibrium swelling for a poly(diethylaminoethyl 
methacrylate-co-hydroxyethyl methacrylate) (poly(DEAEM-co-HEMA)), 
poly(diethylaminoethyl acrylate-co-hydroxyethyl methacrylate) (poly(DEAEA-co-
HEMA), and poly(methacrylaminopropyl ammonium chloride-co-hydroxyethyl 
methacrylate) (poly(MAPTAC-co-HEMA)).  They were able to demonstrate that 
poly(DEAEA-co-HEMA) showed no water sorption at a pH of 8, while water the gels 
  39 
were able to uptake more than 10 times weight of the collapsed gel at a pH of 3.  Using 
poly(DEAEM-co-HEMA) they demonstrated that 1mm thick disks would reach 
equilibrium swelling in approximately 3 hours, displaying weight swelling ratios ranging 
from 1.5 to 2.5 times the original weight of the gel.  Peppas, Hariharan, and am Ende [90] 
performed release studies of oxprendol HCl from poly(DEAEA-co-HEMA) and 
poly(DEAEM-co-HEMA).  Maximum drug release was observed to occur from 1 mm 
disks within 12 hours for poly(DEAEA-co-HEMA) and on the order of one day for 
poly(DEAEM-co-HEMA), with rapid release occurring in the first 5 hours, followed by 
slower release until the device no longer releases. 
Because increasing the number of functional groups results in a lower transition 
pH for swelling, cationic hydrogels of poly(diethylaminoethyl methacrylate-co-ethylene 
glycol monomethyl ether monomethacrylate) (poly(DEAEM-g-EGMMA)) were 
developed by Podual, Doyle, and Peppas [76-77, 88-89], and Podual, Peppas, and 
Schwarte [75].  A small amount of PEGMMA was added to the gels to impart stealth 
capabilities in the body, preventing a rapid immune response from occurring.  The gels 
displayed a transition pH of around 7.1, and displayed volume swelling ratios ranging 
from 8 for highly cross-linked gels to over 40 for lightly cross-linked devices.  Dynamic 
studies showed that disks measuring 1 cm in diameter and 1 mm in thickness would reach 
equilibrium swelling in response to a pH change below the transition pH in 
approximately 5-6 hours.  Microparticles of poly(DEAEM-g-EGMMA) were developed, 
and results showed that the gels reached equilibrium swelling nearly instantaneously to a 
decrease in pH below the transition pH [77].  The gels were also shown to be glucose 
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sensitive by observing their swelling in solutions of different glucose concentrations [88].  
Finally, insulin release was demonstrated in response to change in glucose.  Insulin was 
shown to be completely released from the system within 20 minutes [89]. 
Based on the currently developed formulations of poly(DEAEM-g-EGMMA), the 
hydrogel system would function as an implicit closed-loop system by way of the 
following mechanism, as shown in Figure 2-5.  Small hydrogel particles would be 
injected directly into the bloodstream, where they would be protected from the body’s 
immune response by the ethylene glycol grafts.  As the glucose concentration of the 
blood increases, there will be increased diffusion of glucose to within the gel system.  
Within the gel, the presence of immobilized glucose oxidase will result in the enzyme 
catalyzed oxidation of glucose, forming gluconic acid.  This acid formation will result in 
a slight pH change.  The pH change will not be large because of the presence of buffers 
in the bloodstream, most importantly the bicarbonate buffer system [1].  When the pH 
decreases below the transition pH of the gel, swelling will occur, resulting in an increase 
in the diffusivity of species from the gel by up to a factor of ten.  This results in an order 
of magnitude increase in insulin infusion from the gel, which results in increased glucose 
uptake.  As the glucose concentration decreases, oxidation will decrease, and as hydrogen 
ions naturally diffuse out of the gel, the pH will increase again, resulting in a collapse of 
the particle. 
There have been a number of modeling efforts associated with hydrogels.  These 
can be grouped according to the various steps in the swelling and release process.  A 
review of the different models assuming different transports mechanisms and different 
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methods of viscoelastic chain relaxation can be found in reference [90].  With respect the 
development of control relevant transport models, Lustig and Peppas [91] developed 
scaling laws to describe the diffusion of solutes in hydrogels that do not exhibit swelling 
behavior.  Peppas, Harland, et al. [92] modeled the combined dissolution and diffusion of 
a drug that is released from the non-swelling system. Peppas and Hariharan [93] and 
Albin et al. [74] both developed models describing swelling and release from pH 
responsive hydrogel films, and Podual et al. [94, 95] developed a model describing 
swelling and release from poly(DEAEM-g-EGMMA) spherical particles.  To the 
knowledge of the authors, there have been no previous attempts to simulate the response 
of pH-responsive hydrogels in vivo. 
 
2.5 Conclusions 
 This chapter explained the major details regarding glucose metabolism, diabetes, 
and current and proposed therapeutic methods for treating diabetes.  Included in the 
discussion was a review of all pertinent patient models, control algorithms, and efforts 
toward developing an implicit closed-loop control system.  From the discussion, several 
observations can be made.  First, there is no model in existence that accurately describes 
each species in the glucose metabolism process.  A fatty acid PK has recently been 
proposed [96], but the majority of models and control configurations continue to focus 
solely on glucose and insulin, while a few include glucagon.  Second, with the exception 
of a few MPC algorithms applied to Sorensen’s model, no control algorithm appears to 
be able to prevent hyperglycemia without an additional injection at meal time.  And 
  42 
finally, there exists a need to study the in vivo effectiveness of implicit closed-loop 
control systems.  This will be investigated in a later chapter.  Through simulations of the 
in vivo effectiveness, the hydrogel design characteristics can be optimized so that 
effective implicit-closed loop control can be provided.   
 





Figure 2-1: Pharmacokinetic diagram of the minimal model.  Solid lines represent 
material appearance or disappearance, and dashed lines represent contributions toward 
the kinetic appearance or disappearance.  The ki’s represent the rate coefficients for each 






























Figure 2-2: Pharmacokinetic diagram from Hovorka model [43].  Q1 and Q2 represent the 
mass of glucose in compartments 1 and 2, respectively.  I represents plasma insulin, and 
x1, x2, and x3 represent insulin action toward glucose uptake, production, and exchange 
between the two compartments.  Solid lines represent kinetic appearance or 
disappearance.  Dashed lines represent action by insulin.  Large solid arrows represent a 
single non-continuous source of either glucose or insulin.   
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Figure 2-4: Biphasic insulin response to step increase in glucose, as modeled by Nomura 
et al. [62].  At time zero the glucose concentration is increased from 80 mg/dL to 160 
mg/dL and maintained at the new level.  A basal insulin concentration of 15 mU/L was 
assumed, as the results of the model simulation are given as insulin levels above basal.  
At the time of the glucose change, a sharp spike in insulin occurs, known as first phase 
release.  This response falls off rapidly, followed by a second delayed release phase that 
gradually increases to the steady state insulin value.   
 








Figure 2-5: Schematic of mechanics of pH-responsive cationic hydrogels with glucose 
oxidase, based on the work of Podual [93].  Glucose appearance results in the production 
of gluconic acid, which decreases the system pH.  pH-induced swelling results in 
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 The primary focus of this research was to develop simulations of the in vivo 
efficacy of different types of closed-loop control systems in patients with diabetes 
mellitus. This research had three primary research objectives.  The first was to develop an 
improved model of metabolite and hormone dynamics for both healthy and diabetic 
patients.  The second was to apply principles of process control toward the development 
of explicit closed-loop control systems employing an insulin infusion pump with an 
algorithm to determine the insulin infusion rate.  The final objective was to develop 
mathematical relations describing the implicit closed-loop control system and simulate its 
response.  With each individual objective achieved, the in vivo response of the control 
systems to both basal and non-basal conditions could be observed in order to assess the 
potential effectiveness of such systems within actual patients. 
 
3.1 Patient Model Development 
In order to simulate how insulin and other hormones affect plasma glucose, 
patient models with sufficiently detailed biological information are required. While the 
glucoregulatory system involves multiple metabolites and hormones, most existing 
models focus only on the dynamics of glucose and insulin.  Mathematical models 
describing the dynamics of all metabolic species and hormones that are involved in the 
minute-to-minute control of glucose were developed in order to fully understand the 
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system as one involving more species than simply glucose and insulin.  The models were 
developed by first determining the primary biochemical species (given in Chapter 2).   
Next, the specific tissue sites of the important metabolic dynamics for each 
species were determined, and mass balances were developed around each site.  For this 
objective, both simple pharmacokinetic and complex physiologic models were 
developed.   
 
3.2 Model Parameter Estimation 
With the models developed, the next objective in completing the modeling efforts 
was to identify the model parameter values.  However, as data were not attainable for 
this, the ability to identify even simple models was investigated.  Using both patient data 
and test data, with and without noise, the ability to determine model parameters for a low 
order insulin pharmacokinetic model was investigated.  We carried out this investigation 
by assessing the ability of pre-developed optimization solvers to successfully re-estimate 
the model parameters using data generated by a model with a specified set of parameter 
values.  This investigation was performed for varying levels of model complexity and 
includes an investigation of confidence intervals, output sensitivity to each parameter, 
and numerical effects in the estimation process. 
 
3.3 Explicit Closed-Loop Control 
 Because the developed patient dynamic models were unable to be successfully 
identified, explicit closed-loop control systems have been developed by a number of 
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researchers for three specific models, namely the minimal model [1], the Sorensen model 
[2], and the Hovorka model [3].  For each model, the effectiveness of proportional-
integral-derivative (PID) control, feedforward control, and optimal control was 
investigated in this thesis for different conditions and different model parameter sets.  
Each control system uses a different algorithm, based on glucose levels, to determine the 
insulin infusion rate, assuming release is provided by an implanted pump that allows 
release directly into the bloodstream.  Specifically, the effectiveness of each control 
system was assessed for basal conditions, after a meal, or during exercise.  Finally, a 
controller developed based on Sorensen’s representation of pancreatic insulin secretion 
was developed, and its effectiveness in controlling glucose was assessed.   
 
3.4 Implicit Closed-Loop Control System Development 
 The feasibility of using injectible micro- or nanosphere particles of pH-responsive 
cationic hydrogels was also assessed by investigating the ability of the system to provide 
insulin for basal and non-basal glucose levels.  To achieve this assessment, a model was 
developed describing the dynamics of glucose, insulin, and gluconic acid within the gel.  
The effect of gluconic acid on insulin release was also modeled by considering how the 
system’s pH would change, how this pH would affect swelling, and how swelling would 
affect insulin release.   
With the model developed, simulations were performed with the minimal model 
in order to determine the effectiveness of the hydrogel system at controlling glucose 
within a diabetic patient.  A number of simulations were performed in order to determine 
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the effect of each model parameter, and ultimately, each system design specification, on 
the system’s response.  Next the system was optimized in order to find the parameter set 
that allows for two characteristic conditions to be satisfied: (1) glucose was to be 
maintained at a normoglycemic range during basal conditions; (2) the injectible system 
was to remain active in the body for an extended period of time.  Both the constrained 
and unconstrained optimization problems were considered.  For the unconstrained 
problem, it was assumed that each parameter can take on any physically realistic value.  
For the constrained problem, it was assumed that each parameter may have a physical 
limitation, such as the size of a particle or the number of particles that can exist in the 
body.  Based on the simulations, the effectiveness of the hydrogel system to provide 
intravenous insulin release were determined, and the system’s feasibility is discussed. 
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CHAPTER 4 
PATIENT DYNAMIC MODELING  
 
4.1 Introduction 
The use of models in the development of novel medical therapeutic systems can 
greatly improve the development process.  By being able to perform an accurate 
simulation of the behavior of patients treated by the therapeutic methods, two important 
advantages are realized relative to development without simulation.  First, the use of 
simulation is a significantly cheaper alternative to testing in patients and animals, both in 
terms of dollars spent and time spent in gaining approval for such experiments, the 
development of experimental protocols, and experimental setup and performance.  
Second, a simulation can quickly reveal device design characteristics that will not be 
effective, preventing any catastrophic results from occurring, including the loss of lives.  
In addition to these two primary advantages, the ability of simulations to show the system 
response for a large number of design configurations and scenarios in a relatively short 
amount of time demonstrates that, at the very least, the use of simulations as a precursor 
to experiments is a highly effective way to improve the design process. 
 Two different types of patient models can be developed.  The first type, the 
pharmacokinetic model [1], simply describes the kinetics of absorption and elimination of 
a species for a certain number of theoretical compartments.  Often a single compartment, 
representing the circulation is chosen.  Elimination and absorption kinetics are most often 
described by first order kinetics.  When the model does not match data, the model 
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structure is changed by either increasing the number of compartments used or by 
changing the mathematical description of the kinetic rates. 
 The second type of model developed is the physiologically-based model [2], in 
which the most significant organ tissues are chosen as well-mixed compartments, and the 
concentration of species is assumed to be uniform within that compartment.  Mass 
balances describing blood flow convection, mass transfer within each compartmental 
space, and the metabolic processes are written for each species at each compartment.  The 
result is a large, multi-compartment model based on physiology. 
 Both the pharmacokinetic and the physiologically-based model have their 
advantages and disadvantages.  The physiologically-based model has the potential to be a 
better model for both simulation and for use in model-based control methods, as a result 
of its thorough description of each species in the body.  However, because there are so 
many parameters to be identified  with such a large model, the pharmacokinetic models 
have the advantage that, while perhaps not describing metabolism as accurately as the 
explanatory models, an estimate of the model parameters is easier to obtain, thus making 
them easier to use. 
 Previous work has focused mostly on insulin and glucose modeling, while some 
models do exist that describe glucagon [2], [3], [4], and fatty acids [4], [5].  The purpose 
of this chapter is to develop a model framework to describe all the biochemical species 
associated with glucose metabolism, as given in Chapter 2.  Both the pharmacokinetic 
and the explanatory model framework will be developed.  This is done by first noting the 
relevant tissues and metabolic sources and sinks for each species.  Next, the basic 
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differential equations will be developed for each species and each compartment.  Finally, 
each metabolic source and sink term will be described as a general function of the 
biochemical species involved.  The chapter concludes with a discussion of the potential 




 Model development with respect to the different model frameworks was fairly 
systematic.  To develop the pharmacokinetic model, the methods described in reference 
[1] are employed.  For the development of the physiological models, the methods 
described by Bischoff and co-authors [6-9] were employed.  For both models, the 
biochemical species and each of their metabolic sources and sinks must be known in 
order to develop an accurate model.  For the physiological models, the locations of each 
metabolic source and sink must also be known in order determine the specific 
compartments to be modeled.  To gather this information, physiology textbooks, such as 
[10] and [11], and previously developed explanatory models such as [2] and [12], were 
used.   
 To develop the pharmacokinetic framework, each species was initially assumed to 
be best described as existing in a single compartment.  Each species was determined to be 
a function of its metabolic processes.  Based on the physiology studies, the metabolic 
process equations were described as general functions of the species that are known to 
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affect that particular metabolic process.  Because data were not readily available, the 
models were left in their general form. 
 To develop the physiological models, each organ at which a specific metabolic 
process occurs was assumed to be a well mixed compartment of uniform concentration 
throughout a particular space within the compartment.  As shown in Figure 4-1, each 
compartment is assumed to have three different spatial regions.  First is the vascular 
space, which is in constant contact with blood flow.  The middle space is the interstitial 
space, an area within the capillaries and containing the organ cells.  The inner most 
region is the intracellular space, where the metabolic processes are assumed to occur.  
The volume of each compartment space is considered constant. 
 For each physiological compartment, transient mass balances are written 
according to [9].  For the vascular space, mass transfer is assumed to occur via 
convection from blood flow and from diffusion to the interstitial space.  For the 
interstitial space, mass transfer occurs via diffusion from the vascular space and to the 
intracellular space.  For the intracellular space, mass transfer occurs via diffusion from 
the interstitial space and via the cellular metabolic processes either consuming or 
producing a specific species. Finally, because the kinetic equations cannot be identified 
without data, a list of possible representations is provided in order to complete as much of 
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4.3 Results 
4.3.1 Pharmacokinetic Modeling 
 A description of the various model variables and parameters, including units, is 
provided in Table 4-1.  To develop pharmacokinetic models of each species, the 
significant metabolic processes associated with each species was investigated, and 
summarized in the compartment diagrams given in Figures 4-2 through 4-8.  For each 
species, the dynamic change of species concentration within the constant volume 
compartment was assumed to be a function of both endogenous and exogenous inputs 
and uptake or elimination.  A single compartment was assumed, as no data was used to 
determine the number of compartments best representing the actual kinetics of the 
species.   
   Physiologically, glucose appears endogenously, through gluconeogenesis or 
glycogenolysis, or exogenously, either orally or via an injection.  Glucose disappears by 
being taken into cells and either stored as glycogen, converted to fat, or used in the 
formation of ATP.  The pharmacokinetic description of glucose dynamics is shown in 




−+=       (4.1) 
( )end,Send,S K,A,F,E,G,I,S,tfr =      (4.2) 
( )Sex,S M,tgr =        (4.3) 
( )lime,Slime,S K,E,I,S,thr =       (4.4) 
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As both Hovorka et al. [13] and Cobelli et al. [14] have shown, glucose is 
probably more accurately represented as having two compartments.  Given the recent 
praise of the Hovorka model, (4.1) is likely best represented as two different equations , 
each representing a different compartment.  Endogenous production and most cellular 
uptake would likely occur in a second compartment, and exogenous production, and 
transport to and from cells would be represented in the central compartment.   
 Endogenous glucose production and uptake would be functions of glucose, 
insulin, glucagon, and epinephrine, as well as amino acids, fatty acids, and glycogen.  
Insulin and glucose both act to decrease production, while glucagon and epinephrine act 
to increase production.  Also included in this function would be the glycogen levels, 
which allow for glycogenolysis, and the fatty acid and amino acid levels, which allows 
for gluconeogenesis.  Therefore, these kinetic rates are assumed to be function of the 
other species and metabolites, as well as any kinetic parameters associated with the 
process.  Exogenous glucose would be considered a function of the source, including the 
amount given and the particular absorption kinetics associated with the source. 
 Amino acids play many different roles in glucose metabolism.  Many are 
important for gluconeogenesis.   Some amino acids, especially, lysine and arginine, are 
able to cause an increase in insulin secretion.  Others, including alanine, cause an 
increase in glucagon secretion.  These effects show the importance in including amino 
acids in the overall glucose metabolism process.  Like glucose, amino acids appear as a 
result of both endogenous production and from external sources of proteins.  They are 
taken up into various cells to form proteins or are converted to glucose.  Amino acid 
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pharmacokinetics are shown in the PK diagram of Figure 4-3.  The amino acid mass 




−+=     (4.5) 
( )End,Aendogenous,A K,A,F,E,G,I,S,tfr =     (4.6) 
( )M,tgr exogenous,A =        (4.7) 
( )lime/uptake,Ainationlime/uptake,A K,I,A,thr =      (4.8) 
 
 The amino acid model is very similar to the glucose model.  Given both 
circulation and intracellular amino acids, two compartments may be appropriate for 
amino acid kinetics.  Endogenous production occurs by breaking down proteins.  This 
occurs primarily for gluconeogenesis, making endogenous production a strong function 
of glucose, epinephrine, and glucagon levels.  Insulin is also known to promote protein 
formation, meaning that increased insulin would be expected to decrease production.  
Finally, during starvation, once glucose and fatty acid levels are diminished, amino acids 
become the primary source of fuel, resulting in increased production.  Amino acid uptake 
will depend on the acid levels, and insulin has been shown to increase uptake promote 
protein formation.  Finally, an exogenous source will be a function of the method of 
administration, including absorption kinetics associated with the administration technique 
and the volume administered. 
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 Like glucose and amino acids, fatty acids are produced endogenously and 
supplied exogenously, in the form of a meal.  Fatty acids combine with amino acids to 
form glucose via gluconeogenesis.  In addition, when glucose levels are low, fatty acids 
become the primary source of fuel for the body.  The fatty acid PK diagram is given in 




−+=     (4.9) 
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 A recent paper by Roy and Parker [5] shows a developed fatty acid PK model.  It 
treats fatty acids as existing in a single compartment, while also including additional 
remote compartments, to describe the effects of fatty acids on glucose metabolism.  
Given the uptake and production of fatty acids in certain cells in the body, it may be 
appropriate to represent fatty acids as existing in two circulating compartments in 
addition to any compartments describing action.  However, as fatty acid binding does not 
affect glucose uptake, it may be inappropriate to use remote compartments in the model 
description. 
 Fatty acid production is considered to be a function of glucose, insulin, glucagon, 
and epinephrine.  The existence of the glucose-fatty acid cycle results in a direct 
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dependence on glucose.  Low glucose levels result in low insulin and high glucagon 
levels.  Glucagon is known to increase fatty acid production while also decreasing fatty 
acid conversion to lipids.  Epinephrine is also known to result in increased fatty acid 
production.  However, both glucagon and epinephrine are also responsible for increasing 
the rate of gluconeogenesis, which would result in increased fatty acid elimination.  Thus, 
both fatty acid production and elimination are functions of glucose and the regulatory and 
counter-regulatory hormones of glucose metabolism.  Like glucose and amino acids, the 
exogenous source of fatty acids is assumed to depend on the source type and the amount 
of fatty acid delivered. 
 Insulin is assumed to appear either through endogenous production from the 
pancreas or from an external source.  It is assumed to be degraded primarily at the 
binding sites and at the kidneys.  Figure 4-5 shows the insulin PK diagram.  Insulin 
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Insulin is considered by most to also best be represented as existing in multiple 
compartments.  While Hovorka’s representation of a single insulin compartment being 
  71 
responsible for three different type of insulin action, which vary dynamically, the 
addition of its action on glucagon production and fatty acid and amino acid levels may 
result in the full scale model consisting of many insulin action compartments. 
Insulin secretion is considered to be a function of many variables besides simply 
glucose.  It is considered to be a function of its own values, meaning that insulin would 
be expected to continue to supply insulin at high insulin levels.  Insulin production is also 
increased by an increase in gastrointestinal hormones, including glucagon like peptide-1 
(GLP-1), and  amino acids are known to have a potentiating effect on insulin secretion 
[10].  Finally, epinephrine, when produced at levels to restore falling glucose levels, is 
able to inhibit insulin secretion [15].  An exogenous source will be a function only of the 
amount given, and any absorption kinetics associated with the method of delivery.  
Uptake is assumed to occur only as a function of the insulin concentration and the kinetic 
rates. 
 Glucagon is assumed to appear only endogenously, although the idea of 
exogenous glucagon infusion is gaining acceptance [16].  Glucagon elimination is 
assumed to occur at the liver cell binding sites and the kidneys.  Glucagon dynamics are 





−=      (4.17) 
( )endogenous,GGendogenous,G K,E,A,I,S,tfr =     (4.18) 
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( )inationlime/radationdeg,GGinationlime/radationdeg,G K,G,tgr =    (4.19) 
 
 Glucagon is assumed to exist in only a single compartment.  However, given that 
it also binds to various cells, it may also be best represented as having a central 
compartment, and two different action compartments.  One of these compartments could 
represent the activation of the glucose production, and the other could represent fatty acid 
production.  Perhaps a third action compartment could represent the inhibition of fatty 
acid uptake in some cells. 
 Endogenous glucagon production is a function of glucose, insulin, amino acids, 
and epinephrine.  As the counter-regulatory hormone, glucagon secretion is inhibited by 
high glucose levels.  Because the glucagon-producing alpha cells are downstream of the 
insulin-producing beta cells, the presence of insulin is also able to inhibit glucagon 
secretion [15].  Amino acids are known to increase glucagon secretion, and exercise is 
also known to result in an increase in glucagon levels.  Because most of the effects of 
exercise result from the increased epinephrine production, a functional relationship may 
exist between the two hormones.  Glucagon elimination is assumed to occur as a function 
only of glucagon levels. 
 While epinephrine is present in the body at normal glucose levels, the effects of 
epinephrine on glucose regulation are not usually observed unless the person is exercising 
or if a person is experiencing hypoglycemia and his or her glucagon response is 
insufficient to return glucose levels to normal.  It should be mentioned that the 
sympathetic hormones naturally exist as both epinephrine and norepinephrine.  However, 
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because most norepinephrine is converted to epinephrine, and because most of the effects 
mentioned are in response to the sympathetic nervous system responses to low glucose, 
the epinephrine/norepinephrine complex is simply being lumped together as a single 
hormone.  The appearance of epinephrine in these circumstances is assumed to occur 
endogenously only, and disappearance is assumed to occur via degradation.  The 
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 Given that epinephrine increases glucose levels by either increasing production, 
decreasing uptake, and decreasing insulin secretion, a total of four compartments may be 
appropriate to represent all of the dynamics associated with epinephrine.  Epinephrine 
secretion for the purpose of glucose regulation is a function of both glucose and glucagon 
levels, as previously mentioned.  An additional term, perhaps best represented in the 
kinetic rate parameter, is the increased epinephrine secretion in response to exercise.  
Like the other hormones previously mentioned, epinephrine elimination is assumed to be 
a function only of the epinephrine levels.   
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 GLP-1 is secreted only response to a meal, and as such it is assumed that is 
appearance only occurs endogenously.  To be more accurate, GLP-1 is actually a part of 
many gastrointestinal hormones responsible for what it known as the incretin effect of 
increasing insulin secretion [17].  GLP-1 accounts for more than 70% of the total incretin 
effect, with the remaining effect caused by gastric inhibitory polypeptide (GIP) and a 
minimal effect from other hormones.  For simplicity the two have been lumped together, 
as both are generated in response to a meal and both act to increase insulin production.  
Its disappearance occurs through general degradation at the liver and kidneys.  Figure 4-8 
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 As previously mentioned, the production of GLP-1 occurs as result of the 
digestion process.  As a gastrointestinal hormone, GLP-1 would be a function of the 
glucose levels in a compartment associated with a meal, such as Hovorka’s meal 
description, as shown in the Appendix.  As the hormone is known to increase insulin 
secretion, a two-compartment representation, in which one describes its circulation 
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levels, and the other describes its activation with respect to insulin secretion potentiation, 
may be appropriate.  Elimination is assumed to be a function only of GLP-1. 
 
4.3.2 Physiological Modeling 
 For physiological modeling, the same general sources and sinks are used that 
were used in the pharmacokinetic modeling efforts.  However, all production and 
elimination must be specified according to the tissue region at which the metabolic 
process occurs.  Table 4-2 describes each of the variables of the model, while Table 4-3 
describes each subscript and superscript.  The physiologic diagrams of each metabolic 
species are shown in Figures 4-9 through 4-15.  The initial physiologic equations will 
likely be eliminated upon simplification and identification with data.  Initially, the total 
concentration of each species is assumed to be divided among the ionized version of each 
species, the form of the species bound to receptors, and the unbound form.  Most 
physiologic models developed [2], [9], [12] have assumed that the different species exist 
only in free form.  For completeness, all three terms will be left unless noted.  In addition, 
mass transfer between compartment spaces is left in its general flux form.  
Simplifications such as those used by Sorensen [2] and others developing physiologic 
models can be easily applied to further simplify the expressions. 
 Glucose has previously been described as having appearance in the form of 
endogenous production and disappearance in the form of cellular uptake for fuel or 
storage.  Specifically, endogenous glucose production occurs in the liver primarily.  
Uptake occurs in the liver, the brain, the muscle and fat cells, the gut, and the red blood 
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cells in circulation.  Glucose also diffuses into the pancreas to promote insulin secretion.  
The overall glucose model is shown in Figure 4-9.  To describe this process, Equation 
(4.26) describes the overall glucose balance in circulation.   
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  (4.26) 
 
Each tissue compartment is assumed to have three separated compartmental spaces, each 
with its own uniform concentration of the species, and each able to transport materials to 
and from adjacent spaces.  The glucose equations for the brain compartment spaces are 
given by Equations (4.27) through (4.29).  The brain is known to have a specific daily 
glucose requirement, and as such, the brain utilization rate of glucose can be assumed to 
be a constant. 
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 The liver is the site of glucose production, and is a primary site of insulin-
dependent glucose uptake.  These rates are also dependent on the glucagon and 
epinephrine levels. The glucose balances for the insulin compartment spaces are given by 
Equations (4.30) -(4.32).   
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,     (4.32) 
 
 The kidneys are able to utilize glucose without hormone mediation.  However, as 
glucose levels increase above a threshold value, kidney excretion of glucose become an 
important metabolic sink.  The kidney glucose mass balances are given by Equations 
(4.33)-(4.35). 
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    (4.35) 
 
 When glucose levels are in excess, beyond what the body needs for cellular 
processes and beyond the maximum that can be used for glycogen synthesis and storage, 
the additional glucose is taken into the adipose tissue and converted to fat.  When fuel is 
needed, the fat will then be converted to fatty acids.  The adipose tissue glucose balances 
are given by Equations (4.36)-(4.38). 
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 As was previously mentioned, muscle is one of the two primary locations for 
glycogen storage.  Muscle, along with the liver, is a site at which glucose uptake must be 
insulin mediated.  Epinephrine also affects the rate of glucose uptake into the muscle 
cells.  The glucose mass balances for muscle tissue are described by Equations (4.41)-
(4.43). 
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,     (4.43) 
 
 The gut is the primary location of glucose absorption from a meal.  In addition, 
Sorensen [2] has concluded that the gut itself has a constant glucose requirement, further 
increasing the necessity that it be included as a physiologic compartment of interest.  The 
gut glucose mass balances are given by Equations (4.44)-(4.46). 
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,    (4.46) 
 
 Lastly, with respect to glucose, the natural insulin response of the pancreas 
regarding glucose control is initiated by glucose uptake into the pancreatic cells.  
Therefore, the pancreas will be considered a tissue of interest for a healthy patient.  
Although no insulin secretion is expected to occur, the uptake of glucose into pancreatic 
cells would still be expected in a Type I diabetic patient.  The pancreas glucose mass 
balances are given by Equations (4.47)-(4.49). 
 


































     (4.47) 

























































,     (4.49) 
 
 The glucose model consists of 24 dynamic mass balance equations.  This number 
is considerably greater than the number in the Sorensen model [2] for three reasons.  
First, Sorensen was able to reduce the number of compartmental space equations by 
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investigating the mass transfer between adjacent compartments.  When mass transfer was 
determined to be extremely fast relative to the other rates in the process, the two 
compartments were assumed to be in equilibrium and were considered to be a single 
compartment.  Second, Sorensen considered the pancreas to be a part of the liver, and as 
such did not develop balances for it.  Finally, Sorensen lumped adipose and muscle tissue 
together, designating it as the periphery.  Because this model takes into account fatty acid 
dynamics, this lumping has not been performed. 
 Fatty acids appear in the body as a result of either ingesting a fatty meal or from 
the endogenous production from the breakdown of triglycerides.  They are eliminated by 
utilization by cells when glucose is low, or by being consumed for gluconeogenesis.  
Physiologically, fatty acid metabolism occurs in the blood, the adipose tissue, the liver, 
the gut, and perhaps the kidneys and the pancreas.  Figure 4-10 shows the fatty acid 
compartmental diagram.  The overall blood fatty acid balance is given by Equation 
(4.50). 
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   (4.50)  
 
 The liver is a primary site of importance for fatty acid metabolism.  It is one of the 
two locations of fat storage in the body.  It is also the primary site of gluconeogenesis.  
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Metabolically, this means the both fatty acid uptake and fatty acid production occur in the 
liver.  The liver fatty acid mass balances are given by Equations (4.51)-(4.53). 
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,    (4.53) 
 
 The kidneys are assumed to be a site of significance because of the general 
filtration and reabsorption that occurs with all blood substances.  While it is likely that 
most or all fatty acids would be reabsorbed into the blood upon filtration, the equations 
are still included for completeness, and a decision to eliminate them should be based on 
experimental data in which kidney fatty acid filtration and reabsorption have been 
measured.  In addition, at low glucose concentrations, fatty acids would be the primary 
fuel source for kidney function to continue.  The kidney fatty acid mass balances are 
given by Equations (4.54)-(4.56). 
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 The adipose tissue is the second primary site of importance for fatty acid kinetics.  
Like the liver, fatty acids are stored as triglycerides in the adipose tissue.  When glucose 
levels are low, the triglycerides are converted back to fatty acids and released to be used 
both the body’s cells as fuel and by the liver for gluconeogenesis.  The adipose tissue 
fatty acid balance is given by Equations (4.57)-(4.59). 
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,    (4.59) 
 
 Like glucose, exogenous fatty acid appearance will likely occur as a result of a 
meal.  During digestion, the fats of the meal will be broken down to form fatty acids.  
While the gut likely does not utilize fatty acids during normal conditions, they are the 
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primary fuel source at hypoglycemic conditions.  The gut fatty acid mass balances are 
described in Equations (4.60)-(4.62). 
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,    (4.62) 
 
 To pump blood throughout the body, the heart derives its energy primarily from 
fatty acids.  Therefore, the heart represents a significant source of fatty acid utilization.  
The heart fatty acid balance is given by Equations (4.63)-(4.65).   
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 The resulting fatty acid physiologic model consists of 16 transient mass balances.  
Although the primary sites of importance regarding fatty acid metabolism have been 
listed, other tissues could be included during hypoglycemia conditions.  While the brain 
and the red blood cells cannot use fatty acids as fuel for ATP generation, nearly every 
other cell can.  Therefore, balances for the pancreas and for muscle tissue are included in 
order to model fatty acid metabolism during hypoglycemia and exercise.  Pancreatic fatty 
acid is described in Equations (4.66)-(4.68), and the muscle tissue fatty acid balance is 
described by Equations (4.69)-(4.72).   
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 The overall fatty acid model consists of 22 differential equations, excluding any 
differential equations associated with the metabolic sources or sinks.  Nearly all the 
sources and sinks are likely considered constant, with the exception of those involved 
with the liver and adipose tissue.  Both of those are likely functions of glucose, fatty 
acids, and glucagon, which is known to increase fatty acid production and inhibit liver 
fatty acid uptake.  Uptake is also a function of insulin, as high insulin values are known 
to also promote fat storage in adipose and liver cells.   
 Amino acids are known to appear as a result of ingesting proteins in food.  They 
are also produced endogenously by the breakdown of proteins in various cells.  They are 
taken into the body primarily for protein storage but also for the purpose of 
gluconeogenesis.  During starvation, when glucose and fatty acids are not available, 
amino acids become the primary source of fuel.  However, given that such a condition 
requires days of starving, amino acids as fuel will not be considered.  The primary sites of 
importance for amino acid metabolism are the blood, the liver and kidneys, the gut, and 
the pancreas.  The physiologic diagram of amino acids is given in Figure 4-11.  Equation 
(4.72) describes the overall amino acid balance in blood. 
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 Certain amino acids are known to affect pancreatic hormone secretion.  Arginine 
and lysine are known to potentiate the glucose stimulus for insulin secretion.  Arginine 
and alanine are known to stimulate glucagon secretion directly.  Because of these effects, 
it is assumed that amino acids are being taken into the pancreas in order to produce the 
observed responses.  Amino acid kinetics at the pancreas are described by Equations 
(4.73)-(4.75). 
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,     (4.75) 
 
 Amino acids do not exist in large quantities in the body.  Instead, they are 
primarily stored as proteins throughout body’s many cells and tissues.  There also exist 
plasma proteins that are used for various metabolic functions.  When there is a deficiency 
in a particular plasma protein, it is quickly synthesized.  Proteins of various tissue cells 
are converted to amino acids.  These are then released to the blood and taken up by the 
liver, where the protein is synthesized and released to the plasma.  Because of this, the 
primary site of amino acid activity is the liver.  The liver is able to take in large amounts 
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of amino acids and store them as proteins.  The liver is also the site of gluconeogenesis. 
The mass balances for amino acids in the liver are given by Equations (4.76)-(4.78). 
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,     (4.78) 
 
 The kidneys are also able to store large amounts of proteins that can be easily 
converted to amino acids when needed, although to a lesser extent than the liver.  In 
addition, the kidney is routinely filtering and reabsorbing amino acids.  Like glucose, 
excess amino acids are lost in the urine.  The amino acid balances of the kidneys are 
given by Equations (4.79)-(4.81). 
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,   (4.81) 
 
 The gut is a region of significance because of the appearance of amino acids from 
a meal.  In addition, there will also be a small amount of protein storage resulting from 
amino acid uptake.  The gut amino acid kinetics are described by Equations (4.82)-(4.84). 
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,    (4.84) 
 
 The overall amino acid model has thirteen dynamic equations.  Most of the 
metabolic terms will be functions of insulin and glucagon.  Insulin decreases endogenous 
production and gluconeogenesis, while glucagon promotes gluconeogenesis.  Insulin 
must also be present for protein formation to occur, meaning that its presence results in 
increased amino acid uptake.  Finally, gluconeogenesis will only occur at low glucose 
levels, meaning that glucose levels will also play a role in amino acid metabolism. 
 The given physiologic equations up to now describe the kinetics of the three 
metabolic species glucose, amino acids, and fatty acids.  Also of importance are the 
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different hormones regulating these species.  Insulin appears endogenously via the 
pancreas or exogenously from a delivery system.  It is degraded at its primary action 
sites, the muscle and liver cells, and is also cleared at the kidneys.  These are the regions 
of significance for insulin, as shown in Figure 4-12.  The overall insulin balance in blood 
is given by Equation (4.85).  Insulin is known to circulate in an unbound form [10], so the 
bound terms have been eliminated from this model. 
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LL     (4.85) 
 
 The pancreas is the site of insulin secretion.  The secretion is known to be a 
function of glucose, amino acids, and GLP-1.  All cells at which insulin action does not 
occur are assumed to degrade insulin by the enzyme insulinase.  Therefore, insulin 
degradation is also included at the pancreas.  The pancreas mass balances for insulin are 
given by Equations (4.86)-(4.88). 
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 Insulin action primarily occurs at the liver, where the metabolic processes of 
glucose, amino acids, and fatty acids take place.  It is here that nearly 40% of the insulin 
produced is eliminated via degradation upon binding to liver cells.  The liver insulin 
balances are shown in Equations (4.89)-(4.91). 
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 Insulin action also occurs at the muscle cells, where glucose uptake is facilitated 
by insulin binding.  Like the liver, muscle cells degrade insulin upon the completion of 
the action.  The muscle insulin balances are given in Equations (4.92)-(4.94). 
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,     (4.94) 
 
 In addition to the action sites, insulin is degraded at a slight level in nearly all 
tissues, including the heart, the gut, and the adipose tissue.  For simplicity, these slight 
levels of degradation will be assumed to be lumped into kidney, where the majority of 
insulin degradation occurs via the enzyme insulinase.  For completeness, these regions 
could be modeled, and are shown on the physiologic diagram.  The insulin balances for 
the kidneys are given by Equations (4.95)-(4.97). 
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 The overall insulin balance consists of thirteen equations as a result of reducing 
the insignificant effects of the gut, heart and adipose tissue.  To simulate the effects of 
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oral insulin formulations, the gut could be included.  To account for Type I diabetes, the 
pancreatic insulin release term can be eliminated, and an exogenous source term could be 
added.   
 Glucagon has physiologic kinetics very similar to insulin.  It is produced in the 
pancreas, in response to glucose and amino acids.  It also is affected by insulin secretion 
from the pancreas.  It is degraded primarily at the action sites of glucagon, including the 
liver and adipose tissue.  It is also degraded at the kidneys.  The physiologic diagram of 
glucagon is shown in Figure 4-13.  The overall balance of glucagon in the blood is given 
by Equation (4.98). 
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 The pancreas is the site of glucagon production.  As previously mentioned, this is 
a function of pancreatic insulin, glucose, and amino acids.  The pancreas glucagon mass 
balance is described by Equations (4.99)-(4.101). 
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,     (4.101) 
 
 The liver is one of the primary action sites for glucagon.  Glucagon causes the 
liver to increase the rate of gluconeogenesis.  It also suppresses the rate of fatty acid 
uptake to form triglycerides.  Upon action, glucagon is degraded.  The glucagon balance 
in the liver is given by Equations (4.102)-(4.104). 
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,     (4.104) 
 
 The second primary site for glucagon action is the adipose tissue, where glucagon 
acts to increase the production of fatty acids from stored fat.  Upon the completion of its 
action, the glucagon is degraded at the cells.  The adipose tissue glucagon balance is 
given by Equations (4.105)-(4.107). 
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    (4.107) 
 
 Like insulin, nearly all glucagon that is not used by binding to cells to affect a 
metabolic process will be degraded at the kidneys.  This degradation should be 
considered a function only of the glucagon levels.  The mass balances for glucagon at the 
kidneys is given by Equations (4.108)-(4.110). 
 


































    (4.108) 

























































,     (4.110) 
 
 The resulting glucagon model has 13 dynamic mass balance equations.  This adds 
considerable complexity relative to previous efforts to model glucagon dynamics, notably 
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the one compartment glucagon model of Sorensen.  Given the ability to estimate the 
metabolic processes associated with glucagon, as well as the model parameters, this 
model should represent a significant advancement from previous models. 
  Epinephrine becomes a hormone of significance when glucagon levels are 
insufficient to increase glucose levels to normal.  It is secreted primarily from the adrenal 
medullae, and acts directly on liver cells to increase gluconeogenesis and inhibit uptake 
[11].  It is also able to act at the pancreas to inhibit insulin secretion and increase 
glucagon secretion.  To allow the body to perform properly, fatty acid production is 
increased in the liver and adipose cells.  Finally, during exercise epinephrine acts on the 
heart to increase the flow of blood.  Epinephrine is assumed to be degraded at the target 
cells.  This is represented in the physiologic diagram for epinephrine, shown in Figure 4-
14.  Equation (4.111) shows the overall epinephrine balance in the blood.   
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  (4.111) 
  
For simplicity, the adrenal medullae, which is part of the sympathetic nervous 
system, has been lumped with the brain only for labeling purposes.  Thus, the superscript, 
Br, as shown in Table 4-3, represents the brain and adrenal medullae.  This is the site of 
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epinephrine secretion.  The adrenal medullae epinephrine balance is given Equations 
(4.112)-(4.114). 
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,     (4.114) 
 
 All tissues affected by epinephrine are assumed to be a site of epinephrine 
degradation.  These tissues include the liver,  muscle and adipose tissue, the pancreas, 
and finally the kidneys.  The balances for muscle tissue are given by Equations (4.118)-
(4.120) and the balances for adipose tissue are given by Equations (4.121)-(4.123).  The 
balances for the pancreas are given by Equations (4.124)-(4.126), and finally, the 
balances for the kidney are shown in Equations (4.127)-(4.129). 
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,     (4.129) 
 
 The resulting epinephrine model consists of 19 differential equations.  The 
metabolic processes affected by epinephrine are assumed to be affected by the blood 
levels of the hormone.  Secretion is assumed to be a function of glucose, glucagon, and 
the exercise level of the individual.  High levels will result in increased secretion.  
Finally, while blood flow rates will likely have to be estimated from literature values, 
they can be modeled as a function of the epinephrine levels, to account for the fact that 
epinephrine causes the heart to increase blood flow.    
 The final hormone to model is GLP-1.  It is produced in the gut region and acts to 
increase insulin secretion by binding to the pancreatic beta cells directly [16].  
Elimination occurs at the target cells, and blood GLP-1 is eliminated primarily through 
degradation via the kidneys.  The hormone also plays a role in glucose production in the 
liver and fatty acid production in the adipose tissue.  These regions are therefore 
considered the compartments of significance.  Figure 4-15 shows the physiologic diagram 
for GLP-1.  The overall balance in blood is given by Equation (4.130). 
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The primary degradation site of GLP-1 is the kidneys.  It is assumed that the 
degradation rate is a function of GLP-1 concentration only.  Equations (4.131)-(4.133) 
show the kidney GLP-1 mass balances. 
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   (4.133) 
 
 The gut region is where GLP-1 is secreted in response to a meal.  This secretion is 
assumed to be a function of the meal eaten, such as the size and composition of the meal.  
The balance equations for gut GLP-1 are given by Equations (4.134)-(4.136) 
 
  101 







































   (4.134) 







































































   (4.136) 
 
 The remaining sites, including the pancreas, adipose tissue, and liver, are 
considered important because of the actions performed by GLP-1 at these sites.  It is 
assumed that each intracellular space is a site of degradation for the hormone, and the 
balances have been written to reflect this.  Equations (4.137)-(4.139) show the GLP-1 
balance in the pancreas, followed by the liver with Equations (4.140)-(4.142).  Finally, 
the adipose tissue GLP-1 balances are given by Equations (4.143)-(4.145). 
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 The overall model consists of 120 mass balance equations.  In addition, there will 
be differential or algebraic relationships for each metabolic source or sink term.  This 
system, if fully developed through parameter identification and simplifications, will be 
the most complete description of glucose homeostasis that has been developed. 
 
4.3.3 Metabolic Sources and Sinks 
The metabolic source and sink terms have been left in a general form.  Without 
data, the exact form of the terms cannot be determined.  However, the representation of 
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the metabolic processes of previous models provides a foundation of possible 
representations that will be discussed here for use with data when it becomes available.   
Perhaps the simplest representation of each source or sink is a simple rate law that 
is a particular order with respect to each species known to affect the process.  Most 
commonly, kinetic rates are assumed to be first order with respect to each species 
involved.  The general representation is shown by Equation (4.146). 
 
( ) ( ) ( ) ( )tGtEtAtF)t(S)t(I)t(G)t(kr gfedcbai 1=   (4.146) 
 
Other types of kinetic relationships, including Michaelis-Menten and additive 
relationships have also been used to describe the rate, and could be considered as possible 
descriptions.  Others have made use of a nonlinear equation in which the basal rate is 
multiplied by dimensionless multiplicative terms described by each influencing species.   
 
1G,iE,iA,iF,iG,iI,iS,ibasal,ii MMMMMMMrr =    (4.147) 
 
Where Mi is the multiplicative function in each variable for metabolic process i.  Each M 
will have associated parameters that must be estimated.  It may also be necessary to 
describe the nonlinear functions as differential equations describing the binding a 
hormone to a receptor, in which case the rate is a function of the receptor-bound species, 
which is a function of the circulation species concentrations.   
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In order to capture parameter variability, either among patients, or within a 
specific patient (from exercising, circadian rhythms, etc.), the parameters in each set, ki, 
will likely be functions of time themselves.   
Of notable exception to the above description are the descriptions for exogenous 
glucose and insulin inputs.  The exogenous glucose input will be in the form of a meal, 
and the term will be used to describe glucose absorption from a meal.  Similarly, the 
insulin infusion rate will be input by either the user in the case of an infusion pump, or by 
the release mechanism of the device.  However, for both types, the parameters will still 
be time varying to account for parameter variability.   
 
4.4 Conclusions 
Two different systems of equations have been developed to describe glucose 
homeostasis.  A pharmacokinetic model was provided, with recommendations on the 
number of compartments to develop based on the metabolic processes of each species.  A 
detailed physiological model was developed to more fully describe the process at each 
tissue region.  Finally, several possible equation forms were proposed as possible 
descriptions of the metabolism kinetics.   
The next step in the process would be to identify the model, based on 
simplifications, a literature search for parameter values, and finally, fitting model 
responses to data in order to estimate certain parameter values.  The desired data would 
show recorded observations of the all metabolites and hormones in the different tissue 
regions as a function of time.  If such data were available and parameters were estimated, 
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the developed models would have the potential to be an improvement over existing 
models in their ability to describe the glucoregulatory process.  This could lead to 
multivariable control algorithms, in which multiple metabolites are controlled by the 
precise infusion of multiple hormones.   
  It is quite possible that the physiologic model will consist of over one thousand 
model parameters, and identifying these parameters could take years by itself.  It has been 
suggested that a large number of the model parameters may be constant within specific 
classes of patients.  Such classes could be based on age, gender, ethnicity, and 
bodyweight.  If parameter values are indeed constant within patient classes, the number 
of parameters to be estimated for an individual patient could be dramatically reduced.  
However, given the size of the models, with respect to equations and model parameters, 
and the lack of appropriate data, it was decided that model identification and validation 
was outside the scope of this work.  As the focus of this work is the development of 
improved methods of glucose control, simulations will be performed on existing models 
while noting possible shortcomings of the simulation results. 








Figure 4-1: Spatial diagram of a physiologic compartment.  Each compartment has a 
blood space, where blood flows through capillaries at the region.  Species then diffuse 
into the interstitial space and then into the intracellular space, where metabolic processes 
occur.  The arrows represent mass transfer.   












Table 4-1: Pharmacokinetic Model Variables and Parameters 
Variable Definition Units 
S Plasma Glucose Concentration mmol/L 
A Plasma Amino Acid Concentration mg/L 
F Plasma Fatty Acid Concentration nmol/L 
I Plasma Insulin Concentration mU/L 
G Plasma Glucagon Concentration ng/L 
E Plasma Epinephrine Concentration nmol/L 
G1 Plasma Glucagon-Like Peptide-1 
Concentration 
nmol/L 
ri,endogenous Rate of endogenous production species dependent 
ri,exogenous Rate of exogenous input species dependent 
Mi Quantity of exogenous input species dependent 
Ki,endogenous Kinetic rate coefficients for 
endogenous input 
species, coefficient dependent 
ri,uptake/elimination rate of species disappearance species dependent 
Ki,uptake/elimination Kinetic rate coefficients for species 
disappearance 




















Figure 4-2: Pharmacokinetic model diagram for glucose.  The solid lines represent 
metabolic sources and sinks.  The dashed lines represent actions by the species on the 
metabolic source or sink.  For simplicity, each contribution toward a metabolic action is 




















Figure 4-3: Pharmacokinetic model diagram for amino acids.  The solid lines represent 
metabolic sources and sinks.  The dashed lines represent actions by the species on the 
metabolic source or sink.  For simplicity, each contribution toward a metabolic action is 























Figure 4-4: Pharmacokinetic model diagram for fatty acids.  The solid lines represent 
metabolic sources and sinks.  The dashed lines represent actions by the species on the 
metabolic source or sink.  For simplicity, each contribution toward a metabolic action is 





















Figure 4-5: Pharmacokinetic model diagram for insulin.  The solid lines represent 
metabolic sources and sinks.  The dashed lines represent actions by the species on the 
metabolic source or sink.  For simplicity, each contribution toward a metabolic action is 
represented as first order kinetics in the contributing species.  Note that for a Type I 
diabetic patient, rI,endogenous is approximately zero, and thus all actions associated with 
































Figure 4-6: Pharmacokinetic model diagram for glucagon.  The solid lines represent 
metabolic sources and sinks.  The dashed lines represent actions by the species on the 
metabolic source or sink.  For simplicity, each contribution toward a metabolic action is 















Figure 4-7: Pharmacokinetic model diagram for epinephrine.  The solid lines represent 
metabolic sources and sinks.  The dashed lines represent actions by the species on the 
metabolic source or sink.  For simplicity, each contribution toward a metabolic action is 
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Figure 4-8: Pharmacokinetic model diagram for glucagon-like peptide-1.  The solid lines 
represent metabolic sources and sinks.  The dashed lines represent actions by the species 
on the metabolic source or sink.  For simplicity, each contribution toward a metabolic 





















Table 4-2: Physiologic Model Variables and Parameters 
Variable/Parameter Definition Units 
S Glucose mmol/L 
F Fatty acids nmol/L 
A Amino Acids mg/L 
I Insulin mU/L 
G Glucagon ng/L 
E Epinephrine nmol/L 
G1 Glucagon-Like Peptide-1 nmol/L 
xi Bound form of species i dimensionless 
(i)* Ionized form of species i species dependent 
rijk Metabolic source or sink k, of 
species j in compartment i 
species dependent 
Qi Blow rate of species i in blood L/min 
wi Weight fraction of species i dimensionless 
(jA)i Mass transfer rate of species i species dependent 
Vi Compartment volume of species i L 
pi Plasma protein concentration that 
can bind species i 
species dependent 
 













Table 4-3: Summary of Superscripts and Subscripts For Physiologic Model 
Abbreviation Definition 
A Adipose Tissue 
A  
(metabolic rate subscript) 
Absorption 
B Blood Space 
Br Brain and Adrenal Medullae 
C Intracellular Space 
D Degradation 
G GI Tract 
I Interstitial Space 
K Kidneys 
M Muscle Tissue 
P Pancreas 
P 
(metabolic rate subscript) 
Production (Endogenous) 
U Uptake 






Figure 4-9: Physiologic diagram of glucose metabolism.  Each compartment is divided 
into the blood space, where blood flows, and the interstitial/intracellular space below the 
blood space.  Inlet arrows at each compartment represent species appearance, while outlet 



























Figure 4-10: Physiologic diagram of amino acid metabolism.  Each compartment is 
divided into the blood space, where blood flows, and the interstitial/intracellular space 
below the blood space.  Inlet arrows at each compartment represent species appearance, 



















Figure 4-11: Physiologic diagram of fatty acid metabolism.  Each compartment is divided 
into the blood space, where blood flows, and the interstitial/intracellular space below the 
blood space.  Inlet arrows at each compartment represent species appearance, while outlet 





















Figure 4-12: Physiologic diagram of insulin metabolism.  Each compartment is divided 
into the blood space, where blood flows, and the interstitial/intracellular space below the 
blood space.  Inlet arrows at each compartment represent species appearance, while outlet 
























Figure 4-13: Physiologic diagram of glucagon metabolism.  Each compartment is divided 
into the blood space, where blood flows, and the interstitial/intracellular space below the 
blood space.  Inlet arrows at each compartment represent species appearance, while outlet 






















Figure 4-14: Physiologic diagram of epinephrine metabolism.  Each compartment is 
divided into the blood space, where blood flows, and the interstitial/intracellular space 
below the blood space.  Inlet arrows at each compartment represent species appearance, 
























Figure 4-15: Physiologic diagram of glucagon-like peptide-1 metabolism.  Each 
compartment is divided into the blood space, where blood flows, and the 
interstitial/intracellular space below the blood space.  Inlet arrows at each compartment 
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CHAPTER 5 
 




 While the development of model equations to be used for prediction, data 
interpretation, and simulation is important, the model will not be able to give meaningful 
predictions unless its parameters are accurately determined.  For patient modeling, this 
can often mean finding average parameter values in literature, such as the dog kinetic 
parameters used by Bolie [1], or the organ volumes and blood flow rates of dogs used by 
Tiran [2,3] or humans, as used by Sorensen [4].  More often, however, patient parameters 
will have to be identified by fitting the model to patient data and selecting reasonable 
parameter values that give the closest fit to the data.   
 In the previous chapter, two different model frameworks were developed to 
describe the dynamics of the different biochemical species throughout the body.  The first 
was a pharmacokinetic model, in which each species, with the exception of insulin, was 
assumed to be uniform in a single circulatory compartment.  The second was a 
physiological-based model, in which the significant organ tissues were determined to be 
compartments needed for each species.  Elimination and appearance within each 
compartment was to be described by either first order kinetics of the different species, by 
the dimensionless multiplicative factors of Sorensen’s model, or by use of system 
identification techniques.   
 Unfortunately, the lack of patient data makes it impossible to identify a) the 
number of compartments of the different species for the pharmacokinetic models, and b) 
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the best representation of appearance and elimination kinetics.  While literature data may 
have been acquired to try to determine certain parameters, it was decided that the task of 
searching for literally hundreds of values of volumes and flows for the physiological 
model would be a chore that at worst may end up incomplete and at best may end up 
describing a model that is still not able to be validated without patient data.  Because 
patient data was not able to be acquired in this research, the developed model frameworks 
cannot be taken any further. 
 There are, however, other aspects of model identification that can be explored.  
Parameter identification is in effect a parameter optimization.  Parameters are normally 
chosen to minimize an objective function the data to the model prediction, often while 
satisfying physical constraints.  Most often, the objective function chosen is the sum of 
the squares of errors in the model fit relative to the data, as given by Equation (5.1). 
 
( )( )∑ −=Φ
i
ii xŷy
2     (5.1) 
 
In Equation (5.1), yi is the actual dependent variable value when the independent variable 
is at xi.  The term ŷ(xi) is the model prediction for the same independent variable value.  
As an optimization problem, an initial guess is required in order to search for the optimal 
set of parameters.  Often when optimal parameter sets are given, they are given without a 
discussion of the initial guess used and without a discussion of the uncertainty of the 
parameters.  Rawlings [5] provided a review of parameter estimation of crystallization 
models and found that not only were confidence intervals not being reported, but those 
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intervals, once determined, were often so large that there was no real certainty associated 
with the reported parameter values. 
 In this chapter, identification of kinetic parameters from a simple pharmacokinetic 
insulin model is investigated.  Using a set of generated test data, the ability of a least 
squares optimization routine to estimate the model parameters is explored.  The effect of 
different choices of initial guesses is studied, as well as confidence limits associated with 
the optimal parameter values.  To improve parameter estimation, the use of stiff vs. non-
stiff solvers is investigated, and the improvement in model identification as a result of 
including parameter sensitivities in the optimization routine is studied.   
  
5.2 Methods 
5.2.1 Model Selection and Test Data Generation 
To show the estimation methods for a specific set of data, the pharmacokinetic 
insulin model of Hipszer, Joseph, and Kam will be used [6].  The authors proposed a 
compartmental model for insulin dynamics as shown in Figure 5-1.  Compartments two 
and three are additional compartments that were proposed.  The model equations are 
given by Equations (5.2)-(5.5) below. 
 




1    (5.2) 




2 −=        (5.3) 
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3 −=        (5.4) 
V
xy 1=          (5.5) 
 
 For the model, Aij represents the fractional kinetic elimination rate of insulin from 
the jth compartment to the ith compartment.  Compartment zero represents degradation.  
The model, as defined, consists of three compartments.  To decrease the number of 
compartments, the kinetic rates associated with compartments two, three, or both, are set 
to zero.  The state variable xi represents the mass of insulin in the ith compartment.  The 
variable V represents the insulin distribution volume in the central compartment.  Finally, 
U represents the insulin infusion rate as a function of time.   
Given the dynamic model for insulin in one-, two-, or three-compartments within 
the body, a test set of data was generated.  The initial condition of all states was set at 
zero mU.  At time zero, an insulin pump was turned on, and a step in the insulin infusion 
rate from 0 to 20 mU/min was performed.  At 150 minutes, a second step change occurs, 
with the insulin infusion rate increasing from 20 mU/min to 40 mU/min.  The model 
parameters used for the test data generation were A01 = 0.12 min-1 and V = 15 L.  All 
parameters associated with the two- or three-compartment model were set to zero, 
resulting in a set of data for a one-compartment model.  The resulting profile of the test 
data is given in Figure 5-2.  All sets of test data used for the estimations are given in 
Appendix D. 
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5.2.2 Parameter Estimation and Sensitivity Calculations 
Once the test data were generated, an optimization solver was used to determine 
the optimal values of the parameters for each model, given the test data and a set of initial 
guesses for each parameter set.  Based on the test data and the given initial guess, the 
optimization solver was used to minimize the objective function given by Equation (5.1).   
To further improve the estimation, the sensitivities of each parameter as a 
function of time and the given parameter set were determined.  The sensitivity of any 





















    (5.6) 
 
The sensitivity of the output y with respect to each parameter was determined as a 
function of time for a particular set of model parameters by incorporating the differential 




x +=     (5.7) 
 
In Equation (5.7), S is the ndxnp sensitivity matrix in which nd is the number of 
observations of the output variable y, and np is the number of model parameters.  The 
matrix fx is the mxn matrix of the derivatives of the model system with respect to the 
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individual states.  The matrix fθ is the mxnp matrix of the derivative of the model system 
with respect to the model parameters [7].  The result of the simulation was the predicted 
model response of the state variables as well as the time profile of the sensitivities.  This 
served three purposes.  First, the sensitivities give a strong indication of which 
parameters are most significantly affecting the output measured in the data, which allows 
us to determine the utility of higher order models.  Second, the sensitivity is used to 
calculate the gradient and Hessian of the system, which is used to determine the (1-α)% 
confidence limits associated with each parameter estimate.  Finally, incorporating a value 
of the gradient and Hessian into the optimization solver dramatically improves the 
precision of the parameter estimation, as will be shown later.  For various sets of 
parameter values, sensitivities as a function of time were simulated and plotted for each 
of the compartmental models. 
 
5.2.3 Confidence Limit Determination 
Once the sensitivities for each parameter were determined, the 95% confidence 
interval was determined for each parameter in order to determine a) how narrow the 
range of potential values of the model parameters is, and b) whether or not the actual 
parameter values associated with the test data fall within the interval.  The (1-α)% 
confidence interval was calculated using Equation (5.8). 
 






  (5.8) 
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In Equation (5.8), θ is the actual set of system parameters, θ̂  is the estimated parameter 
set, and α corresponds to the (1-α)% confidence limit.  F represents the F probability 
function, which can found in statistics textbooks [8] or computed with computational 
software.  H is the Hessian matrix, which is the matrix of second derivatives of the 


































~2    (5.9) 
 
Clearly, the Hessian is a npxnp matrix.  To simplify this calculation the Gauss-Newton 
approximation was used, in which the second term of Equation (5.9) is neglected.  This 
approximation usually holds very well when the model fits the data very well or when the 
second derivatives are smaller than the first derivatives [7].  Expressed in matrix notation, 
the Gauss-Newton approximation of the Hessian is then expressed by Equation (5.10). 
 
SSH T2=      (5.10) 
 









θ̂2      (5.11) 
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The estimations from the first part were performed again, this time also reporting the 
95% confidence limits and whether or not each parameter was within the range of its 
estimate. 
 
5.2.4 Estimation with Sensitivity Calculations Included 
The next improvement to the estimation procedure was to incorporate the 
calculation of the gradient and Hessian matrix into the optimization solver.  This required 
incorporating the relationship between the sensitivity matrix and Hessian, as well as the 
relationship between the sensitivity matrix and the gradient, as shown in Equation (5.12).  
 
eS T2−=Φ∇       (5.12) 
 
In Equation (5.12), Φ is the scalar value of the objective function. The vector e is 
a vector of length nd, where each element is the difference between the measured output 
and the model prediction for each time.  The estimations were again repeated for the 
different sets of initial parameter guesses for the different model frameworks.  
Estimations were also performed in which direct model correspondence was used to note 
any difficulties in estimating parameters for a higher order model when a low order 
model is used to generate test data.  For this, a new set of test data was generated, using 
the literature parameter values of the two-compartment model for the simulated test data 
[9]. 
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In order to observe how successful the estimation is with a real system, noise was 
added to the generated test data.  First, a constant noise of 5% was added.  Second, a 
random noise vector was added in order to simulate a real unknown process.  Estimation 
using the previously mentioned initial guess sets was performed a final time. 
Finally, in order to determine the validity of the estimations, simulations were 
performed for a different set of conditions.  Using six estimated parameter sets for the 
two-compartment model, using the test data of the one-compartment model, each model 
was subjected to a series of five step changes.  At time zero, the insulin infusion rate is 
increased to 15 mU/min.  At 150 min, the rate is increased to 25 mU/min.  At 300 min, 
the rate is increased to 35 mU/min.  At 450 min, the rate is increased to 45 mU/min.  
Finally, at 600 min, the rate is increased to 55 mU/min.  Each simulated was plotted on 
the same graph in order to compare the responses of the different parameter sets to the 
same input set. 
 
5.2.5 Computational Methods 
To solve the systems of ordinary differential equations, the MATLAB solvers 
ode45 and ode23s were used [10].  The solver ode45 is a nonstiff solver implementing 
the 5th order Runge-Kutta Dormand-Prince pair to solve the system for each specified 
time.  The solver ode23s is a stiff solver implementing a modified Rosenbrock formula of 
order 2.  Both solvers were used for each initial parameter value set in order to compare 
the effectiveness of stiff vs. nonstiff solvers.   
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To perform the optimization, the MATLAB function “fmincon” was used to 
perform the minimization of a constrained optimization problem.  The function 
“fmincon” can be tailored to fit the desired optimization.  For our problem, a line-search 
method was incorporated into the solver as the means to search for the minimum.  
Initially the Levenberg-Marquartd [11] method is selected as the search method, but 
MATLAB switches to a line search method [12] because the solver “fmincon” is not able 
to handle constraints with the Levenberg-Marquardt method.  The MATLAB source code 
used for parameter estimation is provided in Appendix E. 
 
5.3. Results 
5.3.1 Initial Parameter Estimation 
Initially, the model parameters were estimated for the one- and  two-compartment 
insulin pharmacokinetic models by an initial guess of the parameters that was within 
±200% of the determined model parameters of similar models from literature [13], [9].  
Table 5-1 shows the estimation results for the one-compartment model.  The different 
parameter sets used as initial guesses for the two-compartment model are given in Table 
5-2, and the parameter estimation results for the two-compartment model are given in 
Table 5-3. 
Tables 5-1 and 5-3 show that the estimation of only two model parameters 
strongly depends on the initial starting values assigned to each parameter and that the task 
of estimating four model parameters is even more difficult.  Both tables show that when 
the actual parameter set is chosen as the initial guess, the routine converges quickly on 
  136 
the actual parameters, demonstrating the effectiveness of the routine.  It is not included 
here, but similar work performed for the three-compartment models resulted in the same 
observations.  The estimations for the higher order models often resulted in solutions that 
violated constraints, and given that no constraint was defined for the volume, V, in the 
model, the extremely large values associated with the optimal V show that it also is 
violating physical constraints.  Comparing the different solvers, neither solver appears to 
do an effective job of estimating the model parameters to be the actual values used for the 
test data. 
 
5.3.2 Sensitivity Studies 
The sensitivity of the output with respect to each parameter for each model was 
then determined, using the same sets of initial guesses.  For the one-compartmental 
model, the parameters of importance were A01, V, and y0.  Each was made either very 
large or very small, and the timed sensitivity profile was determined for that particular 
parameter set.  From the sensitivity profile, the relative sensitivity profile was determined 














     (5.13) 
 
The relative sensitivities are scaled to an order of magnitude of 1.  Figure 5-3 
shows the relative sensitivity profile for the parameters when A01 is 0.12 min-1, V is 15 L, 
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and y0 is 15 mU/L.  As can be seen, the model output is highly sensitive to the two 
parameters of the one-compartment model.  The spikes can be attributed to the step 
changes causing a reduction in the relative sensitivity for a brief instant before the 
sensitivities rapidly approach -1 once again. 
Figures 5-4 and 5-5 show the effects of increasing the model parameters on the 
sensitivity profile.  Figure 5-4 was generated by setting A01 to 0.6 min-1, and Figure 5-5 
was generated by setting V to 100 L.  Two observations can be made here.  First, the 
increase of the model parameters to high levels results in overshoot before the relative 
sensitivity with respect to A01 reaches the steady state value of -1.  Second, a high value 
of A01 results in a very rapid approach to the steady state sensitivity, while the large V 
value appears to slow down the approaching of the steady state.  One thing that is clear in 
all three figures, however, is that the output is highly sensitive to the two model 
parameters for both medium and high values of the parameters. 
Sensitivity calculations were also performed for the two- and three-compartment 
models.  Figure 5-6 shows the relative sensitivity profile for the two-compartment model.  
For this simulation, the parameters were set approximately to those reported in literature 
[9].  A01 was set to 0.25 min-1, A12 to 0.05 min-1, A21 to 0.06 min-1, and V to 5 L.  As can 
be seen in the figure, the additional parameters associated with the two-compartment 
model reach a steady state value of 0, while the one-compartment model parameters 
continue to approach a value of -1.  This implies that the system output is relatively 
insensitive to the additional parameters encountered by increasing the complexity of the 
model. 
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Figure 5-7 shows the relative sensitivity profile for the three compartment model.  
Again, the parameters selected were similar to those reported in literature for a three-
compartment insulin model [14].  As expected, the output is insensitive to the additional 
parameters introduced by the third compartment, A13 and A31, as the sensitivities of both 
parameters stay very near zero for the entire duration of the simulation.  The only time 
any sensitivity profile showed results counter to those showed in Figures 5-6 and 5-7 for 
the multicompartment models was when A01 was considerably smaller than A21 and A31.  
This is not typically expected, as it implies that the majority of the insulin from the 
central compartment would be going to the side compartments instead of being 
eliminated from the body.  Such a system would result in the accumulation of insulin in 
the side compartments to very high levels.  Thus, it is concluded that such parameter sets 
are unreasonable, and that reasonable parameter sets show that the output of plasma 
insulin levels appear to be relatively insensitive to additional parameters beyond those 
used for a one-compartment model.   
 
5.3.3 Confidence Limit Determination 
Using the different sets of initial parameter guesses for each model, the 95% 
confidence limits were determined.  They are shown in Tables 5-4 and 5-5 for the one- 
and two- compartment models respectively.  The interval is expressed as a percentage of 
the optimal parameter.  The parameter set number corresponds to the same set of initial 
parameters used in Tables 5-1 and 5-2. 
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Table 5-4 shows that estimation using the one-compartment model and test data 
from the one-compartment model will have fairly low confidence limits, typically lower 
than 10% of the estimated parameter value.  However, the low values also mean that in 
many instances, the actual parameter value is not within the 95% confidence limit of the 
estimated parameter value.  Such an observation casts doubt on the ability to use least 
squares to estimate parameters of dynamic systems.  Table 5-5 shows that the limits are 
much larger for the higher order model.  Parameters for the two-compartment model were 
observed to have 95% confidence limits greater than 200%, meaning that there is no real 
way to know what the parameter value is with any certainty.  Ideally, the estimation 
should produce confidence limits that are fairly narrow but that still contain the actual 
parameter value within the interval.  The values in Tables 5-4 and 5-5 show that using 
only the system of equations and the optimization routine does not result in an estimate of 
parameters that can be considered accurate with any real level of certainty. 
 
5.3.4 Parameter Estimation With Sensitivities 
 Table 5-6 shows the estimated parameter values for the one-compartment insulin 
model when sensitivities are included in the optimization routine, and Table 5-7 shows 
the confidence limits associated with the estimated parameters.  There are several 
observations that can be made.  First, the estimated model parameters are much closer to 
the actual model parameters when sensitivity calculations have been included in the 
routine.  Second, the use of ode23s, the stiff-solver, results in a nearly exact estimate of 
the model parameters, demonstrating a considerable improvement to estimation routines 
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employing a non-stiff solver.  Finally, the calculated 95% confidence limits are very 
small, with the largest confidence interval being within ±2% of the estimated parameter 
value.  For the one-compartment model, parameter estimation that employs both the 
parameter sensitivity dynamics and a stiff differential equation has demonstrated 
superiority over solvers that do not have both features. 
 To further test the effectiveness of the estimation of the one-compartment model 
parameters, different types of noise were added to the data.  The first type of noise 
assumed that each point was 5% larger or 5% smaller in value than the actual test data 
point.  The second type was random noise added to the process.  The estimation results 
for the one-compartment model are given by Table 5-8, and the associated confidence 
limits are given in Table 5-9.  The parameters were estimated very close to the actual 
parameter values in spite of the appearance of noise.  The model fits for the noisy data are 
shown in Figure 5-8 and 5-9.  Even with noise, the parameter estimation routine 
employing both a stiff solver and the parameter sensitivities is able to accurately 
determine the parameter values with low confidence intervals, regardless of the initial 
guess. 
 Table 5-10 shows the parameter estimation results for the one-compartment 
generated test data with the two-compartment model, again employing the parameter 
sensitivity equations in the optimization routine  Table 5-11 shows the confidence limits 
of the estimated parameter values.  There appears to be minimal improvement to the 
parameter estimation of the higher order model.  The optimal parameters are still highly 
dependent upon the initial guess of the parameter set.  While there is an improvement in 
  141 
the size of the confidence intervals, the actual parameter values routinely fall out of this 
95% confidence range, demonstrating the inability of the routine to be able to effectively 
estimate model parameters with any sort of certainty.   
 While estimation of higher order model parameters appears to not be improved by 
the use of sensitivities with respect to converging to the actual parameters with small 
confidence limits, Figure 5-10 shows that the actual model fit is fairly good.  Figure 5-10 
shows the fit of the two-compartment parameters resulting in the highest Φ value to the 
test data generated.  The model appears to fit the data very well, implying that multiple 
parameter sets will be able to fit the data reasonably well.   
 One reason that the two-compartment model may fit the one-compartment model 
well with multiple parameter sets is because of the general differences in the responses 
between the two models to the same input.  To investigate this hypothesis, a set of test 
data from the two-compartment model was generated using parameter set one of Table 5-
8, and the two-compartment model was used to estimate the parameters.  The different 
parameter sets used as initial guesses are given by Table 5-12.  The results of the 
estimation are given in Table 5-13, with the confidence limits for each estimation 
reported in Table 5-14.  For the case of data generated with the two-compartment model, 
like the case with the one-compartment model, the estimated parameter set is highly 
dependent on the choice of initial guess for the parameter set.  Figure 5-11 demonstrates 
that the estimated parameter set with the worst Φ value is still able to fit the data 
particularly well.   
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 An interesting observation from Table 5-9 is that the estimation routine appears to 
work very well as long as the one-compartment model parameters A01 and V are initially 
chosen to be at or near the exact values.  Having an accurate estimate of these parameters 
enables the entire parameter set to be estimated effectively, but the presence of the 
additional parameters prevents the accurate estimation of the parameter set when the one-
compartment parameters are not known accurately.  The significance of the one-
compartment parameters is not great enough, however, to estimate the one-compartment 
parameters from the one-compartment model.   
 Given the ability of the estimated parameters, whether the actual parameters or 
not, to fit the data reasonably well, the ability of the estimated parameter sets to make 
accurate predictions was investigated by subjecting the model patients to a series of five 
step changes, including changes outside the range of the test data. Figure 5-12 shows the 
results.  While the parameter sets differ considerably in some cases, the predictions are 
basically exactly the same for all the different model parameter sets.  This gives a 
stronger argument for the presence of multiple optimal parameter sets. 
  
5.4 Conclusions 
 Given a published insulin pharmacokinetic model, test data has been generated, 
and the ability of an optimization routine to effectively estimate the actual parameter set 
used for data generation was evaluated.  Parameter sets can easily be estimated for 
algebraic relations, but parameter estimation of differential equations without analytical 
solutions is not a trivial matter.  While parameter sets can easily be estimated when there 
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is no input associated with the system, the optimal parameter set of a dynamic model 
consisting of an insulin input is highly dependent on the initial guess of the parameter 
values.  The estimated parameter sets may also not be known with any degree of 
certainty, as 95% confidence limit calculations have shown. 
 Estimation can be improved for a one-compartment model by including the 
sensitivity of the output for each parameter in the estimation, and by using a stiff solver 
with the optimization routine.  This improved routine has demonstrated the ability 
determine the parameter set in different types of noise as well.  For higher order models, 
the parameter estimate is still highly dependent on the initial guess of the parameter set, 
but models generated using the estimated parameters are able to both fit the data and 
make predictions nearly equal to those of the actual parameter set, demonstrating the 
possibility of multiple parameter sets that accurately reflect data. 
 For patient models with a large number of parameters such as the physiological 
models developed in Chapter 4, model identification is best performed by using as many 
data sets as possible to identify as few parameters at a time as possible.  Clearly blood 
values of each species would not be sufficient to accurately estimate hundreds of 
parameters, as it was not sufficient to estimate even 4 parameters in a two-compartment 
model.  Literature values of parameters can effectively be used, but sensitivity studies of 
the outputs with respect to a specific parameter should be used in order to determine how 
important that value is with respect to prediction and response.  For the two-compartment 
model, plasma insulin was fairly insensitive to the two-compartment parameters, and 
estimation depended nearly entirely on the initial guess of the one compartment 
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parameters.  Given literature values of parameters that are insignificant with respect to 
output sensitivity, low order estimation problems should be formulated using as few 
unknown sensitive parameters at a time.  Finally, given literature values of parameter 
with a high degree of sensitivity, the possibility of the existence of multiple optimal 
parameter sets should give the user confidence that the value is likely reasonable enough 
to make effective predictions.  Of course the model should still be validated using a 
different set of output data.  






Figure 5-1: Diagram of the intravenous insulin pharmacokinetic model as proposed by 
Hipszer, Joseph, and Kam [6].  The central compartment represents the plasma.  This 
compartment is assumed to be constantly in exchange with two other compartments that 
do not take in or lose insulin through any means other than exchange with the central 
compartment.  The model order can be reduced by eliminating the side compartments.  
One or both can be eliminated to give a one-, two-, or three-compartment model. 
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Figure 5-2: Graph of test data for insulin as a function of time in response to two step 
changes in the infusion rate of insulin from a pump.  At time zero, the patient of known 
one-compartment model parameters is subjected to step change in insulin infusion from 
zero to 20 mU/min.  At 150 minutes, the patient is again subjected to an insulin infusion 
step change from 20 to 40 mU/min.   























Ode45 1 0.12 15 0 0.12 15 
Ode23s 1 0.12 15 0 0.12 15 
Ode45 2 0.1333 10.1 38.5 0.165 10.98 
Ode23s 2 0.1333 10.1 1.5x10-10 0.12 15 
Ode45 3 0.06 15 284 0.0597 29.5 
Ode23s 3 0.06 15 323 0.0521 33.8 
Ode45 4 0.12 22.5 560 0.0505 35.6 
Ode23s 4 0.12 22.5 6.2 0.1058 16.98 
 



















Table 5-2: Initial Two-Compartment Parameter Sets Used For Estimation 
Parameter Set A01 (min-1) V (L) A12 (min-1) A21 (min-1) 
1 0.12 15 0 0 
2 0.2 6 0.2 0.2 
3 0.1 6 0.2 0.2 
4 0.2 6 0.1 0.2 
5 0.2 6 0.2 0.1 
6 0.2 3 0.2 0.2 




























Ode23s 1 0.12 15 0 0 0 
Ode23s 2 0.229 6.7 0.0463 0.462 1060 
Ode23s 3 0.6 1.1772 0 0.4694 2.00x104 
Ode23s 4 0.318 5.67 0.273 0.433 21.1 
Ode23s 5 0.106 16.1697 0.4079 0.35 303 
Ode23s 6 0 2.12x105 0.6 4.17x10-4 8.76x104 
Ode45 1 0.12 15 0 0 0 
Ode45 2 0.19 9.47 0.6.00 0.323 3.74 
Ode45 3 0 1.60x105 0 0 8.73x104 
Ode45 4 0.219 8.22 0.599 0.523 3.01 
Ode45 5 0.153 11.8 0.6 0.1886 1.0256 
Ode45 6 0 3.46x104 0 0 8.74x104 
 






























Figure 5-3: Relative sensitivity profile for one-compartment model, with A01=0.12 min-1, 
V=15 L, and y0=15 mU/L.  Plasma insulin is highly sensitive to both parameters.  At time 
0 and 150 min, a change in the sensitivity is observed as a result of the step change in 
insulin infusion at those times.  The steady sensitivity is quickly re-established in both 
cases. 



























Figure 5-4: Relative sensitivity profile for one-compartment model, with A01 = 0.6 min-1, 
V = 15 L, and y0 = 15 mU/L.  The output insulin is highly sensitive to both one-
compartment model parameters.  A change in sensitivity is observed at time 0 and 150 
min, in response to the insulin infusion step changes.  The large elimination value causes 
the sensitivity to approach its steady state level very rapidly. 































Figure 5-5: Relative sensitivity profile for one-compartment model, with A01 = 0.12 min-
1, V = 100 L, and y0 = 15 mU/L.  Sensitivity dynamics are observed at time 0 and 150 
min in response to the insulin infusion step changes.  At high volumes, both sensitivities 
return to their steady state values very slowly. 
































Figure 5-6: Relative sensitivity profile for two-compartment model, with A01= 0.25 min-1, 
A12=0.05 min-1, A21=0.06 min-1, and V = 5 L. The output response is highly sensitive to 
the one-compartment parameters, V and A01, while the parameters added as a result of 
increasing the model order have steady state values of zero.  The output appears to be 
insensitive to the two-compartment parameters. 



































Figure 5-7: Relative sensitivity profile for three-compartment model, with A01 = 0.25 
min-1, A12 = 0.4 min-1, A13 = 0.02 min-1, A21 = 0.14 min-1, A31 = 0.04 min-1, V = 3.5 L. The 
output is highly sensitive to the one-compartment model parameters, A01 and V.  It 
appears to be insensitive to the higher order model parameters, which all have a steady 
state value of zero. 







Table 5-4:  Confidence Intervals  
For One-CompartmentModel  
Solver 
 
Parameter Set A01 (min-1) V (L) 
Ode45 1 0% 0% 
Ode23s 1 0% 0% 
Ode45 2 2% 2% 
Ode23s 2 6% 6% 
Ode45 3 11% 10% 
Ode23s 3 12% 12% 
Ode45 4 2% 2% 
Ode23s 4 1% 1% 
 







Table 5-5: Confidence Intervals 












Ode23s 1 Exact Exact Exact Exact 
Ode23s 2 92 166 308 92 
Ode23s 3 1.6x109 2.2x109 4x109 1.6x109 
Ode23s 4 244 134 442 244 
Ode23s 5 70 134 213 70 
Ode23s 6 66 80 202 66 
Ode45 1 Exact Exact Exact Exact 
Ode45 2 605 670 1834 605 
Ode45 3 Inf Inf Inf Inf 
Ode45 4 189 222 588 189 
Ode45 5 58.1 69 178 58 
Ode45 6 Inf Inf Inf Inf 
 















Table 5-6:  Parameter Estimation For One-Compartment Model,  
Using Sensitivity Calculations 
Solver 
Parameter  
Set A01 (min-1) V (L) Φ (mU2/L2) 
Ode45 1 0.12 15 0 
Ode23s 1 0.12 15 0 
Ode45 2 0.113 15.8 11.1 
Ode23s 2 0.12 14.995 3.89x10-5 
Ode45 3 .1212 14.8184 9.37 
Ode23s 3 0.1201 14.9882 2.69x10-4 
Ode45 4 0.125 14.4 11.8 
Ode23s 4 0.12 14.9953 5.5x10-5 
 
















Table 5-7:  Parameter Confidence Intervals For One-Compartment Model 





(%) V Interval (%) 
Ode45 1 0 0 
Ode23s 1 0 0 
Ode45 2 2 2 
Ode23s 2 <1 <1 
Ode45 3 2 2 
Ode23s 3 <1 <1 
Ode45 4 2 2 
Ode23s 4 <1 <1 















Table 5-8:  Noisy Data Parameter Estimation For One-Compartment  
Model, Using Sensitivity Calculations 
Noise Type 
Parameter  
Set A01 (min-1) V (L) Φ (mU2/L2) 
5% 1 0.1199 15.0137 219 
Random 1 0.1236 14.2 35 
5% 2 0.12 15 219 
Random 2 0.1234 14.2 33 
5% 3 0.1199 15.0128 219 
Random 3 0.1266 13.85 35 
5% 4 0.12 15 219 


















Table 5-9:  Noisy Data Confidence Limits For One-Compartment  
Model, Using Sensitivity Calculations 
Noise Type 
 
Parameter Set A01 (%) V (%) 
5% 1 10 10 
Random 1 4 4 
5% 2 10 10 
Random 2 4 4 
5% 3 10 10 
Random 3  4 
5% 4 10 10 
Random 4 4 4 






























Figure 5-8: Model fit for test data generated with one-compartment model and 5% bias 
for each measurement.  Model parameters are A01 = 0.119 min-1 and V = 15.01 L.  The 
model fits exactly within the data, and the estimated parameter set is nearly identical to 
the actual parameter set of the generated data without the addition of noise. 































Figure 5-9: Model fit for random noise added to test data.  Model fit is for A01 = 0.1262 
min-1 and V = 13.9 L.  This parameter set represents the worst fit to the noisy data.  The 


















Table 5-10:Parameter Estimation for Two-Compartment Model,  
Using Sensitivity Calculations 
Solver Parameter Set 
A01 







Ode23s 1 0.12 15 0 0 0 
Ode23s 2 0.246 7.32 0.578 0.6 4.23 
Ode23s 3 0.2401 7.49 0.5993 0.5999 3.78 
Ode23s 4 0.264 6.82 0.507 0.6 6.04 
Ode23s 5 0.269 6.6815 0.492 0.6 6.6191 
Ode23s 6 0.3399 5.29 0.338 0.6 16.8 
Ode45 1 0.12 15 0 0 0 
Ode45 2 0.231 7.78 0.558 0.439 9.88 
Ode45 3 0.2407 7.47 0.5548 0.4778 9.92 
Ode45 4 0.263 6.84 0.543 0.558 10.1 
Ode45 5 0.281 6.40 0.5052 0.5867 10.48 
Ode45 6 0.3744 4.80 0.32 0.6 17 
 














Table 5-11: Confidence Limits For Two-Compartment Model,  
Using Sensitivity Calculations 
Solver Parameter Set A01 (%) A12 (%) A21 (%) V (%) 
Ode23s 1 Exact Exact Exact Exact 
Ode23s 2 37 42 110 37 
Ode23s 3 36 43 111 36 
Ode23s 4 39 40 106 39 
Ode23s 5 39 40 105 39 
Ode23s 6 44 36 97 44 
Ode45 1 Exact Exact Exact Exact 
Ode45 2 47 71 169 47 
Ode45 3 48 62 163 48 
Ode45 4 50 59 150 50 
Ode45 5 48 51 134 48 
Ode45 6 41 33 88 41 






























Figure 5-10: Model fitting of two-compartment model to one-compartment test data.  A01 
= 0.34 min-1, A12 = 0.338 min-1, A21 = 0.6 min-1, and V = 5.29 L.  The model fit appears 
to be nearly on top of the plot. 













Table 5-12: Parameter Sets For Two Compartment Estimation 
Parameter Set A01 (min-1) V(L) A12 (min-1) A21 (min-1) 
1 0.2 6 0.05 0.06 
2 0.3 6 0.05 0.06 
3 0.1 6 0.05 0.06 
4 0.2 9 0.05 0.06 
5 0.2 3 0.05 0.06 
6 0.2 6 0.08 0.06 













Table 5-13: Two-Compartment Model Parameter Estimation 
Using Two-Compartment Model Test Data 
Solver Parameter Set 
A01 







Ode23s 1 0.2 6.00 0.05 0.06 0 
Ode23s 2 0.2384 5.05 0.0648 0.0937 3.89 
Ode23s 3 0.191 6.27 0.0481 0.0541 0.332 
Ode23s 4 0.157 7.6 0.031 0.034 11.2 
Ode23s 5 0.2922 4.12 0.085 0.16 14 
Ode23s 6 0.2003 5.99 0.05 0.06 0.011 
Ode45 1 0.2 6.00 0.05 0.06 0 
Ode45 2 0.239 5.03 0.0655 0.0967 3.03 
Ode45 3 0.192 6.26 0.047 0.054 0.241 
Ode45 4 0.158 7.57 0.0299 0.0288 9.44 
Ode45 5 0.2946 4.09 0.086 0.162 15 
Ode45 6 0.2005 5.99 0.0504 0.0606 0.002 
 












Table 5-14: Two-Compartment Model Confidence Limits  
Using Two-Compartment Model Test Data 
Solver Parameter Set A01 (%) A12 (%) A21 (%) V (%) 
Ode23s 1 0 0 0 0 
Ode23s 2 3 7 9 3 
Ode23s 3 1 3 3 1 
Ode23s 4 4 17 15 4 
Ode23s 5 8 12 19 8 
Ode23s 6 <1 <1 <1 <1 
Ode45 1 0 0 0 0 
Ode45 2 3 7 9 3 
Ode45 3 7 2 2 7 
Ode45 4 3 17 13 3 
Ode45 5 9 12 19 9 
Ode45 6 <1 <1 <1 <1 


































Figure 5-11: Two-compartment model fit for test data generated by two-compartment 
model.  Data parameters are A01 = 0.2 min-1, A12 = 0.05 min-1, A21 = 0.06 min-1, and V = 
6 L.  Model parameters are A01 = 0.2922 min-1, A12 = 0.085 min-1, A21 = 0.16 min-1, and 
V = 4.12 L. The model fit appears to be directly on top of the data plot. 
 
 












































Figure 5-12: Generation of data for different parameter sets of two-compartment model.  
Model parameters based on estimation of two-compartment parameters using one-
compartment test data.  All parameter sets fit on the same trajectory, with very little 
difference among the predicted profiles.  Each legend entry represents the optimal 
parameter set from that particular initial guess parameter set. 
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CHAPTER 6 
EXPLICIT CLOSED-LOOP CONTROL SIMULATIONS 
 
6.1 Introduction 
 As previously discussed, Type I diabetes is a medical affliction associated with 
the body’s inability to provide the necessary insulin to maintain normal glucose levels.  
While the metabolic pathways associated with glucose homeostasis are complex, it was 
shown in previous chapters that the system can be treated as a chemical process.  
Through either pharmacokinetic or physiologic modeling, the system’s states, inputs, 
outputs, and parameters can be formulated and identified with patient data.  By treating 
glucose metabolism as a chemical process, chemical engineering principles such as 
process control can be applied to maintain normal glucose levels. 
 An important part of the control process is the definition of all controlled, 
manipulated, and state variables.  A simple system could be one in which only one 
variable is controlled with only one output.  Specifically for glucose regulation, glucose 
would be the lone controlled variable and insulin would be the single manipulated 
variable.  A more complex system could involve maintaining all the metabolites at certain 
levels.  As discussed in previous chapters, the concentrations of other metabolites can 
affect glucose levels as well.  This multi-output control could be designed such that all 
the hormones of significance could be used as manipulated variables.   
 Effective explicit closed-loop control can only be realized when the necessary 
sensors, control algorithms, and actuators (delivery systems) are developed.  For an 
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intravenous delivery system, both the sensors and the pumps should be implantable.  
Sensors should be in place to give the values of all controlled variables at sample times 
on the order of minutes to provide minute-to-minute control of the variable.  The 
implanted pumps should be able to supply all the manipulated variables for multiple days 
in order to prevent having to refill the reservoirs too frequently.   
 The control algorithm developed will depend on the availability of measurements 
for each species as well as the ability to effectively infuse the manipulated variable 
species.  To date, most developed control methods focus on controlling glucose using 
insulin.  The lack of effective fatty acid or amino acid sensors to be implanted makes the 
use of these species for feedback measurements in multivariable control infeasible at 
present.  While recent research efforts have focused on the implementation of a control 
system utilizing glucagon, such work is relatively recent, and the large majority of 
glucose control still focuses on insulin as the single manipulated variable. 
 As discussed in Chapter 4, the use of models facilitates the investigation of 
control system effectiveness by allowing simulations to be performed that capture the 
glucose response to various conditions, including meal consumption and exercise.  By 
implementing the control algorithm as the source of insulin secretion, the effectiveness of 
the control system with respect to maintaining normal glucose levels can be investigated 
without the use of experiments. 
 This chapter investigates the effectiveness of explicit closed-loop control through 
simulations with existing patient models.  Various methods of single input-single output 
control are applied to study the effectiveness of insulin infusion algorithms with respect 
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to maintaining acceptable glucose levels in different situations encountered by diabetic 
patients.   
 
6.2 Methods 
To study the effectiveness of different control algorithms, the control algorithms 
are used to determine the infusion rate for various patient models.  The ability of the each 
controller to maintain normal glucose levels in response to meal and exercise is 
investigated by noting the glucose response and the insulin infusion profile as a function 
of time for each situation, using each model. 
 
6.2.1 Patient models 
 Three different patient models have been used to assess closed-loop controller 
performance.  The first is the minimal model of Bergman and Cobelli [1].  The modified 
form by Furler et al. [2] to describe dynamics without pancreatic insulin release is 
described by equations (6.1)-(6.3). 
 
( ) ( )( ) ( ) ( ) ( )tDtXtGGtGP
dt
tdG
b +−−−= 1    (6.1)  
( ) ( )( ) ( )( )bb ItIPXtXPdt
tdX
−+−−= 32    (6.2) 
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G is the plasma glucose concentration, X is a term proportional to the insulin 
concentration in the “remote compartment”, which represents the compartment of insulin 
action (i.e., insulin bound to liver and peripheral cells), and I represents plasma insulin 
levels.  D represents an external glucose source, such as a meal or an oral or injected 
glucose dose.  U represents an exogenous insulin source.  The parameters P1, P2, P3, and 
n represent first order kinetic elimination rates for each state variable, and V represents 
the insulin circulation volume.  The model equations are derived from the 
pharmacokinetic diagram of Figure 2-1, as shown in Appendix A.  The average 
parameter values for a Type I diabetic patient are given in Table 6-1. 
 To simulate control using an explanatory model, the Sorensen model [3] is used.  
Originally developed as a healthy patient model, it includes 3 additional ordinary 
differential equations (ODEs) to describe pancreatic insulin release as a function of 
glucose.  To simulate a diabetic patient, the pancreatic insulin release term is set to zero, 
and the three ODEs of the secretion are eliminated.  The resulting model consists of 19 
ODEs describing glucose, insulin, and glucagon dynamics throughout the different organ 
systems of the body, including the gut, brain, blood, periphery, liver, and kidneys.  The 
compartmental diagrams of the model are given in Figures 6-1 through 6-3.  The model 
parameters and their literature values are given in the appendix. 
 Finally, because of its recent gain of acceptance among control engineers, 
Hovorka’s model [4] will be used.  The model equations are given in Appendix B, and 
the pharmacokinetic diagram of the model is given in Figure 2-3.  The model’s two 
glucose compartments and three insulin action compartments correspond to what most 
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reviewers say are the most accurate pharmacokinetic descriptions of glucose and insulin, 
including Sorensen [3] and Cobelli et al. [5]. 
 
6.2.2 Meal Models 
 To describe the absorption of a meal, the description of used by Fisher [6] is 
chosen, as given in Equation (6.4). 
 
( ) ( )( )mealttbexpAtD −−=     (6.4) 
 
The parameter b represents the absorption rate of the meal.  The parameter A represents 
the size of the meal.  Because the integral of the equation from t0 to infinity gives the 
total size of the meal, A can be determined to be the following quantity: 
 
bMA meal=       (6.5) 
 
The parameter tmeal represents the time at which the meal begins digestion.  Bequette [7] 
adds a 20 minute time constant to the meal to account for the physiological process of 
digestion before the glucose begins to appear in the blood.  This time constant, 
interpreted as the inverse of the parameter b, is equal to 0.05 min-1.  When t is less than 
tmeal, the variable D is zero.   
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For Sorensen’s model, Equation (6.4) is substituted into the gut glucose equation 


















=    (6.6) 
 
The model is derived in Appendix F.  The variable Ameal represents the percent 
availability of the meal consumed.  The variable tmax represents the time, from the 
beginning of the meal consumption, for the absorption rate to reach its maximum.  This 
model represents a meal as a two compartment chain.  Each compartment has a kinetic 
elimination rate coefficient of 1/tmax.  Compartment one has no input, and is initially 
described as the amount of total available glucose.  Compartment two has the output of 
compartment one as its input, and the absorption of glucose into the blood as its output.  
The meal absorption rate is described as the concentration in compartment two multiplied 
by its rate coefficient. 
 
6.2.3 Exercise Models 
Roy and Parker [8] and Lenart and Parker [9] proposed two different exercise 
models.  Both models assumed that exercise increases metabolism, and that the increase 
in metabolic rates is best described as a function of the exercise levels, which are 
described by the current oxygen consumption levels as a percentage of maximum oxygen 
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consumption level, PVO2max.  The first description is used with the minimal model to 
match published exercise data.  It is combined with Equations (6.1) through (6.3) to give 
the total description of the patient, as shown in Equations (6.7) through (6.13) 
 
( ) ( )( ) ( ) ( ) ( ) ( ) ( )tGtGtDtGtXGtGP
dt
tdG
upprodb −++−−−= 1   (6.7) 
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tdX
−+−−= 32     (6.8) 
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The new state variables Gprod, Gup, Ie, and PVO2max represent the glucose 
production rate, glucose uptake rate, insulin removal rate, and exercise intensity, 
respectively.  Each parameter ai represents the kinetic rate coefficient for the increase or 
decrease in metabolic rate for each type of exercise enhanced process.  The parameter τex 
is the time constant for changing from one exercise level to another.  The final parameter 
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of Equation (6.13) represents the maximum exercise level that will be achieved.  The 
model is simple, basing rate increases on first or second order kinetics.  Given the 
pharmacokinetic-type description of the exercise model in [8], this model is also applied 
to Hovorka’s model.   
 The model in reference [9] was developed for use with the Sorensen model.  It is 
similar to the model in reference [8] in that it is based on PVO2max, which is also 
described by Equation (6.13) in this model.  However, there are some key differences that 
need to be mentioned.  First, the reported blood flow rates had to be modified according 
to literature of reported blood flow for different exercise levels.  Second, by the very 
nature of differences between the two model types, specifically their equations describing 
metabolism, the metabolic effects of exercise with respect to glucose production and 
uptake and insulin elimination had to be developed to fit the Sorensen model form.  To 
do this, specific dimensionless multiplicative factors representing exercise contributions 






)m(PGUM += 1     (6.14) 
 
The parameter mEM represents the mass of exercise muscle and PGUE represents the 
exercising muscle glucose uptake rate.  It is described by Equation (6.15) 
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1    (6.15) 
 
The variable τEGU is the time constant associated with increasing glucose uptake from one 
exercise level to another level.  The variable ePGUE represents the maximum uptake rate 
for a particular level of exercise.  The effect of exercise on glucose production is found 
the same way, using the basal production rate and the mass of exercising muscle.  The 
primary difference is that the production rate of exercising muscle is set equal to the 
uptake rate of exercising muscle, assuming glucagon is able to produce enough glucose to 





mPGUM += 1     (6.16) 
 
Finally, regarding insulin removal, insulin peripheral uptake was modified to account for 
the observation that uptake increases by a factor of 3.4 when 100% of a person’s muscle 
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The parameter mTM represents the total mass of muscle of the individual.  The remaining 
model parameters are defined in Appendix C.  The authors [9] modified the parameter F 
in order to maintain constant insulin uptake rates in response to increased blood flow 
rates.  All exercise parameters for the models in references [8] and [9] are given in Table 
6-2. 
 
6.2.4 Control Algorithms 
 To investigate the effectiveness of control in response to meals and exercise in 
diabetic patients, several control algorithms were employed.  The algorithms are used to 
determine the infusion parameter U(t) for each model.  Each algorithm will now be 
described. 
 The first method studied was a simple feedback control system utilizing the 
proportional plus integral plus derivative (PID) control algorithm.  The feedback process 
control diagram is shown in Figure 6-4.  The PID algorithm is described by Equation 
(6.18). 
 














           (6.18) 
 The parameter Kc is the proportional gain, τI is the integral time, and τD is the 
derivative time.  The variable y corresponds to the system outputs.  In this case y 
corresponds to the system’s glucose concentration.  The controller is based on the error in 
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y relative to its set point.  To maintain basal conditions, ysetpoint is set to be the basal 
glucose concentration.  The controller was designed for each model by subjecting the 
model to a step change in the insulin infusion rate, and then fitting the data by a first 




























   (6.19) 
 
K is the process gain, defined as the change in the output variable in response to a unit 
change in the manipulated variable.  M is the magnitude of the step change, τ is the time 
constant, defined as the time for the output to reach approximately 63% of its steady state 
value, and θ is the time delay in the process.  Given the step response data, a FOPTD 
model can be regressed.  Once the FOPTD model was determined, the controller tuning 
parameters Kc, τI, and τD were calculated using the Internal Model Control (IMC) PID 
tuning guidelines given in reference [10].  The controller tuning equations are shown in 
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The parameter τc is the desired closed-loop process time constant.  Increasing the 
value of τc results in increasingly conservative control.  For parameter tuning, τc was 
taken to be equal to the process time delay.  Once the PID tuning parameters were 
initially determined, they were tuned by increasing and decreasing the different actions in 
order meet the desired control objectives.  These objectives are discussed in the next 
section. 
The second type of algorithm used employs feedforward control.  Feedforward 
control is based on the idea that, given a known value of the disturbance, a controller can 
be designed such that corrective action is taken before the disturbance enters the process.  
Ideally, the disturbance never affects the process.  While this is not the case in reality, 
feedforward control is able to significantly reduce the effects of measured disturbances 
on a process.  Figure 6-5 shows a schematic of feedforward control, and Figure 6-6 
shows a feedforward control scheme combined with a feedback scheme. 
The feedforward control algorithm is defined by converting the patient model into 
transfer functions for the manipulated variable and the disturbance variable.  For low 
order models this can usually be performed manually.  For higher order models, such as 
the Sorensen model, it is best to develop FOPTD models for the different input variables, 
and developing the control law based on the simplified models.  Once the transfer 
functions for each input is determined, the feedforward controller is determined from 
Equation (6.23). 




GG −=      (6.23) 
 
In Equation (6.23) the variable GD represents the disturbance transfer function, and GU 
represents the manipulated variable transfer function.  As previously mentioned, this 
control setup is usually used in combination with a feedback controller.  The combined 
feedback/feedforward method was also employed as a potential control system. 
 The third type of control system employed model predictive control (MPC).  
MPC uses measurements of the system outputs and a model of the system to predict 
future state and output values.  The model predictive control block diagram is given in 
Figure 6-7.  Based on the predictions, a control scheme is given in which the value for the 
manipulated variable is determined for the next M time steps in order to bring the system 
to a desirable level.  The control scheme is determined by minimizing an objective 
function of the outputs and inputs.  Constraints can also be incorporated into the MPC 
problem in order to produce a control scheme that keeps the system within necessary 
operating conditions.  The typical setup for MPC implementation of a linear model is 

























jk uSuRuuQCxCx    (6.24) 
maxjkmin uuu ≤≤ + , j = 0, 1, …, N-1     (6.25) 
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maxjkmin yyy ≤≤ + , j = j1, j1 +1, …, j2     (6.26) 
maxjkmin uuu Δ≤Δ≤Δ + , j = 0, 1, …, N    (6.27) 
 
 Equation (6.24) represents the linear model and quadratic objective function.  C, 
H, Q, R, and S are weighting matrices, specified by the designer.  Equations (6.25) 
through (6.26) represent the system constraints.  Once the optimization problem is 
solved, the first control move is executed, and the problem is resolved at the next step.  
 As a final method of control, a physiological pancreatic secretion model was used 
to determine the body’s natural response to glucose.  For this controller, Sorensen’s 
pancreas model [3] was used.  The equations and model parameters for pancreatic insulin 
release for a healthy patient are given in the Appendix. 
 
6.2.5 Control Objectives 
 The overall objective of control with respect to insulin dependent diabetes is to 
mimic a healthy pancreas as much as possible.  In this regard, the controller should be 
able to keep glucose levels at the patient’s basal level during normal fasting conditions.  
Ideally, the patient should remain in the normal range after meal consumption and during 
exercise as well.   
 These objectives were considered when designing different controllers for 
different patient models, using average parameters.  First, the basal insulin infusion rate 
allowing glucose levels to remain at their steady-state, basal values was determined.  
Then, beginning with a simple feedback algorithm, a controller was developed to try to 
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satisfy the objectives with respect to a meal disturbance.  If the controller type was not 
successful, a different type of controller was tested.  If the controller was successful, it 
was then used to maintain glucose levels for exercise. 
 After the performance of the control strategies was determined, the model was 
investigated in order to determine why a given control strategy was or was not successful.  
With these investigations in place, different conclusions can be drawn regarding the 
ability to apply explicit process control to a diabetic patient. 
 
6.2.6 Computational Methods 
 To perform the control simulations, three different computational steps needed to 
be performed.  First, each dynamic model was programmed in order to simulate its 
behavior when no controller is present.  Second, each control system was designed.  
Finally, the control system was implemented with each patient model in order for closed-
loop simulations to be performed. 
 MATLAB was used to perform all simulations.  The MATLAB function ode45 
[12], which is based on the 5th order Runge-Kutta Dormand-Prince Pair, was used to 
solve the sets of differential equations,.  To determine the steady state insulin infusion 
rates, each state variable was set to zero, and the equations were algebraically solved to 
determine the basal state values.  Given the basal state values, the basal infusion rate 
could easily be calculated from state equations involving insulin infusion.   
For the Sorensen model, because of the nature of the equations, initialization 
required an iterative process.  The insulin basal values of the diabetic patient are assumed 
  188 
to depend on the steady state infusion rate.  The nature of the glucose equations are such 
that a plasma glucose value is needed to determine the glucose value of the other states.  
Thus, the iteration is performed for a specific infusion rate by guessing a plasma glucose 
value, using it to determine the initial values of glucose concentrations in the various 
tissues (liver, periphery, gut, etc.), and then using those values to determine if the plasma 
glucose values match.  The MATLAB source code for this initialization is provided in 
Appendix G, and Sorensen [3] discusses it more fully, including iteration diagrams. 
To design the PID controllers, FOPTD models were developed using the 
Microsoft Excel Solver to minimize the sum of squared residuals.  Sorensen provided the 
FOPTD models for his diabetic patient model in reference [3].  As previously mentioned, 
the PID parameters were determined using reference [10].  PID control was implemented 
in MATLAB by treating U(t) as the manipulated variable.  Feedforward control and 
feedforward-feedback control were implemented using MATLAB Simulink.  MPC was 
implemented using the Model Predictive Control Toolbox in MATLAB.  To simulate the 
healthy patient response, the healthy patient Sorensen model was used. 
 
6.3. Results 
6.3.1 Generation of Healthy Patient Response 
 The healthy glucose and insulin responses for a 50 g oral glucose disturbance and 
an exercise session are given in Figures 6-8 and 6-9.  The healthy model glucose response 
shows a maximum spike to slightly under 12 mmol/L.  While this is high for a meal, it is 
a reasonable expectation for a glucose load of this size, as shown by oral glucose 
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tolerance test (OGTT) data in references [3] and [13].  As glucose levels fall, they fall 
slightly below 4 mmol/L before leveling off at the basal rate.  All of this occurs within 
two hours of the ingested oral glucose load.  The healthy patient exercise model shows a 
30 minute exercise period at a moderate intensity of 60 % VO2max.  As the figure shows, 
the glucose level stays above 4 mmol/L during and after exercise.  Glucose levels fall 
slightly initially as the blood flow rates change.  This is followed by a sharp rise in 
glucose resulting from the rapid increase in glucose production relative to uptake.  After 
exercise, a short spike is observed as the blood flows return to normal.  This is followed 
by a sharp drop resulting from total glucose production decreasing much faster than total 
uptake.  As uptake rates return to normal, the steady state condition is approached. 
 
6.3.2 Control of Glucose Using the Minimal Model 
Using the model parameters of Table 6-1, the steady state insulin infusion rate to 
maintain glucose levels at 4.5 mmol/L was determined to be approximately 16.667 
mU/min.  Note that for P1 = 0 min-1, the model assumes that only insulin-dependent 
uptake occurs.  As such, any glucose in excess of what the current insulin infusion can act 
on will simply remain in the circulation.  In this way, the glucose compartment of a Type 
I diabetic patient can be considered similar to a storage tank.   
Figure 6-10 shows the simulation of a diabetic patient ingesting 50 g of glucose 
orally with only the basal infusion of insulin to enhance glucose uptake.  Upon ingestion, 
the glucose concentration approaches a new steady state at approximately 28 mmol/L.  
When insufficient insulin is available to enhance glucose uptake, nothing beyond the 
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basal glucose uptake will occur.  Because glucose-dependent uptake is assumed to be 
non-existent, the additional glucose is simply added to the circulation, as in the situation 
in which more of a substance is added to a storage tank.   
Figure 6-11 shows the glucose response to a step change in the insulin infusion 
rate.  The model clearly demonstrates the behavior of an integrating system, as the step 
change causes a continuous decline in the glucose level.  The parameters of the FOPTD 
model are given in Table 6-3, as are the PID control parameters.  The glucose response to 
the 50 g glucose ingestion with the tuned PID controller is shown in Figure 6-12.  The 
two lines included in the glucose plot represent the upper and lower limits observed by a 
healthy patient in response to the same glucose input.  The controller gain and derivative 
time were maximized to decrease the glucose excursion to as small in magnitude as 
possible.  The integral time of 3300 minutes essentially eliminates integral action.  The 
addition of integral action results in heavy oscillations in the glucose response that often 
results in severe hypoglycemia being realized, as well as steady state offset.  At the 
optimal control configuration, the glucose excursion still rises above the specified upper 
limit.  The insulin infusion rate had no upper limit, and the resulting infusion rate of 
nearly 600 mU/min is not sufficient to prevent the excursion.  The infusion rate is clearly 
above the rate of the healthy patient and my be infeasible as an upper limit for an infusion 
pump. 
Given the relatively poor performance of PID control to effectively control the 
glucose response, at even high infusion rates, feedforward control was employed in order 
to provide control before the glucose excursion is realized.  Because the feedforward 
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controller design equation is based on process and disturbance variable transfer functions, 
the minimal model was subjected to a step increase in the disturbance variable, and a first 
order plus time model was estimated from the response.  The model parameters are given 
Table 6-3.  Because there is no time delay in the disturbance model, the resulting 
feedforward equation would be physically unrealizable, as the negative delay implies the 
controller responds in anticipation of a disturbance that has yet to be measured.  The 
controller is approximated by adding the 30 minute process delay to the time constant to 
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Figure 6-13 shows the glucose response with feedforward control only, and 
Figure 6-14 shows the response when feedforward control is implemented with a PID 
controller to provide control of both the excursion and the glucose levels.  As Figure 6-13 
shows, because the controller is based only on the disturbance, there is no counter-
regulation as glucose is falling to prevent hypoglycemia.  In addition, the gain is still not 
large enough to prevent the excursion, and it appears that infusing insulin in response to 
the oral glucose at the time of appearance does not offer any advantages to PID control.   
Figure 6-15 shows that as PID control is implemented with feedforward-control, a 
tradeoff exists between the approach of hypoglycemia vs. hyperglycemia.  The originally 
developed feedforward controller, when used in conjunction with PID control, prevents 
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the hyperglycemia excursion, but at the cost of severe hypoglycemia.  Because this can 
lead to coma or death, such an occurrence is not an option in design.  To prevent this 
from happening, the feedforward controller gain was reduced by two orders of 
magnitude, and the results are nearly identical to those of PID control alone.  Therefore, 
feedforward control appears to offer no advantages to PID control. 
For the MPC controller to be developed, the minimal model first had to be 
linearized by performing a Taylor series expansion at the steady-state basal condition.  
Given the state-space model, the MPC controller is designed by selecting values for the 
weights, H, S, Q and R, the constraints on glucose and insulin infusion, and the control 
and prediction horizons. For MPC design, Q was set to 1 and R, H, and S were set to zero.  
The only constraint established was that the insulin infusion rate could not go below zero.  
Finally, both horizons were set to 14 discrete time steps, assuming a sample time of 5 
minutes.  Figure 6-15 shows the linearized minimal model MPC-controlled glucose 
response to the 50 g glucose sample.  By adjusting the control and prediction horizons, 
the controller can be adjusted to minimize the excursion or prevent hypoglycemia, but the 
minimum excursion that prevents hypoglycemia is still 20 mmol/L.  To be consistent, the 
control profile was used on the non-linearized minimal model, and the results are shown 
in Figure 6-16.  From the figure it can be seen that the actual model and the linearized 
model give quite different responses.  The actual glucose excursion is consistent with 
those previously shown for this model.  The figure also shows that control based on the 
linear model would result in severe hypoglycemia.  It is conceivable, however, that a 
nonlinear MPC controller would likely be better able to handle the hypoglycemia, as the 
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linear controller applied was not adjusting in real time as a nonlinear controller would.  
The linear controller could be adjusted in real time for the linear model, but only the data 
record of the linear profile was used for the nonlinear model.  Regardless, both 
controllers were still unable to prevent hyperglycemia while using perhaps infeasible 
insulin rates, meaning that MPC controlled glucose poorly. 
Finally, the nonlinear pancreas model of Sorensen [3] was used to simulate a 
controller that emulates human behavior.  It should be noted, however, that an 
investigation of the pancreas model reveals that pancreatic insulin release is simply being 
modeled as a nonlinear proportional-plus-derivative (PD).  Nonetheless, given its success 
in predicting OGTT responses in healthy patients, it was employed in its exact form, as 
shown in Figure 6-17.  Both hyperglycemia and severe hypoglycemia are predicted, 
meaning that either the Sorensen pancreas is not an accurate portrayal of the healthy 
pancreas, or that certain shortcomings of the minimal model prevent it from being 
controlled, even by natural means.   
While it is possible that neither model is adequate, there are shortcomings to the 
minimal model that may render control impossible.  First is the assumption that P1 is zero 
for a Type I diabetic patient.  This parameter set was given by Furler et al. [2] and has 
been used by other control engineers, including Fisher [6], Ollerton [14], and Bequette 
[7].  As previously mentioned, this implies that glucose can neither be produced nor taken 
up independently of insulin.  Both Sorensen and Hovorka assume that glucose can 
contribute to uptake and production in the absence of insulin, and both models are 
preferred to the minimal model today.  Allowing P1 to be nonzero would naturally lead to 
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increased glucose uptake at high insulin, as well as increased production at low insulin.  
Also problematic with the minimal model is that the single kinetic rate coefficient for all 
insulin binding, P3, is consistently on the order of 10-4 min-1, a full two orders of 
magnitude slower than other processes.  This leads to the 30 minute time delay as seen by 
the FOPTD regression.  Sorensen and Hovorka improve upon this by including multiple 
action terms, which allow certain processes to occur much quicker than others, as binding 
is not considered slow for each process.  From a control standpoint, this could be 
overcome by being able to adjust the manipulated variable before the disturbance is 
encountered, such as through the priming bolus that nearly every successful control 
implementation with the minimal model has used.  This could also be used to provide 
feedforward control if the controller was able to measure the disturbance in real time, but 
the disturbance was subject to some time delay that prevented it from affecting glucose 
immediately.  Physiologically, this may be what the incretins, especially glucagon-like 
peptide-1, are actually doing.  Perhaps by being released in response to glucose in the gut, 
and then causing insulin release, insulin is being released into the blood before the 
glucose has been passed from the GI tract. 
 
6.3.3 Control of Glucose Using the Sorensen Model 
The Sorensen model for a diabetic patient is unique in that the steady state 
conditions are a function of the steady state infusion rate.  This is in contrast to the 
minimal model, in which a specific rate is given for a specific basal set of conditions, and 
the integrating behavior of the model results in the rapid increase or decrease in glucose 
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concentration.  To remain consistent, the basal condition of 4.5 mmol/L and 15 mU/L 
were chosen for glucose and insulin respectively.  Trial and error was then used to 
determine which steady infusion rate yielded this basal condition.  The basal insulin 
infusion was found to be approximately 21.45 mU/min. 
Figure 6-18 shows the Sorensen model glucose response to a 50 g glucose source.  
By inspection of the figure, two things are evident.  First, there is no integrating behavior, 
as the glucose level is restored to normal in spite of only the basal insulin.  This shows 
that glucose is able to mediate uptake independently of insulin.  Second, the excursion is 
minimal, already lower than any controller was able to achieve for the minimal model.  
Given the relatively low magnitude of the excursion, the first type of control attempted 
was simply proportional control, without any integral or derivative action.  The response 
with this controller is shown in Figure 6-19 with a controller gain of 13 
(mU/min)/(mmol/L).  The Sorensen model is easily controlled using the simplest control 
algorithm that can be developed.  Neither hyper- nor hypoglycemia are ever approached, 
and the maximum insulin infusion is less than even the maximum of the pancreas model 
used to describe a healthy patient.   
The ease at which the Sorensen model is controlled can be explained by an 
investigation of the model glucose response at steady state with no insulin infusion, as 
shown in Figure 6-20.  Given no insulin, the Sorensen model predicts a glucose 
concentration below 10 mmol/L.  In reality, untreated Type I diabetic patients typically 
achieve glucose levels between 20 and 70 mmol/L [15].   Given this discrepancy, the 
Sorensen model appears to overestimate the effect of glucose levels on the body’s 
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glucose uptake rates into liver and muscle cells, as less insulin is required to bring 
glucose to a certain level than is expected in a patient.   
Mathematically, these shortcomings appear in the liver glucose uptake equations 
and curve fitting of Sorensen’s development work [3].  First, an investigation of the 
Sorensen model plots of the effect of glucose on uptake shows that the data does not fit 
the mathematical representation, with the model predicting nearly twice the glucose 
uptake than what was observed in data for high glucose values.  Second, data were not 
used to fit the insulin contribution to uptake.  Assumptions based on canine studies were 
used to develop the equation specifying that tripling the insulin concentration results in a 
doubling of the uptake rate over time.  Finally, a plot of the predicted uptake vs. actual 
uptake shows a poor fit, in which the predicted uptake is usually greater than the actual 
uptake observed.  Given the ease of control and the physiological shortcomings, the 
Sorensen model was not used in further studies in this work. 
 
6.3.4 Control of Glucose Using the Hovorka Model 
The steady state initial condition was determined by defining the basal glucose 
level, and then setting each dynamic equation to zero.  The basal insulin infusion was 
found to be 7.3 mU/min.  Given the basal condition, the model glucose response to the 50 
g glucose ingestion with a basal amount of insulin being provided is shown in Figure 6-
21.  Like the Sorensen model, glucose mediated uptake does appear to play a role in 
naturally decreasing glucose levels in response to the input.  However, the process is 
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more gradual than that shown by the Sorensen model, implying that role of glucose in 
uptake is not emphasized as strongly as it is by the Sorensen model. 
Given the small magnitude of the glucose excursion, proportional control was 
initially employed to try to control the process.  The results are shown in Figure 6-22.  
Simple control based only on a proportionality of the glucose residuals is shown to be all 
that is needed for tight glucose control.  Neither hyper- nor hypoglycemia are 
approached, and glucose values are brought to normal very rapidly.  Figure 6-24 show the 
controller’s ability to regulate glucose during 30 minutes of moderate (PVO2max = 60) 
exercise.  Two observations can be made regarding the figure.  First, it appears that a new 
steady state is reached after exercise.  Mathematically, this results from the glucose 
uptake rate being modeled much slower than the rate used in the exercise model used 
with the Sorensen model.  If the model parameters were modified to match the 
physiological considerations used in Parker’s other exercise model, this offset would not 
occur, as the glucose levels would return to normal much faster.  Second, even with the 
offset, the change in glucose from the basal level is minimal, showing that the controller 
is able to maintain normal levels during both meals and exercise. 
The ease of control with the Hovorka model brings into question the validity of 
the model.  If the model is indeed accurate, then how inaccurate can the Sorensen model 
actually be when very similar simulation results were produced?  One major difference 
between the models is that when insulin is removed, the glucose concentration becomes 
steady at 22.4 mU/L, a quantity that is consistent with physiological observations. So 
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whether the model is inaccurate or not, the Sorensen model still has fundamental issues 
that should be resolved before its use is acceptable. 
One noticeable characteristic of the Hovorka model is the use of relatively low 
insulin values to achieve a certain glucose level.  The basal insulin level calculated for 
this Hovorka model is considerably smaller than the values determined for the minimal 
and Sorensen models, as well as the reported average values of basal secretion from the 
pancreas [14].  In addition, the amount of insulin used to reject the glucose disturbance 
was less than a third of the insulin secretion of the healthy pancreas model used by 
Sorensen.  Based on these findings, the Hovorka model may have a problem with 
overpredicting the effects of insulin on metabolism.  One difference between the model 
of Hovorka and the model used in this work is that Hovorka’s model is based on 
subcutaneous infusion, whereas the control simulations assume intravenous infusion.  
This difference was accounted for by eliminating time constants associated with insulin 
transport from the subcutaneous tissue to the blood.  It may be possible that the over 
prediction of insulin loss during the subcutaneous infusion may cancel the over-
prediction of action from the actual plasma insulin.   
 
6.4 Conclusions 
 Control of glucose during an ingestion of an oral glucose load was simulated 
using the minimal model, the Sorensen model, and the Hovorka model.  Using the 
minimal model, no method of closed-loop control proved effective at keeping glucose 
levels below a hyperglycemic limit without also experiencing severe hypoglycemia.  
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These results may be a result of assuming no glucose-dependent uptake or production of 
glucose.  The assumption of a single insulin action that is characterized by very slow 
kinetic rates results in long time delays for the model.  With the Sorensen model, control 
can easily achieved by simply using proportional control.  However, given the relatively 
low glucose values at zero insulin, as well as the poor agreement between liver glucose 
uptake data and the Sorensen uptake model, the Sorensen model has physiological 
shortcomings that prevent the simulation results from being considered accurate. Using 
the increasingly popular Hovorka model for control simulations resulted in proportional 
control being highly effective at maintaining normal glucose levels in response to both a 
meal and exercise.  However, the ability of low insulin levels relative to pancreatic 
secretion to effectively control glucose brings up the possibility that the Hovorka may 
overestimate the role of insulin in glucose metabolism.   
 Assuming that Hovorka’s model is indeed accurate, explicit-closed loop control 
appears to be a feasible method of use in the treatment of insulin dependent diabetes 
mellitus.  However, such control will depend on other factors, including the development 
of effective implantable sensors and an implantable infusion pump.  In addition, the 
ability of the controller to handle measurement noise, sensor time delays, and delays in 
the changing the pump flow rate will also have to be investigated.  Such considerations 
do not have to be made with implicit closed-loop control, the focus of the next chapter. 







Table 6-1: Minimal Model Patient Parameters For Type I Diabetic Patients [2] 
Parameter Value Units 
P1 0 min-1 
P2 0.025 min-1 
P3 0.000013 L mU-1 min-2 
n 5/54 min-1 
V 12.0 L 
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Figure 6-1: Flow diagram of the Sorensen insulin model [3].  Material flow is 
represented by the arrows.  The dotted lines represent an interface at which mass 
transfer between intercompartmental spaces can occur.  The solid line within a 
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Figure 6-3: Flow diagram of the Sorensen glucagon model [3].  Arrows represent inflow 
and outflow of material through a compartment.  The dotted line represent an interface 













Table 6-2: Model Parameters For the Exercise Models  
For Minimal Model [8] and Sorensen Model [9] 
Parameter Model Value Units 
a1 Minimal 6.11x10-4 mmol L-1 min-1 
a2 Minimal 0.9 min-1 
a3 Minimal 5.56x10-8 mmol L-1 min-1 
a4 Minimal 7.22x10-6 mmol L-1 min-1 
a5 Minimal 0.00002 min-1 
a6 Minimal 0.00025 mU L-1 min-1 
a7 Minimal 0.009 min-1 
τEX Minimal 5/3 min 
τEX  Sorensen 5/4 min 
τEGU Sorensen 30 min 
ePGUa (PVO2max = 8) Sorensen 0 mg min-1 kg-1  
ePGUa (PVO2max = 30) Sorensen 32 mg min-1 kg-1 
ePGUa (PVO2max = 60) Sorensen 85 mg min-1 kg-1 
QGL (PVO2max = 30) Sorensen 9.8 dL min-1 
QGL (PVO2max = 60) Sorensen 6.1 dL min-1 
QGK (PVO2max = 30) Sorensen 8.1 dL min-1 
QGK (PVO2max = 60) Sorensen 5.3 dL min-1 
QGP (PVO2max = 30) Sorensen 50.6 dL min-1 
QGP (PVO2max = 30) Sorensen 99.1 dL min-1 





Figure 6-4: Schematic diagram of a PID feedback control process.  At a point where two 
arrows intersect, the plus or minus indicates that the particular signal is being added or 
subtracted at the junction.  The output signal is compared to the setpoint, and a PID 
control action is taken based on this measurement to produce U.  U and the disturbance 























Figure 6-5: Schematic of a feedforward control process.  The plus signs at the 
intersection of arrows means the two signals are added.  The controller output, U, 
is determined by the disturbance.  The process then interacts with both the 



















Figure 6-6: Schematic of combined feedforward and feedback control.  The feedforward 
control signal is determined for a measurement of the disturbance, and the feedback 
control signal is based on output signal error relative to the set point.  The two signals are 
combined to give U(t), the process input.  The process interacts with the input and the 

























Figure 6-7: Schematic diagram of model predicted control.  Based on the current input, a 
model is used to predict the value of the output.  The actual measured output is used to 
determine the model residual.  The residual is used to more accurately predict future 
outputs, based on the current process input U.  Given the output setpoints and output 
predictions, the controller determines the optimal U profile to minimize a specified 
objective function.  If the disturbance can be measured, it can be used with the predictor 
to develop a feedforward-feedback controller.  If the setpoints change, the optimal 




































Figure 6-8: Sorensen model simulated response of a healthy patient to a 50 g oral glucose 
load ingested at t = 60 min.  Glucose is expected to rise to nearly 12 mmol/L, fall to 
slightly below 4 mmol/L, and return to basal rate within 2 hours of ingesting the load.  
The insulin infusion rate rises sharply to 150 mU/min before sharply falling and giving a 
proportional 2nd phase response. 







































Figure 6-9: Simulation of healthy patient glucose and insulin responses to a thirty-minute 
session of moderate (60% VO2max) exercise.  Exercise begins at 160 minutes and stops at 
time 190 min.  Maximum glucose rise is between 5 and 5.2 mmol/L, while lowest point 
on the profile is greater than 4 mmol/L, so hypoglycemia is never observed.  Insulin 
peaks at 60 mU/min, in response to increased hepatic production and higher peripheral 
blood flow.   








































Figure 6-10: Minimal model glucose profile of a Type I diabetic patient ingesting a 50 g 
glucose sample.  Ingestion begins at 200 minutes.  In the presence of no additional insulin 
beyond the basal infusion, the patient approaches a new steady state glucose 
concentration in the hyperglycemic realm. 
 
  








































Figure 6-11: Glucose response of the minimal model to a unit step increase in the insulin 
infusion rate at time 200 min.   
 







Table 6-3: First Order Plus Time Delay (FOPTD)  
and PID Tuning Parameters 
Parameter Value Units 
K -6.4 mU L mmol-1 min-1 
τ 3300 min 
θ 30 min 
τc 30 min 
Kc 12 mU L mmol-1 min-1 
τI 3300 min 
τD 40 min 
K (disturbance) 1.08x105 mU L mmol-1 
τ (disturbance) 1.08x105 min 
θ 0 min 









































Figure 6-12: PID-controlled glucose response of the minimal model to a 50 g glucose 
ingestion at time 200 min.  Kc = 12 (mU/min)/(mmol/L), τI = 3300 min, and τD = 40 min. 










































Figure 6-13: Minimal model simulation of feedforward-controlled glucose response to 50 
g glucose ingestion at time 200 min.   










































Figure 6-14: Minimal model simulation of feedforward-feedback-controlled glucose 
response to 50 g glucose ingestion at time 200 min.  The line with x’s shows the original 
feedforward controller, while the solid line shows the modified controller developed by 
reducing the controller gain to prevent hypoglycemia.   
  









































Figure 6-15: Linearized minimal model simulation of Model Predictive Control 
implementation for diabetic patient who consumes a 50 g of glucose at time 200 min.  
The lines in the top figure represent the specified upper and lower limits of glucose.   










































Figure 6-16: Minimal Model Simulation of glucose response to a 50 g glucose ingestion 
at time 200 min.  Control is established by using the insulin infusion profile of the 
linearized minimal model MPC simulation.  The solid horizontal lines on the top figure 
represent the upper and lower limits of glucose. 
 
 














































Figure 6-17: Minimal model glucose response to a 50 g glucose ingestion with pancreatic 
type controller.  The horizontal lines on the top graph show the upper and lower glucose 
limits for good control. 














































Figure 6-18: Sorensen Model glucose response to 50 g glucose ingestion at time 200 min.  
The horizontal lines in the top graph represent the upper and lower limits for good 
glucose control. 













































Figure 6-19: Sorensen model proportional-controlled glucose response to 50 g glucose 
ingestion at time 200 min.  The horizontal line on the top graph represents the lower limit 
glucose concentration to prevent hypoglycemia.  The upper limit is the top of the graph. 














































Figure 6-20: Sorensen model glucose steady-state response when there is no insulin being 
infused.  
















































Figure 6-21.  Hovorka model glucose response to 50 g glucose ingestion.  Insulin is 
infused at a constant rate to keep the insulin concentration at the basal level.  The two 
horizontal lines in the upper graph show the upper and lower limits of glucose to prevent 
hyper- and hypoglycemia. 
 

















































Figure 6-22: Hovorka model proportional-controlled glucose response to a 50 g glucose 
ingestion.  The lower glucose limit for good control is given by the horizontal line on the 
top graph. 
 

















































Figure 6-23: Hovorka model proportional-controlled glucose response to moderate 
exercise.  Exercise intensity level is at 60% of VO2max, and is 30 minutes in duration.  
Neither the upper nor the lower glucose limits can be seen on the screen, as they are both 
outside the range of the data. 
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CHAPTER 7 
IMPLICIT CLOSED-LOOP SYSTEM DESIGN 
 
7.1 Introduction  
 The goal of implicit closed-loop glucose control in Type 1 diabetic patients is to 
be able to release a specific amount of insulin in response to the levels of glucose in the 
bloodstream without the need for equipment such as sensors or pumps.  To this end, 
Peppas [1,2] has proposed the use of cationic, pH-responsive hydrogels of poly(diethyl 
aminoethyl methacrylate-g-ethylene glycol monomethyl ether monomethacrylate) 
(poly(DEAEM-g-EGMMA)) as a means to provide such control.   
A cationic hydrogel system in which glucose oxidase has been immobilized 
would result in excess glucose in the environment being oxidized to form gluconic acid.  
The resulting acid would cause the local pH of the system to decrease, resulting in 
swelling of the hydrogel.  This swelling results in an increase in the mesh size of the gel.   
When insulin is incorporated into the gel, the increased mesh size results in 
increased mass transfer of insulin from the gel.  As glucose is removed from the 
environment, the amount of oxidation is decreased, resulting in an increase in pH.  This 
results in reversible swelling and deswelling as a result of the concentration of glucose in 
the environment.  Such a system allows insulin to be released entirely as a function of the 
glucose levels in the bloodstream, resulting in the desired closed-loop control. 
Before such a device can be implemented, testing in patients would be required to 
verify efficacy in release.  One way to reduce the amount of testing required is through 
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the use of models.  With models, a mathematical representation of the hydrogel dynamics 
can be combined with a mathematical model of a Type 1 diabetic patient’s glucose and 
insulin dynamics to simulate the effects implementing the hydrogel system.   
Such a hydrogel device model would have to describe the diffusion of glucose to 
within the hydrogel, the oxidation of glucose to form gluconic acid, the elimination of 
gluconic acid via diffusion, the effect of gluconic acid on the local pH of the system, the 
effect of pH on the swelling of the gel, and finally the effect of swelling on the mass 
transfer coefficients of the various species involved.  The approach taken here is to model 
the simplest dynamics first and then to add complexity as the desirable characteristics are 
able to be simulated.   
The first goal in modeling the gel dynamics is to verify that a lower limit mass 
transfer coefficient exists such that two primary features in insulin release result.  First, in 
the absence of a disturbance change in glucose (i.e., a meal), the insulin should be 
released from the gel over a long period of time.  Second, the release rate from a gel in 
the absence of a glucose disturbance should be at the physiologic levels of basal insulin 
release, either from a healthy pancreas or from a pump.  Because it is not realistic to 
expect a constant infusion rate from a gel device, the more appropriate objective would 
that the gel should be able to demonstrate rapid oscillatory swelling and deswelling in 
order maintain glucose levels within a physiological basal range.  This work aims to 
achieve such objectives.   
First, a simple model is developed describing insulin and glucose dynamics within 
the gel in basal, high pH conditions.  Second, an engineering analysis is performed using 
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reported literature values and basic assumptions to determine reasonable parameter 
values for the simple model.  Finally, the model parameters are varied by orders of 
magnitude to determine their effects on release with the minimal model [3], as they relate 
to the two desired primary features.   
 
7.2 Methods 
7.2.1 Model Development 
In order to describe the dynamics of the release system, it is important to 
understand each step in the process.  A block diagram of the process is given in Figure 7-
1.   
When the glucose concentration in the blood is greater than normal levels, a 
concentration gradient exists between the glucose in the blood and the equilibrium levels 
within the polymer system.  This results in the diffusion of glucose into the system.  
However, as glucose is diffusing within the gel, the presence of immobilized glucose 
oxidase results in the homogenous oxidation of glucose to form gluconic acid.  This 
species will now exist in greater concentrations than that in the external environment (the 
gluconic acid concentration in the blood is assumed to be zero, based on the idea that 
blood acts as a perfect sink for foreign hydrogen ions as the pH is rapidly regulated by 
the buffers in the blood), resulting in passive diffusion of ionic species to the external 
environment.   
The presence of gluconic acid results in a pH change at the local environment, 
resulting in a change in the size of the gel.  This swelling also results in an increase in the 
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diffusion coefficients of species through the hydrogel system.  This increase in the 
diffusion coefficient results in increased diffusion of insulin from the gel to the external 
environment.  Therefore, in order to model the system, the diffusion of glucose, gluconic 
acid, and insulin must be modeled, along with the effect of gluconic acid on the local pH 
and the effect of pH on the size of the hydrogel. 
Assuming no dynamics associated with metabolic glucose uptake or production, 
the dynamics of glucose in the external environment is described by Equation (7.1). 
 
( ) ( )GB NAdt
GVd
−=      (7.1) 
 
In Equation (7.1) VB is the distribution volume of the bloodstream, G is the blood glucose 
concentration, and the mass transfer area, A, is given by Equation (7.2). 
 
24 RNA g π=       (7.2) 
 
Here, Ng is the number of hydrogel spheres are in the bloodstream, and R 
represents the radius of a hydrogel particle.  NG is the mass transfer flux from the 
bloodstream to the gel interior, as given by Equation (7.3). 
 
( )DGG GGL
DN −=      (7.3) 
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In Equation (7.3), DG is the diffusion coefficient of glucose within the hydrogel network, 
L is the diffusion length across the gel, and GD is the glucose concentration within the 
hydrogel.  For simplicity, spatial considerations have been eliminated and it is assumed 
that the internal glucose concentration beyond the characteristic diffusion length from the 
outside radius is uniform throughout the gel.   
While a more accurate description would be one that included gradient terms, the 
purpose of the model is to investigate the feasibility of the hydrogel device as a control 
system, and a simplified model allows such feasibility to be determined.  When the 
distribution volume of the bloodstream is assumed constant, Equations (7.1) through (7.3) 











    (7.4) 
 
As with Equation (7.1), the dynamics of glucose within the hydrogel can be 
described by a basic material balance, as shown in Equation (7.5). 
 
( ) ( ) GDGDD rVNAdt
GVd
−=    (7.5) 
 
In Equation (7.5), VD is the volume of the particle environment. The parameter rG is the 
rate of glucose oxidase-catalyzed glucose oxidation.  This reaction is given in Equations 
(7.6) and (7.7) [4].  
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222 OHidGluconicAcOGlucose
eOxidasecosGlu +⎯⎯⎯⎯ →⎯+   (7.6) 
2222 22 OOHOH
Catalase +⎯⎯ →⎯    (7.7) 
 
In the reaction, glucose is oxidized by glucose oxidase to form gluconic acid and 
hydrogen peroxide.  As hydrogen peroxide is a toxic substance and must be eliminated 
from the body, catalase is also immobilized into the gel network.  Catalase catalyzes the 
decomposition of hydrogen peroxide to form water and oxygen.  Therefore, it is assumed 
that the oxygen content is enough to ensure that the glucose oxidation can occur freely, 
without oxygen limitations [1].   
The rate of oxidation is described by Michaelis-Menten kinetics for enzyme 







= max      (7.8) 
 
Here, Vmax describes the maximum rate of reaction and is directly proportional to the 
amount of enzyme immobilized into the gel system.  In addition, Ks describes the 
concentration of glucose when the reaction is proceeding at exactly half the maximum 
rate.  This equation is derived in Appendix H.  The volume of the gel system, VD, is 




4 RNV gD π=      (7.9) 
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Because the cationic hydrogel system will swell in response to pH, VD cannot be removed 
from the derivative.  Figure 7-2 shows the dynamic swelling response of two different 
hydrogel microspheres [2].  When the particle size is on the order of 30 μm, the swelling 
and deswelling are showed to occur on the order of one minute or less.  Since minute to 
minute control is the objective, and because the particles will be an order of magnitude 
smaller than 30 μm, the assumption is made that the volume change will occur much 
quicker than the observed time scale of minutes. Therefore, a quasi steady-state volume 
assumption can be made, allowing for the volume to be removed from the derivative.  
Combining Eqs. (7.2) and (7.3) with Equations (7.5), (7.8) and (7.9) results in the 
















3    (7.10) 
 
The dynamics of insulin within the gel is primarily driven by two processes.  The 
first is the diffusion of solution insulin from the gel to the external environment.  The 
second is the dissolution of any undissolved insulin in the hydrogel solution.  If the 
assumption is made that the insulin concentration within the gel is below the saturation 
concentration of insulin (8 mg/mL), then the dynamics of insulin within the gel reduces 
to the following equation: 
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( ) ( )IDD NAIVdt
d
−=    (7.11) 
 
The terms VD and A have previously been defined, ID is the insulin concentration in the 




DN DII −=     (7.12) 
 
Using the simplifications of Equations (7.2) and (7.9), and assuming again that the time 
scale of importance is greater than the time scale associated with the change in the 












3     (7.13) 
 
The insulin infusion rate from the gel is merely the absolute value of the dynamic change 
in insulin mass within the gel system, as described by Equation (7.11).  Combining 
Equations (7.2), (7.11), and (7.12) results in the expression for the insulin infusion rate 








   (7.14) 
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Finally, the dynamics of insulin in the external environment can be determined in an 
analogous manner to the dynamics of glucose in the external environment.  Neglecting 
the metabolic production and elimination of insulin within the body, the accumulation of 






B =      (7.15) 
 
Assuming the circulation volume is constant, Equation (7.15) is simplified to the 






=      (7.16) 
 
It should be noted that the dynamics of insulin and glucose, as given by Equations (7.4) 
and (7.16) assume no metabolic production or elimination of either species.  In reality 
these effects clearly exist, and in order to use the dynamic equations to simulate the in 
vivo response of the system, a patient model must be chosen, and the form of the model 
chosen will determine the form of the glucose and insulin dynamic equations. 
The ability of the gel to both sense glucose and change its transport properties in 
response to its presence is made possible by the production of gluconic acid.  Gluconic 
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acid dynamics was represented in a similar manner to the representation of glucose and 















3    (7.18) 
 
The gluconic acid production rate is equivalent to the device glucose oxidation rate.  
Gluconic acid is then assumed to passively diffuse down a concentration gradient into the 
external environment.   
While the presence of gluconic acid is integral to the implicit control process, it is 
important to think in terms of pH for two reasons.  First, the gel response, as investigated 
by experimentalists, is generally shown as a function of pH, and will thus be modeled as 
such.  Second, and more importantly, the pH of the body cannot sustain significant pH 
changes, and therefore an analysis of the type of pH changes in the bloodstream must be 
performed in order to ensure safety during the device’s use.   
There are two primary phenomena that determine the effect of the production of 
gluconic acid on the pH of the local environment of the gel system.  One is the existence 
of biological buffers that keep the pH of the system tightly controlled.  The other is the 
concept of Donnan equilibrium. 
The purpose of a buffer is to maintain a system’s pH within a certain range.  It is 
composed of a base and its conjugate acid. 
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HBufferHBuffer ↔+ +     (7.18) 
 
The buffer base usually exists as an ionic salt.  When an acid or base is present in the 
system, the pH change is minimized by either the quenching of the foreign acid by the 
buffer base or by the quenching of the foreign by the buffer acid.  The buffer system 




BufferBaselogpKpH a +=     (7.19) 
 
In the Henderson-Hasselbalch equation, the buffer pKa and the concentrations of acid and 
base in the system determine the pH of the system.  When gluconic acid is produced in 
the gel, the gel buffer quenches the foreign acid to form more of the buffer acid.  The new 








0    (7.20) 
 
Therefore, to determine the pH as a function of gluconic acid, only the gluconic acid 
concentration, the buffer pKa, and the initial buffer and base concentrations, as designated 
by the subscript “0”, are needed.   
 While the concentrations of the major buffer species in the blood are readily 
found in medical physiology texts [5] or clinic biochemistry texts [6], these values will 
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not be the same inside the gel environment.  Because there are negatively charged 
methacrylate groups immobilized on the polymer backbone of the gel, there will 
inevitably be different concentrations of ionic species in the gel compared to the 
bloodstream.  This is known as the Donnan effect [7].  When Donnan equilibrium is 
established, all charges are balanced at the cost of having different species concentrations 
across a semi-permeable membrane, which for this case is the gel device.  The 
concentration differences for species across the membrane are described using the 







=      (7.21) 
 
For the ith ionic species, the ratio of gel concentration to the blood concentration is 
simply the Donnan ratio raised to the power of the valence of the ionic species.  The 
















σϕϕ     (7.22) 
 
Equation (7.22) has been derived in Appendix I.  It is based on the assumption of ideal 
Donnan equilibrium.   
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As discussed by Siegel in reference [9], there are many assumptions made for this 
relationship to be valid.  Among those are the assumption that ion activity is equal to its 
concentration, that the fixed amine groups of the polymer backbone can be assumed to 
have a single ionization constant, K (or pKg), that bulk electroneutrality does indeed hold, 
and that the species concentrations are given with respect to the fluid solvent within the 
gel, not the entire gel volume.  Siegel has pointed out that the possibility of positive ions 
in plasma associating with the amine groups, resulting in the ideal Donnan equilibrium 
assumption being invalid.  However, provided there exists an anion in relatively high 
concentration, the assumptions are applicable.  For the purpose of simulations, ideal 
Donnan equilibrium is assumed valid.   
The variable pKg represents the pKa of the methacrylate functional group of the 
polymer backbone.  The variable σ represents the density of functional groups in the 
polymer.  This is a design parameter for this system.  These two variables can be selected 
by choosing specific materials.  The variable φ represents the volume fraction of the 
polymer in the device system.  Because the gel is assumed to be swollen as a result of 
absorbed water, the actual volume fraction of polymer will be significantly smaller than 







polymer 1===ϕ     (7.23) 
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The volume fraction is simply the total polymer volume divided by the total volume.  
Given a collapsed polymer volume v, the total volume of the device is characterized by 
the volume swelling ratio Q.  Q is defined as the volume of swollen polymer complex to 





RQ =      (7.24) 
 
The product Qv denotes the total device volume, and it is easily shown that the volume 
fraction is merely the inverse of the swelling ratio.  Given  value of swelling ratio, the 
polymer design characteristics, and the ionic concentrations of the different species in the 
blood and the gel, the Donnan ratio can be determined using a nonlinear system solver 
and used to determine the buffer acid and base concentrations within the gel, as well as 
the normal pH within the gel as a result.  Given the gel pH and buffer concentrations, the 
pH as a function of gluconic acid concentration can then easily be determined. 
 Peppas and co-authors [1, 2] have demonstrated a dramatic increase in the 
swelling ratio for poly(DEAEM-g-EGMMA) when subjected to a pH below 7.1.  These 
results are given in Figures 7-3 and 7-4.  Using the quasi steady-state assumption with 
respect to volume swelling, it is assumed that swelling ratio will rapidly approach its 
equilibrium value provided as shown in Figures 7-3 and 7-4.  For the purposes of 
simulation, only empirical models were needed to describe the effects of pH on swelling.  
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Based on the form of the curve of the results shown in Figure 7-3, a hyperbolic tangent 
relationship was used, as indicated below: 
 
( )DpHCtanhBAQ +⋅+=     (7.25) 
 
It can be seen in Figure 7-3 that a hyperbolic tangent relationship does not perfectly 
reflect the swelling profile, as the gel continues to swell as the pH drops.  However, 
because the pH of the system will not deviate from the range of 7.0 in the gel to 7.4 of the 
blood, it was concluded that such a relationship is adequate for the interval selected.   
 Figure 7-4 also shows the swelling effects of pH for gels of different crosslinking 
ratios.  Clearly, as the crosslinking ratio is increased, the gel is unable to repel as much, 
resulting in a much more stiff device.  To quantify this effect, empirical relationships 
using the data of Figure 7-4 were developed.  Based on the hyperbolic relationships, at 
maximum and minimum swelling, the hyperbolic tangent function can be approximated 
as unity.  This allows A and B to be determined based on the asymptotic swelling values. 
 
maxQBA =+      (7.26) 
minQBA =−      (7.27) 
 
From an inspection of Figure 7-4, Qmin does not change significantly as a function of 
crosslinking ratio, and it was approximated as 3 at crosslinking ratios lower than 0.02 and 
2 at crosslinking ratios of 0.02 or greater.  
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Clearly Qmax is strongly dependent on crosslinking, and the maximum swelling 
values were plotted as a function of crosslinking ratio, as shown in Figure 7-5.  A 
decaying exponential was chosen to describe the data, simply because it gave the best fit.  
The relationship is described by Equation (7.28). 
 
( )[ ]005084940 .X.expQmax −−=    (7.28) 
 
This fit was based on the data observation that a crosslinking ratio, X, of 0.005 (moles 
crosslinking agent/moles monomer) has a maximum swelling ratio of approximately 40.  
As shown in Figure 7-6, parameter C exhibited no crosslinking dependence, and so an 
average value of -10 was chosen.  Finally, because the swelling transition is supposed to 
occur at the gel pKg, the hyperbolic tangent functions inflection point was assumed to 
occur when the pH is equal to the pKg.  Taking the second derivative of the function 
shows that the hyperbolic tangent function goes to zero at this point.  To show this 
mathematically, the parameter D is described by Equation (7.29). 
 
gpKCD ⋅−=      (7.29) 
 
With parameters A, B, C, and D expressed as a function of crosslinking ratio, the swelling 
ratio for any pH can now be performed as long as the crosslinking ratio is known.  Given 
the swelling and crosslinking ratio, the remaining transport parameters can be determined 
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as well.  Diffusion of a species within the gel is based on the size of species relative to the 





213121≅ξ     (7.30) 
 
Equation (7.30) is based on the assumption of isotropic stretching of the polymer chains 
during the swelling process.  The cube root of the swelling ratio represents the relative 
increase in size of a chain.  The parameter Cn is known as the characteristic ratio and is 
taken to be 14.4 for poly(DEAEM-g-EGMMA) [1].  The parameter lc is simply the length 
of the bond between two carbon atoms.  The parameter N is taken to be the number of 
repeating units between two crosslinks.  Combined, N and lc give the average length of 
the unstretched chain.  Each cross-linking agent has four functional groups, enabling to 
link four polymer chains together.  However, each chain is shared between two 






≅      (7.31) 
 
Given the mesh size, the swelling ratio, and the size of the particle being transported, the 






















   (7.32) 
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Y is a constant assumed to be one for this and most other polymeric systems [1], and rH,i 
is the hydrodynamic radius of the particular species.  Equation (7.32) is a scaling law 
based on statistical thermodynamics and the probability that both enough free volume 
exists for the solute to move through the gel and that the gel network conformation is 
such that the solute can move through it as well. 
 The final process associated with model development is with respect to the 
degradation of the polymer.  At this point, the authors know of no attempts to make 
degradable cationic hydrogels, but it is noted that such a system must be degradable in 
order to prevent a gradual accumulation of polymer within the patient.  The development 
of degradable systems is an ongoing project in the Peppas laboratory at the University of 
Texas at Austin.  
 As an approximation of degradation, the works of Langer and co-authors [11] and 
Anseth and co-authors [12] have been studied and adapted for crosslinked gels.  Langer 
and co-authors showed that microparticles of 50:50 poly(D,L-lactic-co-glycolic acid)  
(PLGA) degrade by the cleaving of bonds on the polymer chains, resulting an increase in 
the porosity of the spheres.  This bond cleavage was modeled as a zero order process 
because all bonds are equally likely to be cleaved.  Anseth and co-authors investigated 
the bulk degradation of hydrogels of poly(lactic acid-b-ethylene glycol-b-lactic acid) 
(poly(LA-b-EG-b-LA)) and assumed first order kinetics with respect to the degradable 
units. 
 To develop pH-responsive hydrogels that are degradable, a degradable 
crosslinking agent must be used.  As the system degrades, instead of the average pore 
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size increasing, the mesh size will increase.  With respect to bond cleavage, the only 
degradation that occurs will be respect to the bonds between a chain and the crosslinking 
agent.  Based on this analysis, the degradation rate was assumed to be first order in the 
crosslinking ratio only.   
 
( ) ( )tXk
dt
tdX
d−=     (7.33) 
 
As the ratio decreases, insulin will be able to diffuse faster from the gel, until a certain 
threshold value is reached in which the insulin will be rapidly dumped from the device.  
The goal of design will then be to ensure that insulin is essentially depleted from the 
device before such degradation occurs. 
 Finally, given the model of hydrogel dynamics, implicit-closed loop control can 
be investigated by incorporating the model into a patient model.  For this purpose, the 
minimal model [3,13], as described in Chapter 6, was used. 
 
7.2.2 Parameter Determination 
To perform the simulations, numerical values are needed for each parameter.  
Many of the parameters could not be determined from experiment, requiring other 
methods.  Model parameters were determined in three ways.  First, available values from 
literature were used when applicable.  Second, parameters from the simulation results of 
references [14] and [4] were used as first approximations for some of the values.  Finally, 
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intuitive reasoning was used to determine approximate values of the remaining 
parameters.  
 Reference [13] provided the basal concentrations of glucose and insulin, as well 
as the parameter values of the patient model.  References [14] and [4] were used to 
determine both the hydrodynamic radius for the different species and their associated 
solvent diffusion coefficients, Di,0.  The degradation rate, kd, was approximated as the 
same order of magnitude as the random scission rate given in reference [11].  The 
parameter values for Vmax, Ks, pKg, and σ were initially approximated using the 
parameters of reference [4].  Finally, the concentrations of buffer species were taken from 
references [5] and [6]. 
 To determine the maximum loading of insulin within the gel, the saturation 
concentration of insulin in water was used [14].  It was then assumed that insulin is 
always dissolved within the gel.  The average particle size was given an upper limit of 5 
μm.  In order to be able to circulate in the bloodstream, the particles must be able to flow 
through the capillaries.  Given the average capillary internal diameter of 5-9 μm [5], the 
gel would likely have to be much smaller than this value.  The nominal values of all 
parameters are summarized in Table 7-1. 
The final parameter, Ng, was determined based on the particle size and some 
assumptions about the administration of the device.  It was assumed that the gels would 
be injected into the bloodstream in a solution that does not cause them to swell initially.  
A patient using insulin injections will likely inject between 3/10 to 1 mL of U-100 insulin 
daily for basal insulin [15]. U-100 means that the insulin solution contains 100 units per 
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mL of solution.  A device designed to provide insulin for multiple days would have inject 
a higher volume of solution every few days.  As an initial assumption, it is assumed that 
10 mL of solution will be injected into the bloodstream periodically.  To be comparable 
to intravenous injections of other species, such glucose [16], which has previously been 
injected in solutions at up to 50 wt%, the particles should only represent up to 5 wt% (wt) 
of the injection solution.  Assuming the particles have a density of approximately unity, 
the entire volume of particles can only equal 5 cubic centimeters.  Therefore, Ng is 
determined by noting that the total number of particles must have a volume no greater 
than 5 cm3.  Table 7-2 shows the maximum number of assumed particles for different 
particle sizes. 
 It should be noted that, assuming rapid diffusion and rapid oxidation, the gluconic 
acid concentration within the gel would reach a maximum value equal to the glucose 
value in the blood stream.  In the worst case, a scenario would occur in which all the 
gluconic acid from the gels is released into the bloodstream.  Given that the total particle 
volume is only 5 cm3, compared to the body’s volume of more than 3 L of plasma [7], the 
acid concentration would likely be considerably diluted.  Finally, considering the plasma 
carbonate buffer concentration of 25 mmol/L, it can be assumed that gluconic acid would 
be quenched nearly instantaneously with nearly no impact on the buffer system.  
Therefore, the gluconic acid concentration in the bloodstream is considered to be zero at 
all times. 
 Finally, the model neglects any immune response effects on the delivery system.  
The presence of ethylene glycol grafts has been assumed to provide stealth 
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characteristics, although the duration of the system in blood has not been determined.  
The small size of the particles also means that they could be eliminated via opsonization 
[17], in which the particles are enveloped and ultimately eliminated by the body.  While 
these concepts are extremely important with respect to the system design, it is assumed 
here, for the sake of investigating feasibility with respect to insulin release and glucose 
control effectiveness, that immune response effects are not present. 
 
7.2.3 Simulation Objectives 
There were two primary objectives associated with model simulations.  First was 
to investigate the effects of each parameter on the systems ability to perform.  These 
simulations were performed by choosing up to five different values for each parameter, 
each increasing by an order of magnitude.  The second objective was to design a gel that 
is able to effectively provide adequate glucose control.  To achieve satisfactory control, 
three criteria were used.  First, insulin release from the gel should be sustainable for at 
least two to three days.  If a patient is injecting daily, there has been no improvement 
over the currently used regimen.  Second, the device should be able to provide a basal 
level of insulin throughout the day.  As a specified basal value cannot be expected from a 
polymeric device, this criterion establishes that glucose should stay within a normal range 
of 70 to 100 mg/dL (3.9 to 5.6 mmol/L) during the day.  Finally, the response of the 
device to a glucose infusion should result in a rapid increase in insulin diffusion, in order 
to provide adequate control of the disturbance.  Using the simulation results and the 
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control criteria, the parameters were adjusted in order to select the optimal gel design that 
results in effective control.   
 
7.2.4 Computational Methods 
 All simulations were performed in MATLAB.  To solve the differential equations, 
the MATLAB function ode23s was used, which is based on a modified Rosenbrock 
function to solve stiff systems [18].  To solve the system for the Donnan ratio, the 
function fsolve in the MATLAB Optimization Toolbox was used.   
 An investigation of the system equations shows that swelling is a function of pH.  
However, the pH is a function of the buffer concentration in the gel, and the buffer 
concentration is a function of the Donnan ratio.  Because the Donnan ratio is a function 
of the swelling ratio, the system had to be solved iteratively in order to simultaneously 
determine the gel pH and the swelling ratio. 
 Finally, the system was initialized by providing the design characteristics and the 
basal values of the patient model.  The initial values of the device insulin and cross-
linking ratio were provided.  The initial concentrations of device glucose and gluconic 
acid were determined using iterations.  Because transport was pH dependent, the initial 
pH, gel swelling, diffusion coefficients, Donnan ratio, and state values had to be 
determined simultaneously.  The source code used to perform the simulations is provided 
in Appendix J. 
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7.3 Results 
7.3.1 Parameter Effects on Device Insulin Release 
 Before the gel’s ability to control glucose levels is investigated, the system must 
be designed such that insulin is able to be infused at realistic levels for a period of 
multiple days.  Thus, the transport of insulin was investigated initially to ensure that 
sufficient release can be achieved.  The primary design characteristics important to 
release are the duration of the release from the device and the magnitude of the insulin 
infusion rates.  All investigations were performed at basal conditions. 
 Figures 7-7 and 7-8 show the effects of insulin loading on the device behavior.  
The upper limit on insulin loading was established to be the saturation concentration of 
insulin in water.  Figure 7-7 shows that insulin loading had no effect on the duration of 
release.  As shown in Figure 7-8, insulin loading did affect the flow rates that were 
achievable.  Mathematically, this is easily seen in Equation (7.14), where the 
concentration driving force is directly dependent on the insulin concentration within the 
gel.  Increasing or decreasing the insulin loading causes a directly proportional increase 
or decrease in the release rates. 
 Figures 7-9 and 7-10 show the effects of the number of particles assumed to be 
circulating at any time.  Because the total number of particles possible is size dependent, 
these results were all determined for a gel with an average collapsed radius of 1.5 μm.  As 
with insulin loading, the number of gels circulating played no role in the duration of 
release.  This can be explained simply by investigating Equation (7.13).  Assuming 
uniform insulin concentrations, each gel will have the same insulin profile, dependent 
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only upon the mass transfer coefficient and the concentration gradient of insulin.  Also 
like insulin loading, the number of gels has a directly proportional effect with respect to 
changing the infusion rate from the polymeric device.  This can also be seen in Equation 
(7.14), in which insulin infusion is directly proportional to the number of circulating 
particles. 
 Figures 7-11 and 7-12 show the effects of the collapsed particle radius on the gel 
release characteristics.  For each simulation, the number of gel particles in circulation 
was set at 3.54x107.  The maximum Ng for a particle of radius 1.5 μm is 3.54x1010, and 
the number was decreased by 3 orders of magnitude in order to ensure the number was 
feasible for bigger particles, in accordance with Table 7-2.  Both figures show a strong 
dependence on particle size.  As the particle size was increases, the duration of insulin 
release  increased.  This was a result of the increased diffusion path from gel to the 
circulation.  Mathematically, it is seen in Equation (7.13) that the gel insulin 
concentration change is inversely proportional to the particle size.  The infusion rate, 
however, will depend on the flux and the gel surface area, resulting in a directly 
proportional relationship between insulin infusion and the collapsed size of the particle. 
 Figures 7-13 and 7-14 show the effects of the diffusion coefficient on the gel 
characteristics.  The duration of release was a strong function of the order of magnitude 
of the diffusion coefficient.  An order of magnitude decrease in the diffusion coefficient 
resulted in an increase in the duration of release from the microparticle.  As shown in 
Figure 7-14, decreasing the diffusivity also resulted in a decrease in the insulin infusion 
rate, although the device was able to infuse this level of insulin for a longer period of 
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time.  Mathematically, this can be analyzed by an investigation of the model equations.  
As insulin flux is proportional to the diffusion coefficient, a higher coefficient will result 
in a higher insulin release rate.  The higher infusion rate, when the particle size, the 
number of gels, and the insulin loading are maintained constant, means the gels are losing 
their insulin at a faster rate, thus leading to a shorter duration of release. 
While the diffusion coefficient of glucose could also have been investigated, it 
was assumed here that it will likely always be approximately an order of magnitude 
larger than the insulin coefficient, as a result of the much smaller hydrodynamic radius 
and its known diffusion coefficient in water relative to that of insulin.  Thus, a change in 
the glucose coefficient was implied when the change was made in the insulin coefficient. 
 Figures 7-15 and 7-16 show the effects of the gel crosslinking ratio on the gel 
insulin release characteristics.  As the figures show, decreasing the initial crosslinking 
ratio resulted in an increase in the insulin infusion rate and a decrease in the duration of 
the gel release, as more was released at a time.  Mathematically, this can be explained by 
observation of Equations (7.30) and (7.31).  Physically, as the crosslinking ratio 
decreases, the average gel mesh size will be larger, as there will be more repeat units 
between crosslinks.  In addition, as previously mentioned, the lower crosslinking ratio 
will also lead to higher swelling ratios for the same pH environment.  Because the 
swelling ratio also contributes to the mesh size, the crosslinking ratio affects the mesh 
size in both fashions.  An investigation of Equation (7.32) shows that both a larger mesh 
size and a higher swelling ratio lead to an increase in the diffusion coefficient. 
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7.3.2 Parameter Effects on Glucose-Induced Swelling 
 The parameters investigated were those primarily responsible for the insulin 
release magnitude and duration.  In addition, to provide minute-to-minute control of 
glucose, the gel must be able to rapidly swell and de-swell in response to changing 
glucose conditions.  While the diffusion of glucose is important, this transport will be 
related to the transport of insulin, and the gel will have to be designed based on the 
glucose diffusion rate that allows insulin to diffuse at a reasonable level.  Of more 
importance are the effects of glucose on swelling and release.  Given that release will be 
based on the previously mentioned parameters for a given swelling ratio, glucose 
sensitivity is primarily based on swelling.  While realistically, glucose sensitivity would 
also depend on thermodynamic interactions with other components of the system, the 
model neglects these interactions.  Thus, the important design characteristics are the rate 
of glucose oxidation to form gluconic acid and the resulting pH from the formation. 
 Figures 7-17 and 7-18 show the effect of glucose oxidase immobilization with 
respect to gluconic acid formation and pH.  As the figures show, gels with enzyme 
loadings greater than 0.1 μM did not display different glucose sensitive characteristics by 
increasing the enzyme loading.  At this loading upper limit, all glucose was oxidized very 
rapidly.  As Figure 7-17 shows, high loading resulted in a high gluconic acid 
concentration, whereas low loading resulted in a low acid concentration.  As shown by 
Figure 7-18, this resulted in a low pH at basal conditions for high loading, and a high pH 
at basal conditions for low loading.  For low loading, the high pH resulted in low insulin 
release, which caused glucose levels to rise.  However, the low loading resulted in only a 
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small amount of gluconic acid produced for the glucose rise, and the pH decrease was 
very slow.  For high loading, the insulin infusion rate was initially high, causing glucose 
to fall.  The drop in glucose caused an equal drop in gluconic acid, raising the pH 
rapidly.  This rise causes insulin release to decrease, resulting in a rise in glucose.  This 
process cycles between high and low release rates, with the goal being to keep glucose 
oscillating in a physiologically acceptable range. 
 Figures 7-19 and 7-20 show the effects of varying the pKg of the monomer used 
in the hydrogel.  As can be seen, the pH in the device was below the transition pH of all 
three devices at basal conditions.  This resulted in a large insulin infusion rate, causing 
glucose, and ultimately gluconic acid, to decrease at a rapid rate.  This decrease caused 
the pH to increase.  As the transition pH was reached, the system collapsed, and gluconic 
acid ultimately began to increase.  As Figure 7-19 shows, however, when the pKg of the 
monomer increased, it became more difficult to ever approach the transition pH.  Given 
the conditions, the monomers of pKg 7.5 and 8 were not able to approach their transition 
pH values before gluconic acid was completely depleted.  Therefore, no transition would 
ever occur, and these systems would not be able to collapse. 
 Figures 7-21 and 7-22 show the effects of the functional group loading on the 
glucose response.  Given the same initial gluconic acid concentrations, an increase in the 
functional group loading resulted in an increase in the basal state pH of the system.  This 
allowed the state of the gel to be controlled such that the device was in the collapsed state 
at basal conditions.  Mathematically, this is because the functional group loading directly 
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affects the Donnan ratio, which is used to determine the buffer species concentrations 
within the gel.   
 An interesting phenomenon was the sharp rise and fall of the pH in Figure 7-22.  
This occurred because of the recursive relationship between the pH and the swelling 
ratio.  The pH determined the swelling ratio of the species.  However, because the 
swelling ratio also contributed to the Donnan ratio, the swelling ratio affected the internal 
pH of the system.  Thus, as the pH change caused the sharp rise in the device swelling 
ratio, the sharp rise resulted in a sharp drop of the pH.   
 
7.3.3 Optimization of the Hydrogel Device for Insulin Release 
 The optimal design of the device occurs in three phases.  The first phase is to 
ensure that release can happen for a long enough duration.  The second phase is to then 
make sure that the steady release is occurring at a high enough delivery rate to be 
physiologically beneficial.  Finally, the system must be optimized in order to ensure 
glucose response occurs rapidly and effectively enough to maintain normal levels during 
basal conditions.   
 The duration of insulin release was shown to depend only upon the diffusion 
coefficient and the particle size.  For an intravenous device, the particle size is limited by 
the size of the capillaries.  Given an average capillary diameter of between 5 and 9 μm, 
the gels have to be able to flow through the capillaries without getting stuck.  
Realistically, the particles should then be designed on the submicron level.  Using 5 μm 
as the upper limit for the swollen device diameter results in the maximum collapsed 
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particle radius of 1.35 μm.  However, such a device would only be able to pass through 
capillaries one gel at a time, and as such the gels would likely not be circulating at a 
uniform number concentration, as assumed for a pharmacokinetic model.   
 Based on the development of Equation (7.32), Di,0 is actually the diffusion 
coefficient in the pure solvent.  As shown in Table 7-2, this value is on the order of 10-7 
cm2/s.  As shown in Figure 7-13, this is 4 orders of magnitude greater than a coefficient 
value that causes a larger particle to be depleted within two hours of circulation.  Insulin 
release will not be at the desired duration for diffusion coefficients on the order of 10-15 
cm2/s, a value that is not feasible for a mesh particle system.  On the other side, assuming 
the diffusion coefficient in pure solvent was used, the particles would have to be on the 
order of one mm in diameter.  Such a system would not be able to circulate.  In addition, 
the quasi steady-state assumption would no longer be valid, and the time constants and 
delays associated with viscoelastic swelling and relaxation would have to be considered.  
Thus, based on the transport requirements, such a device is not feasible for use as an 
intravenous delivery system. 
 While the previous paragraph essentially renders the hydrogel system infeasible 
as an intravenous insulin delivery device, optimization continued with the assumption 
that a gel could be developed with the necessary diffusion coefficient-particle size 
combination that results in release for a duration of three days or longer.  Given the 
release duration, the necessary insulin infusion rate could be achieved simply by 
increasing or decreasing the insulin loading or number of particles accordingly.  For the 
case in which large particles and fast diffusion is assumed, insulin loading and the 
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number of particles will have to be reduced by several orders of magnitude to achieve 
desired levels, as infusion rates will be very high.  In contrast, the slow diffusion and 
small particle assumption will require maximum insulin loading and the maximum 
number of gels that can feasibly be in circulation. 
 To optimize the gel for glucose response, two primary objectives must be 
achieved.  First, the gel must be collapsed at basal levels of glucose and lower, and it 
must expand upon achieving high glucose levels.  Second, this response must be fast.  To 
achieve the second objective requires a high enough enzyme loading to result in a 
gluconic acid concentration within the gel that is able to cause pH changes in the 
presence of buffers.  The first objective can be achieved by careful selection of the type 
and amount of monomer used in the device.  For this optimization, the desired swelling 
ratio of 3 in the basal state was specified.   
Based on this value, different combinations of pKg and functional group loading 
were used in the determination of the Donnan ratio and ultimately the pH.  This pH was 
then used to determine the swelling ratio of the system. If this value did not match the 
original value, the process was used again until the swelling ratios converged.  As was 
often the case, this iterative process diverged to a large swelling ratio, resulting in the low 
pH values seen in section 6.3.2.  Figure 7-23 shows a plot of the specified swelling ratio 
vs. the actual ratio for a monomer loading of 1 M.  The large slopes usually resulted in 
divergence to the flatter regions of the graph.   
 Figure 7-24 shows the same iterative routine used with a monomer loading of 4 
M.  At the low swelling ratio region, the curves became flatter, indicating that the higher 
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monomer loading allows the collapsed state to be achieved at the basal condition.  Based 
on the figure, the first glucose response objective was achieved by using a monomer with 
pKg of 7.0-7.1, at a loading of 4 M or greater.  Based on this optimization sequence, and 
the assumption that size and diffusion limitations are neglected, the gel insulin infusion 
and glucose response are shown in Figure 7-25 for basal conditions. 
The change in glucose resulted in an order of magnitude change in the insulin 
infusion rate.  In this way, the control system was most similar to a simple switching 
mechanism as opposed to a real controller.  Thus, the implicit closed-loop control system 
was quite inferior to a controller developed using process control principles.  
Furthermore, the oscillations that occurred resulted in alternating conditions of 
hyperglycemia and hypoglycemia, although this behavior may have been a consequence 
of using the minimal model, given its shortcomings from Chapter 6. 
 
7.4 Conclusions 
 A model has been developed describing the processes associated with implicit 
closed-loop control, including glucose diffusion into the gel, the oxidation of glucose to 
form gluconic acid, the effect of gluconic acid on the gel pH, the gel pH effect on gel 
swelling, and swelling effects on transport.  Each model parameter was varied by several 
orders of magnitude in order to show parametric effects on release duration, insulin 
delivery rates, and glucose responsiveness.  Given the fundamental parametric 
understanding, the gel was then optimized for glucose control in Type I diabetic patients.  
Based on physiological considerations, the requirement of small particles and the 
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inherently fast diffusion times associated with a mesh network result in the conclusion 
that the use of pH-responsive hydrogels as an intravenous implicit closed-loop glucose 
control system is likely infeasible, as delivery cannot be sustained for a long enough 
duration to offer any advantage to current treatment methods.   




Figure 7-1: Block diagram of the implicit closed-loop control process.  Glucose diffuses 
into the hydrogel along a concentration gradient.  Within the gel, glucose is oxidized to 
form gluconic acid, which causes the pH to decrease within the gel.  The pH change 
results in swelling of the gel network, resulting in an increase in both the particle size and 
the diffusion coefficients of solutes through the gel.  This causes an increase in insulin 
infusion, which increases glucose uptake.  As the glucose production rate decreases, 
diffusion will decrease, causing less oxidation, an increase in pH, a decrease in volume 
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Figure 7-2: Dynamic swelling response of pH-sensitive hydrogel spherical particles to 
step changes in pH [2].  The circles represent a particle radius of 30 μm, squares 
represent a particle radius of 170 μm, and the diamonds represent a particle radius of 300 
μm.   
 
 







































Figure 7-3: Typical equilibrium swelling curve for pH-sensitive cationic hydrogel. 





































Figure 7-4: Equilibrium swelling response of pH-sensitive cationic hydrogels as a 
function of pH and crosslinking ratio [1].  Circles represent a crosslinking ratio of 0.005, 
squares represent 0.01, diamonds represent 0.02, and triangles represent a ratio of 0.04. 
 
































Figure 7-5: Maximum swelling ratio of pH-sensitive cationic hydrogel as a function of 
the crosslinking ratio.  The line represents an exponential function used to fit the data. 
 























Figure 7-6: Change of hyperbolic tangent parameter C with respect to crosslinking ratio.  









Table 7-1: Nominal Parameter Values Used For Hydrogel 
Device Simulations 
Parameter Value Units 
ID,0 1x108 mU L-1 
Rcollapsed 5 μm 
DI,0 1.41x10-13 cm2 s-1 
DG,0 6.9x10-12 cm2 s-1 
lc 1.54 Å 
L 0.5 μm 
pKg 7.1 dimensionless 
σ 1.0 M 
pHblood 7.4 dimensionless 
X0 0.004 dimensionless 
kd 0.001 min-1 
Cenz 1 μM 
Vmax 51.6Cenz mmol L-1 min-1 
KS 0.6187 mmol L-1 
rI 16 Å 
rG 2.5 Å 
[H+]blood 3.98x10-8 M 
[Na+]blood 142 mM 
[K+]blood 4.2 mM 
[Ca2+]blood 1.2 mM 
[Cl-]blood 108 mM 
[HCO3-]blood 25 mM 
[CO2]blood 1.224 mM 
Carbonate Buffer pKa 6.33 dimensionless 
 



















Table 7-2: Particle Size Effects on Maximum Number of 
Circulating Particles 









































Figure 7-7: Fraction of insulin released as a function of time and the initial gel insulin 
concentration.   









































Figure 7-8: Insulin infusion rate as a function of time and initial gel insulin concentration.   

































Figure 7-9: Fraction of insulin released as a function of time and the number of 
circulating gels.  The particle is assumed to have a collapsed state radius of 1.5 μm.  






































Figure 7-10: Insulin infusion rate as a function of time and the number of circulating 
hydrogel particles.  Particles are assumed to be 1.5 μm in radius in the collapsed state. 
 
































Figure 7-11: Fraction of insulin released as a function of time and collapsed particle size.  
For all sizes, it is assumed that 3.54 x 107 gels are in circulation. 








































Figure 7-12: Insulin infusion rate as a function of time and the collapsed particle size.  
For the simulations, there are 3.54x107 particles in circulation. 
 
































Figure 7-13: Fraction of insulin released as a function of time and the diffusion 
coefficient of insulin, Di,0.   
 












































Figure 7-14: Insulin infusion rate as a function of time and the insulin diffusion 
coefficient, Di,0. 
 






































Figure 7-15: Fraction of insulin released as a function of time and the initial crosslinking 
ratio of the hydrogel network. 
 








































Figure 7-16: Insulin infusion rate as a function of time and crosslinking ratio.  The rapid 
fall is a result of the high infusion rates causing the particle to collapse and, thereby 
decreasing the infusion rate.  The rapid rise of the rate for X = 0.04 is a result of a rapid 
swelling as the glucose concentration increases. 
 






































Figure 7-17: Gluconic acid concentration as a function of time and enzyme loading.  The 
initial value is the gluconic acid concentration at basal conditions.  For low loading, low 
gluconic acid levels result in low infusion rates, causing a rise in glucose levels.  The 
high loading results in all glucose being oxidized rapidly, leading to very high infusion 
rates.  This causes glucose to drop until the insulin infusion drops to a level that causes a 
glucose rise again.  For glucose oxidase loading above 0.1 μM, the response does not 
change with increasing loading. 






























Figure 7-18: Gel pH as a function of time and enzyme loading.  When there is 
insufficient enzyme to oxidize glucose, the gel exists in the collapsed state for basal 
glucose levels, and the pH level changes slowly.  As glucose oxidase is increased, the gel 
is at a lower pH for the given glucose concentration, and pH changes are more rapid for 
changing glucose levels.  Above 0.1 μM, the enzyme response does not change, 
indicating enzyme saturation for the particular level of glucose. 
 







































Figure 7-19: Gluconic acid concentration as a function of time and the pK of the 
monomer used in the hydrogel device.  Identical behavior is seen for systems with 
monomer pKs of 7.5 and 8.0.   
 
 






























Figure 7-20: Gel pH as a function of time and the pK of the monomer used in the 
hydrogel.   
 





































Figure 7-21: Gluconic acid as a function of time and the functional group loading in the 
hydrogel device.   
 






























Figure 7-22: Gel pH as a function of time and function group loading in the hydrogel 
device. 
































Figure 7-23: Results of device optimization for optimal pKg and monomer loading.  For 
each pKg value, a Q is specified and used with a monomer loading of 1 M to determine 
the Donnan ratio.  The Donnan ratio is then used to calculate pH and the actual Q.  If Q 
actual does not match Q specified, the process is performed again until the two swelling 
ratios converge. 
 































Figure 7-24: Results of device optimization for optimal pKg and monomer loading.  For 
each pKg value, a Q is specified and used with a monomer loading of 4 M to determine 
the Donnan ratio.  The Donnan ratio is then used to calculate pH and the actual Q.  If Q 
actual does not match Q specified, the process is performed again until the two swelling 
ratios converge. 
 
















































Figure 7-25: Minimal model implicit closed-loop controlled glucose response at basal 
conditions, over a period of 2.8 days.  NG = 5x1010, DI,0 = 1.41x10-15 cm2/s, Rcollapsed = 
1.35 μm, σ = 1 M, enzyme loading = 0.1 μM, and pKg = 7.0. 
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 As the role of chemical engineering in the development of solutions of today’s 
medical and biological problems continues to grow, the application of systems 
engineering toward the development of optimal materials and optimal drug delivery 
regimens will increase.  By considering the body to be a complex chemical process and 
medical problems as behaviors of the process, the systems engineer can develop solutions 
to today’s medical problems in the same way that solutions are developed in a chemical 
plant.  The treatment of Type I diabetes mellitus is a problem that can be investigated by 
treating glucose homeostasis as the process, and controlling glucose levels to prevent 
hyperglycemia and hypoglycemia as the control objective. 
 The goal of this research was to investigate diabetes treatment from a systems 
engineering standpoint.  Specifically, the goal was to perform simulations that 
demonstrate the efficacy of both explicit and implicit closed-loop control methods with 
respect to controlling glucose levels for basal conditions, during a meal, and during 
exercise.  To perform the simulations, three objectives had to be met.  First, an identified 
patient model was either to be developed or retrieved from literature.  Second, insulin 
pump algorithms were to be developed using principles of process control, and the ability 
of these algorithms to control glucose was to be investigated.  Finally, a process model 
describing the implicit closed-loop control process utilizing pH-responsive cationic 
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hydrogel microspheres was to be developed and used in simulations to optimize the 
delivery of insulin to control glucose levels. 
 Two different model frameworks were developed to describe the significant 
features of the glucose homeostasis process.  Included in the models were the primary 
fuels, glucose, fatty acids, and amino acids.  Also included in the models were the 
primary hormones involved in the process, including insulin, glucagon, epinephrine, and 
glucagon-like peptide-1.  Both a simple pharmacokinetic model framework and a 
physiological model were developed.  The model parameters have not been identified, 
because appropriate data to perform the parameter estimation were not easily acquired.  
The subject of parameter estimation was investigated to determine how well parameters 
can be estimated using nonlinear least squares algorithms.  It was determined that typical 
estimates have large confidence intervals and are highly dependent on an initial guess of 
the parameter values.  Estimation can be improved by utilizing the dynamic sensitivity 
equations in the estimation routine and by using a stiff differential equation solver.  It was 
also shown that different parameter sets can result in satisfactory fits to data, thus making 
is possible that multiple parameter sets may be able to both fit the data and predict future 
results. 
 Insulin infusion algorithms were investigated by implementing them in the 
minimal model [1], the Sorensen model [2], and the Hovorka model [3], using a range of 
model parameters.  Using the minimal model, it was observed that no method of control 
was able to reduce the glucose excursion resulting from a 50 g oral glucose ingestion 
without also resulting in severe hypoglycemia.  This was attributed to the model’s 
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possible underprediction of the role of glucose in glucose uptake.  Both the Sorensen 
model and Hovorka model simulations showed that simple proportional control can be 
used to control glucose in response to oral ingestion.  An investigation of the Sorensen 
model shows that the role of glucose in glucose uptake is likely overstated, making 
simulation results with the Sorensen diabetic model questionable with respect to 
accuracy.  The Hovorka model, while able to control glucose during both a glucose 
ingestion and exercise, may overestimate the role of insulin in glucose uptake, as 
predicted infusion rates are much lower than those rates seen in literature [4]. 
 To perform simulations of implicit closed-loop control, a model describing the 
dynamics of glucose diffusion and oxidation, gluconic acid production and diffusion, and 
the changes in the gel pH, device swelling, and device transport properties was developed 
using the quasi steady-state assumption with respect to the particle size.  It was shown 
that the particle size is limited for intravenous use by the diameter of the capillaries, and 
that at the maximum particle size, the diffusion coefficient of insulin in the gel system 
would have to be several orders of magnitude lower than what is realistically possible.  It 
was concluded that microspheres of pH-responsive cationic hydrogels are infeasible for 
use in intravenous insulin delivery. 
 In conclusion, the developed models have the potential to be more descriptive 
than existing models describing the glucose homeostasis system, if patient data of 
sufficient richness becomes available.  Ideally, the data would describe the individual 
effects of each metabolic species on each metabolic rate associated with glucose 
metabolism.  Second, implicit closed-loop control via the intravenous route is not 
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feasible, as release would occur too quickly to be useful.  Finally, the effectiveness of 
intravenous explicit closed-loop control is model dependent, but given its superiority 
relative to the hydrogel in the ability to give a precisely determined insulin dose, the use 
of implanted pumps shows more promise than the use of a polymeric system at utilizing 
the intravenous route to control glucose in diabetic patients. 
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APPENDIX A 
MINIMAL MODEL DERIVATION 
 
To derive minimal model, the pharmacokinetics of the system must be known or 
assumed.  Bergman and Cobelli [1] assumed that glucose metabolism occurred in a single 
well-mixed compartment, that insulin metabolism occurred in one compartment, and that 
any insulin action that affects glucose metabolism occurs only after insulin is bound to 
cells, representing this bound insulin in a “remote” compartment.  They considered three 
primary glucose reactions, excluding the removal of glucose from the kidneys at or above 
a threshold glucose value.  The three reactions were glucose uptake into liver, glucose 
production by the liver, and glucose uptake by the periphery, defined as all other tissue 





−−=     (A.1) 
 
Where the subscripts L and P represent the liver and periphery, respectively.  Because the 
liver is both producing and consuming glucose, the two terms were combined to form the 
net hepatic glucose production rate, NHGP.  Based on physiologic knowledge, NHGP 
was known to have a dependence on both glucose and insulin.  There is also a base level 
of glucose produced independently of concentration.  Based on these assessments, NHGP 
was expressed mathematically by Equation (A.2). 
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( ) ( )[ ] ( )tGtIkkRtNHGP ,prod ′+−= 210    (A.2) 
 
The variable I’(t) represents the insulin concentration in the remote compartment, and by 
inspection it can be seen that the elimination rates are modeled as simple reaction 
kinetics.  NHGP is assumed to be first order with respect to glucose and first order with 
respect to remote compartment insulin.   
Glucose uptake into the periphery is also known to have a glucose dependence 
and an insulin dependence.  To account for the fact that glucose uptake is linear with 
glucose concentration, but not necessarily proportional, the authors introduced a constant 
into the relationship to describe peripheral uptake by Equation (A.3). 
 
( )[ ] ( ) 043 ,P,upP,up RtGtIkkR +′+=     (A.3) 
 
Combining Equations (A.2) and (A.3), results in the equation of glucose 
pharmacokinetics, as shown by (A.4). 
 
( ) ( ) ( ) ( ) ( )[ ] ( )tGtIkkkkRR
dt
tdG
P,upprod ′+++−−= 42310   (A.4) 
 
Insulin is assumed to be produced by the pancreas and eliminated by either uptake 
or degradation. 
 




−=      (A.5) 
 
For diabetic patients, insulin is production is taken to be zero.  All insulin elimination is 
assumed to occur via first order kinetics in insulin.  The rate coefficient of each first order 
process is combined to form the elimination coefficient, n.  Using these assumptions, 
Insulin kinetics, assuming insulin infusion from a source at a rate U(t), is given by 
Equation (A.6). 
 





−=     (A.6) 
 
The parameter V is the total insulin distribution volume. 
 A portion of the insulin in the body is used to increase glucose uptake into liver 
and muscle cells.  The rest is degraded and eliminated.  The pharmacokinetics of insulin 
bound to these cells was assumed to have first order rates of appearance and elimination 
upon being used to enhance uptake. 
 




65    (A.7) 
 
Equations (A.4), (A.6), and (A.7) form the primary equations of the minimal 
model.  Because the estimation of up to 8 model parameters (V, ki, and (Rprod-Rup)0), the 
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authors simplified the model by first defining a variable to replace bound insulin, as 
shown by Equation (A.8). 
 
( ) ( ) ( )tIkktX ′+= 42      (A.8) 
 
With this new proportional variable defined, the authors defined the collective parameters 
given by Equations (A.9-A.12). 
 
311 kkP +=       (A.9) 
52 kP =       (A.10) 
( )4263 kkkP +=      (A.11) 
( ) 010 GPRR upprod =−      (A.12) 
 
As a final modification, Furler and co-authors [2] noted that the bound insulin 
term should not increase above its basal value unless insulin is above its basal value.  The 
authors also defined the reference glucose value, G0, as the basal glucose value.  When all 
these modifications are combined, the result is the minimal model as it is used today: 
 
( ) ( )( ) ( ) ( ) ( )tDtXtGGtGP
dt
tdG
b +−−−= 1    (A.13)  
( ) ( )( ) ( )( )bb ItIPXtXPdt
tdX
−+−−= 32    (A.14) 
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+−=       (A.15) 
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APPENDIX B 
HOVORKA MODEL EQUATIONS 
 
 Unlike the minimal model, Hovorka et al.[3] did not develop collective terms.  
This makes the model straightforward to understand by simply following the process 










1 1−++−++−=   (B.1) 




2 +−=       (B.2) 
( ) ( )
GV
tQtG 1=           (B.3) 
 
Insulin 







−=          (B.4) 
 
Insulin Action 




1 +−=         (B.5) 
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2 +=         (B.6) 




3 +=         (B.7) 
 
Metabolic Sources and Sinks 
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Table B-1: Hovorka Model Variable Definition 
Variable Definition Units 
G Plasma Glucose Concentration mmolL-1 
Q1 Glucose Mass In Compartment 1 mmol 
Q2 Glucose Mass In compartment 2 mmol 
F01 Insulin-indep. Glucose Flux mmol (Lmin)-1 
FR Renal Glucose Clearance mmol (Lmin)-1 
UG Glucose Absorption Rate mmol (Lmin)-1 
I Plasma Insulin Concentration mU L-1 
x1 Insulin Action On Glucose Transport min-1 
x2 Insulin Action on Glucose Uptake min-1 
x3 Insulin Action on Glucose Production min-1 
 






Table B-2: Hovorka Model Parameter Definitions and Values 
Parameter Definition Value Units 
k12 Transfer Rate 0.066 min-1 
ka1 Deactivation Rate 0.006 min-1 
ka2 Deactivation Rate 0.06 min-1 
ka3 Deactivation Rate 0.03 min-1 
kb1 Activation Rate 3.07e-5 min-1 
kb2 Activation Rate 4.92e-5 min-1 
kb3 Activation Rate 1.56e-4 min-1 
ke Insulin Elimination From Plasma 0.138 min-1 
VI Insulin Distribution Kinetics 0.12 L kg-1 
VG Glucose Distribution Volume 0.16 L kg-1 
AG Carbohydrate Bioavailability 0.8 unitless 
tmaxG Time to Maximum Absorption 40 min 
EGP0 Insulin Independent Glucose Prod. 0.0161 mmol kg-1 min-1 
F01 Insulin-Independent Glucose Flux 0.0097 mmol kg-1 min-1 
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APPENDIX C 
SORENSEN MODEL EQUATIONS 
 
Like the Hovorka Model, the Sorensen model [4] mass balances can derived 
simply by writing mass balances for each species at each compartment.  Figures 6-2 
through 6-4 are the diagrams showing the compartment diagrams for each species.  
Sorensen assumed all kinetics can be described by non-dimensional multiplicative factors 
for each species, and that each factor is in the form of a hyperbolic tangent function.  He 
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dGV −−+++=    (C.3) 
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Gut:    
( ) GGUGHGGGGG rGGQdt











dGV −+−+=      (C.5) 
 
Kidney: 
( ) KGEKHGKKGK rGGQdt
dGV −−=        (C.6) 
 
Periphery: 
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Parameter values: 
VGBV = 3.5 dL  GGB = 5.9 dL/min  TB = 2.1 min 
VBI = 4.5 dL  QGH = 43.7 dL/min  TGP = 5.0 min 
VGH = 13.8 dL  QGA = 2.5 dL/min  rBGU = 70 mg/min 
VGL = 25.1 dL  QGL = 12.6 dL/min  rRBCU = 10 mg/min 
VGG = 11.2 dL  QGG = 10.1 dL/min  rGGU = 20 mg/min 
VGK = 6.6 dL  QGK = 10.1 dL/min  rBPGU = 35 mg/min 
VGPV = 10.4 dL  QGP = 15.1 dL/min  rBHGP = 155 mg/min 
VPI = 67.4 dL  τI = 25 min  rBHGU = 20 mg/min  




G = glucose concentration (mg/dL) 
I = insulin concentration (mU/L) 
M = multiplier of basal metabolic rate (dimensionless) 
Q = vascular blood water flow rate (dL/min) 
r = metabolic source or sink rate (mg/min) 
T = transcapillary diffusion time constant (min) 
V = volume (dL) 
τ = time constant (min) 
t = time (min) 
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First subscript : Physiologic Compartment 
B = brain 
G = gut 
H = heart and lungs 
L = liver 
P = periphery 
A = hepatic artery 
 
Second subscript: Physiologic Subcompartment 
I = interstitial fluid space 
V = vascular blood water space 
 
Metabolic Rate Subscripts: 
BGU = brain glucose uptake 
GGU = gut glucose utilization 
HGP = hepatic glucose production 
HGU = hepatic glucose uptake 
KGE = kidney glucose excretion 
PGU = peripheral glucose uptake 
RBCU = red blood cell glucose uptake 
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First Superscript: 
G = glucose model 
I = insulin model 
Г = glucagon 
B = basal value 
 
Second Superscript 
0 = initial value (normalized) 




Brain:   
( )BHIBBIB IIQdt
dIV −=         (C.25) 
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dIV −+−+=       (C.28) 
 
Kidney: 
( ) KICKHIKKIK rIIQdt
dIV −−=         (C.29) 
 
Periphery: 

















dIV −−=        (C.31) 
 
Metabolic Sources and Sinks: 
( )PIRGIGHIALICLIC rIQIQFr ++=        (C.32) 
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Parameter values: 
VIB = 0.26 L  QIB = 0.45 L/min   TIP = 20 min 
VIH = 0.99 L  QIH = 3.12 L/min   FLIC = 0.40 
VIG = 0.94 L  QIA = 0.18 L/min   FKIC = 0.30 
VIL = 1.14 L  QIK = 0.72 L/min   FPIC = 0.15 
VIK = 0.51 L  QIP = 1.05 L/min    
VIPV = 0.74 L  QIG = 0.72 L/min   




I = insulin concentration 
Q = vascular plasma flow rate (L/min) 
r = metabolic source or sink rate (mU/min) 
F = fractional clearance (dimensionless) 
T = transcapillary diffusion time constant 
V = volume (L) 
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First Subscript:  Physiologic Compartment 
B = brain 
G = gut 
H = heart and lungs 
L = liver 
P = periphery 
A = hepatic artery 
 
Second Subscript:  Physiologic Subcompartment 
I = interstitial fluid space 
V = vascular plasma space 
 
Metabolic Rate Subscripts: 
KIC = kidney insulin clearance 
LIC = liver insulin clearance 
PIC = peripheral insulin clearance 
 
First Superscript: 
I = insulin model 
B = basal value 
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Parameter Values: 
VГ = 11310 mL 
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Nomenclature: 
Variables: 
G = glucose concentration (mg/dL) 
I = insulin concentration (mU/L) 
Г = glucagon concentration (pg/mL) 
V = glucagon distribution volume (mL) 
r = metabolic source or sink rate (pg/min) 
M = multiplier of basal metabolic rate (dimensionless) 
t = time (min) 
 
Metabolic Rate Subscripts: 
PГC = plasma glucagon clearance 
MГC = metabolic glucagon clearance 
PГR = pancreatic glucagon release 
 
First Superscript 
G = glucose 
I = insulin 
Г = glucagon 
B = basal value 
 
  315 




















21        (C.40) 
( ) 111.XY =           (C.41) 
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−= α          (C.45) 
 
Parameter Values 
α = 0.0482 min-1 
β = 0.932 min-1 
γ = 0.575 U/min 
K = 0.00747 min-1  
Q0 = 6.33 U 
M1 = 0.00747 min-1  
M2 = 0.0958 min-1 
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Nomenclature : 
P =  Potentiator (dimensionless) 
I =  Inhibitor (dimensionless) 
Q =  labile insulin (U) 
S =  Secretion Rate (U/min) 
X,Y =  Intermediate Variables (dimensionless) 
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APPENDIX D 
TEST DATA FOR PARAMETER ESTIMATION 
Table D-1: One-Compartment Data 
Generated with Stiff Solver 
Time (min) U (mU/min) y (mU/L) 
0 20 0 
1 20 1.2565 
2 20 2.3709 
3 20 3.3594 
4 20 4.2361 
5 20 5.0138 
6 20 5.7036 
7 20 6.3156 
8 20 6.8587 
9 20 7.3398 
10 20 7.7672 
11 20 8.1459 
12 20 8.4825 
13 20 8.7797 
14 20 9.0454 
15 20 9.2797 
16 20 9.4871 
17 20 9.6728 
18 20 9.8368 
19 20 9.9804 
20 20 10.1097 
21 20 10.2248 
22 20 10.3254 
23 20 10.4141 
24 20 10.4941 
25 20 10.5655 
26 20 10.6282 
27 20 10.6824 
28 20 10.7313 
29 20 10.7753 
30 20 10.8143 
31 20 10.8485 
32 20 10.878 
33 20 10.9045 
34 20 10.9285 
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35 20 10.9499 
36 20 10.9686 
37 20 10.9846 
38 20 10.9989 
39 20 11.0119 
40 20 11.0235 
41 20 11.0339 
42 20 11.0429 
43 20 11.0506 
44 20 11.0574 
45 20 11.0636 
46 20 11.0692 
47 20 11.0742 
48 20 11.0786 
49 20 11.0825 
50 20 11.0857 
51 20 11.0885 
52 20 11.0911 
53 20 11.0935 
54 20 11.0956 
55 20 11.0975 
56 20 11.0992 
57 20 11.1007 
58 20 11.1019 
59 20 11.1029 
60 20 11.1038 
61 20 11.1046 
62 20 11.1054 
63 20 11.1061 
64 20 11.1068 
65 20 11.1073 
66 20 11.1078 
67 20 11.1083 
68 20 11.1086 
69 20 11.1089 
70 20 11.1092 
71 20 11.1094 
72 20 11.1096 
73 20 11.1097 
74 20 11.1099 
75 20 11.1101 
76 20 11.1102 
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77 20 11.1103 
78 20 11.1105 
79 20 11.1106 
80 20 11.1107 
81 20 11.1107 
82 20 11.1108 
83 20 11.1109 
84 20 11.1109 
85 20 11.1109 
86 20 11.1109 
87 20 11.111 
88 20 11.111 
89 20 11.111 
90 20 11.111 
91 20 11.111 
92 20 11.111 
93 20 11.111 
94 20 11.111 
95 20 11.1111 
96 20 11.1111 
97 20 11.1111 
98 20 11.1111 
99 20 11.1111 
100 20 11.1111 
101 20 11.1111 
102 20 11.1111 
103 20 11.1111 
104 20 11.1111 
105 20 11.1111 
106 20 11.1111 
107 20 11.1111 
108 20 11.1111 
109 20 11.1111 
110 20 11.1111 
111 20 11.1111 
112 20 11.1111 
113 20 11.1111 
114 20 11.1111 
115 20 11.1111 
116 20 11.1111 
117 20 11.1111 
118 20 11.1111 
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119 20 11.1111 
120 20 11.1111 
121 20 11.1111 
122 20 11.1111 
123 20 11.1111 
124 20 11.1111 
125 20 11.1111 
126 20 11.1111 
127 20 11.1111 
128 20 11.1111 
129 20 11.1111 
130 20 11.1111 
131 20 11.1111 
132 20 11.1111 
133 20 11.1111 
134 20 11.1111 
135 20 11.1111 
136 20 11.1111 
137 20 11.1111 
138 20 11.1111 
139 20 11.1111 
140 20 11.1111 
141 20 11.1111 
142 20 11.1111 
143 20 11.1111 
144 20 11.1111 
145 20 11.1111 
146 20 11.1111 
147 20 11.1111 
148 20 11.1111 
149 20 11.1111 
150 20 11.1007 
151 40 12.3911 
152 40 13.5032 
153 40 14.4918 
154 40 15.3665 
155 40 16.1442 
156 40 16.8321 
157 40 17.4445 
158 40 17.9845 
159 40 18.467 
160 40 18.8924 
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161 40 19.2698 
162 40 19.6074 
163 40 19.9054 
164 40 20.1665 
165 40 20.4017 
166 40 20.6112 
167 40 20.7946 
168 40 20.9553 
169 40 21.1006 
170 40 21.2305 
171 40 21.345 
172 40 21.4437 
173 40 21.5318 
174 40 21.6116 
175 40 21.6831 
176 40 21.7462 
177 40 21.801 
178 40 21.8478 
179 40 21.8905 
180 40 21.9292 
181 40 21.964 
182 40 21.9947 
183 40 22.0214 
184 40 22.044 
185 40 22.064 
186 40 22.0822 
187 40 22.0988 
188 40 22.1136 
189 40 22.1266 
190 40 22.138 
191 40 22.1475 
192 40 22.1558 
193 40 22.1634 
194 40 22.1703 
195 40 22.1766 
196 40 22.1822 
197 40 22.1872 
198 40 22.1914 
199 40 22.195 
200 40 22.198 
201 40 22.2007 
202 40 22.2032 
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203 40 22.2055 
204 40 22.2075 
205 40 22.2094 
206 40 22.2111 
207 40 22.2126 
208 40 22.2138 
209 40 22.2149 
210 40 22.2157 
211 40 22.2164 
212 40 22.217 
213 40 22.2176 
214 40 22.2182 
215 40 22.2187 
216 40 22.2192 
217 40 22.2196 
218 40 22.22 
219 40 22.2203 
220 40 22.2206 
221 40 22.2209 
222 40 22.2211 
223 40 22.2212 
224 40 22.2214 
225 40 22.2215 
226 40 22.2215 
227 40 22.2216 
228 40 22.2217 
229 40 22.2217 
230 40 22.2218 
231 40 22.2219 
232 40 22.2219 
233 40 22.222 
234 40 22.222 
235 40 22.222 
236 40 22.2221 
237 40 22.2221 
238 40 22.2221 
239 40 22.2222 
240 40 22.2222 
241 40 22.2222 
242 40 22.2222 
243 40 22.2222 
244 40 22.2223 
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245 40 22.2223 
246 40 22.2223 
247 40 22.2223 
248 40 22.2223 
249 40 22.2223 
250 40 22.2222 
251 40 22.2222 
252 40 22.2222 
253 40 22.2222 
254 40 22.2222 
255 40 22.2222 
256 40 22.2222 
257 40 22.2222 
258 40 22.2222 
259 40 22.2222 
260 40 22.2222 
261 40 22.2222 
262 40 22.2222 
263 40 22.2222 
264 40 22.2222 
265 40 22.2222 
266 40 22.2222 
267 40 22.2222 
268 40 22.2222 
269 40 22.2222 
270 40 22.2222 
271 40 22.2222 
272 40 22.2222 
273 40 22.2222 
274 40 22.2222 
275 40 22.2222 
276 40 22.2222 
277 40 22.2222 
278 40 22.2222 
279 40 22.2222 
280 40 22.2222 
281 40 22.2222 
282 40 22.2222 
283 40 22.2222 
284 40 22.2222 
285 40 22.2222 
286 40 22.2222 
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287 40 22.2222 
288 40 22.2222 
289 40 22.2222 
290 40 22.2222 
291 40 22.2222 
292 40 22.2222 
293 40 22.2222 
294 40 22.2222 
295 40 22.2222 
296 40 22.2222 
297 40 22.2222 
298 40 22.2222 
299 40 22.2222 
300 40 22.2222 
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Table D-2: One-Compartment Data Generated with 
Nonstiff Solver 
Time (min) U (mU/min) y (mU/L) 
0 20 0 
1 20 1.2564 
2 20 2.3708 
3 20 3.3592 
4 20 4.2357 
5 20 5.0132 
6 20 5.7028 
7 20 6.3144 
8 20 6.8567 
9 20 7.3379 
10 20 7.7646 
11 20 8.143 
12 20 8.4786 
13 20 8.7762 
14 20 9.0404 
15 20 9.2747 
16 20 9.4823 
17 20 9.6664 
18 20 9.8296 
19 20 9.9746 
20 20 10.1033 
21 20 10.2175 
22 20 10.3185 
23 20 10.408 
24 20 10.4873 
25 20 10.5577 
26 20 10.6205 
27 20 10.6762 
28 20 10.7256 
29 20 10.7693 
30 20 10.8079 
31 20 10.842 
32 20 10.8721 
33 20 10.899 
34 20 10.923 
35 20 10.9446 
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36 20 10.9637 
37 20 10.9807 
38 20 10.9957 
39 20 11.0088 
40 20 11.0202 
41 20 11.0302 
42 20 11.039 
43 20 11.0469 
44 20 11.0539 
45 20 11.0605 
46 20 11.0664 
47 20 11.0718 
48 20 11.0766 
49 20 11.0808 
50 20 11.0845 
51 20 11.0876 
52 20 11.0902 
53 20 11.0924 
54 20 11.0943 
55 20 11.0958 
56 20 11.0972 
57 20 11.0985 
58 20 11.0997 
59 20 11.101 
60 20 11.1023 
61 20 11.1035 
62 20 11.1046 
63 20 11.1055 
64 20 11.1064 
65 20 11.1071 
66 20 11.1077 
67 20 11.1081 
68 20 11.1085 
69 20 11.1087 
70 20 11.1088 
71 20 11.1089 
72 20 11.1089 
73 20 11.1089 
74 20 11.1089 
75 20 11.109 
76 20 11.1092 
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77 20 11.1094 
78 20 11.1097 
79 20 11.1099 
80 20 11.1101 
81 20 11.1104 
82 20 11.1105 
83 20 11.1107 
84 20 11.1108 
85 20 11.1109 
86 20 11.111 
87 20 11.111 
88 20 11.111 
89 20 11.111 
90 20 11.111 
91 20 11.1109 
92 20 11.1108 
93 20 11.1107 
94 20 11.1106 
95 20 11.1106 
96 20 11.1106 
97 20 11.1106 
98 20 11.1106 
99 20 11.1108 
100 20 11.1109 
101 20 11.111 
102 20 11.1112 
103 20 11.1113 
104 20 11.1115 
105 20 11.1116 
106 20 11.1118 
107 20 11.1119 
108 20 11.1119 
109 20 11.112 
110 20 11.112 
111 20 11.112 
112 20 11.112 
113 20 11.1119 
114 20 11.1118 
115 20 11.1117 
116 20 11.1115 
117 20 11.1114 
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118 20 11.1112 
119 20 11.111 
120 20 11.1109 
121 20 11.1107 
122 20 11.1105 
123 20 11.1104 
124 20 11.1103 
125 20 11.1102 
126 20 11.1102 
127 20 11.1102 
128 20 11.1103 
129 20 11.1104 
130 20 11.1105 
131 20 11.1106 
132 20 11.1106 
133 20 11.1107 
134 20 11.1107 
135 20 11.1108 
136 20 11.1108 
137 20 11.1108 
138 20 11.1109 
139 20 11.1109 
140 20 11.1109 
141 20 11.1109 
142 20 11.111 
143 20 11.111 
144 20 11.111 
145 20 11.111 
146 20 11.0073 
147 20 10.8805 
148 20 11.0814 
149 20 11.754 
150 20 12.8278 
151 40 14.0177 
152 40 14.9647 
153 40 15.7863 
154 40 16.5146 
155 40 17.1599 
156 40 17.7316 
157 40 18.2386 
158 40 18.689 
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159 40 19.0888 
160 40 19.4433 
161 40 19.7575 
162 40 20.036 
163 40 20.283 
164 40 20.5025 
165 40 20.6974 
166 40 20.8701 
167 40 21.023 
168 40 21.1584 
169 40 21.2783 
170 40 21.3847 
171 40 21.4796 
172 40 21.564 
173 40 21.6388 
174 40 21.705 
175 40 21.7635 
176 40 21.8151 
177 40 21.8607 
178 40 21.9012 
179 40 21.9374 
180 40 21.9699 
181 40 21.9989 
182 40 22.0247 
183 40 22.0474 
184 40 22.0674 
185 40 22.0849 
186 40 22.1001 
187 40 22.1135 
188 40 22.1252 
189 40 22.1357 
190 40 22.1454 
191 40 22.1543 
192 40 22.1625 
193 40 22.1699 
194 40 22.1765 
195 40 22.1823 
196 40 22.1872 
197 40 22.1914 
198 40 22.1949 
199 40 22.1978 
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200 40 22.2001 
201 40 22.202 
202 40 22.2036 
203 40 22.205 
204 40 22.2064 
205 40 22.208 
206 40 22.2097 
207 40 22.2114 
208 40 22.213 
209 40 22.2144 
210 40 22.2157 
211 40 22.2168 
212 40 22.2178 
213 40 22.2185 
214 40 22.2191 
215 40 22.2195 
216 40 22.2197 
217 40 22.2198 
218 40 22.2197 
219 40 22.2196 
220 40 22.2195 
221 40 22.2193 
222 40 22.2192 
223 40 22.2193 
224 40 22.2195 
225 40 22.2199 
226 40 22.2204 
227 40 22.2208 
228 40 22.2213 
229 40 22.2217 
230 40 22.2221 
231 40 22.2225 
232 40 22.2228 
233 40 22.223 
234 40 22.2232 
235 40 22.2233 
236 40 22.2233 
237 40 22.2232 
238 40 22.2231 
239 40 22.2229 
240 40 22.2226 
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241 40 22.2223 
242 40 22.222 
243 40 22.2216 
244 40 22.2213 
245 40 22.221 
246 40 22.2207 
247 40 22.2206 
248 40 22.2205 
249 40 22.2207 
250 40 22.2209 
251 40 22.2213 
252 40 22.2217 
253 40 22.2222 
254 40 22.2226 
255 40 22.2231 
256 40 22.2236 
257 40 22.224 
258 40 22.2243 
259 40 22.2246 
260 40 22.2248 
261 40 22.2249 
262 40 22.225 
263 40 22.2249 
264 40 22.2248 
265 40 22.2245 
266 40 22.2242 
267 40 22.2238 
268 40 22.2234 
269 40 22.2229 
270 40 22.2223 
271 40 22.2218 
272 40 22.2212 
273 40 22.2207 
274 40 22.2202 
275 40 22.2198 
276 40 22.2195 
277 40 22.2193 
278 40 22.2193 
279 40 22.2196 
280 40 22.2199 
281 40 22.2202 
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282 40 22.2206 
283 40 22.2209 
284 40 22.2212 
285 40 22.2214 
286 40 22.2216 
287 40 22.2218 
288 40 22.2219 
289 40 22.222 
290 40 22.2221 
291 40 22.2221 
292 40 22.222 
293 40 22.222 
294 40 22.2219 
295 40 22.2218 
296 40 22.2217 
297 40 22.2216 
298 40 22.2215 
299 40 22.2215 
300 40 22.2215 
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Table D-3: Test Data with 5% Noise 
Time (min) U (mU/min) y (mU/L) 
0 20 0 
1 20 1.1936 
2 20 2.4895 
3 20 3.1914 
4 20 4.4479 
5 20 4.7631 
6 20 5.9888 
7 20 5.9998 
8 20 7.2016 
9 20 6.9728 
10 20 8.1555 
11 20 7.7386 
12 20 8.9066 
13 20 8.3407 
14 20 9.4977 
15 20 8.8157 
16 20 9.9615 
17 20 9.1892 
18 20 10.3286 
19 20 9.4814 
20 20 10.6152 
21 20 9.7136 
22 20 10.8417 
23 20 9.8934 
24 20 11.0188 
25 20 10.0372 
26 20 11.1596 
27 20 10.1483 
28 20 11.2678 
29 20 10.2365 
30 20 11.3551 
31 20 10.3061 
32 20 11.4219 
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33 20 10.3593 
34 20 11.4749 
35 20 10.4024 
36 20 11.517 
37 20 10.4354 
38 20 11.5489 
39 20 10.4613 
40 20 11.5747 
41 20 10.4822 
42 20 11.595 
43 20 10.498 
44 20 11.6102 
45 20 10.5104 
46 20 11.6226 
47 20 10.5205 
48 20 11.6326 
49 20 10.5283 
50 20 11.64 
51 20 10.5341 
52 20 11.6456 
53 20 10.5388 
54 20 11.6504 
55 20 10.5426 
56 20 11.6542 
57 20 10.5456 
58 20 11.657 
59 20 10.5477 
60 20 11.659 
61 20 10.5494 
62 20 11.6607 
63 20 10.5508 
64 20 11.6621 
65 20 10.552 
66 20 11.6632 
67 20 10.5529 
68 20 11.6641 
69 20 10.5535 
  335 
70 20 11.6646 
71 20 10.5539 
72 20 11.665 
73 20 10.5543 
74 20 11.6654 
75 20 10.5546 
76 20 11.6657 
77 20 10.5548 
78 20 11.666 
79 20 10.555 
80 20 11.6662 
81 20 10.5552 
82 20 11.6663 
83 20 10.5553 
84 20 11.6664 
85 20 10.5554 
86 20 11.6665 
87 20 10.5554 
88 20 11.6665 
89 20 10.5554 
90 20 11.6665 
91 20 10.5555 
92 20 11.6666 
93 20 10.5555 
94 20 11.6666 
95 20 10.5555 
96 20 11.6666 
97 20 10.5555 
98 20 11.6666 
99 20 10.5555 
100 20 11.6667 
101 20 10.5556 
102 20 11.6667 
103 20 10.5556 
104 20 11.6667 
105 20 10.5556 
106 20 11.6667 
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107 20 10.5556 
108 20 11.6667 
109 20 10.5556 
110 20 11.6667 
111 20 10.5556 
112 20 11.6667 
113 20 10.5556 
114 20 11.6667 
115 20 10.5556 
116 20 11.6667 
117 20 10.5556 
118 20 11.6667 
119 20 10.5556 
120 20 11.6667 
121 20 10.5556 
122 20 11.6667 
123 20 10.5556 
124 20 11.6667 
125 20 10.5556 
126 20 11.6667 
127 20 10.5556 
128 20 11.6667 
129 20 10.5556 
130 20 11.6667 
131 20 10.5556 
132 20 11.6667 
133 20 10.5556 
134 20 11.6667 
135 20 10.5556 
136 20 11.6667 
137 20 10.5556 
138 20 11.6667 
139 20 10.5556 
140 20 11.6667 
141 20 10.5556 
142 20 11.6667 
143 20 10.5556 
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144 20 11.6667 
145 20 10.5556 
146 20 11.6667 
147 20 10.5556 
148 20 11.6667 
149 20 10.5556 
150 20 11.6558 
151 40 11.7716 
152 40 14.1784 
153 40 13.7672 
154 40 16.1349 
155 40 15.337 
156 40 17.6737 
157 40 16.5722 
158 40 18.8838 
159 40 17.5437 
160 40 19.837 
161 40 18.3063 
162 40 20.5878 
163 40 18.9101 
164 40 21.1748 
165 40 19.3816 
166 40 21.6417 
167 40 19.7548 
168 40 22.0031 
169 40 20.0456 
170 40 22.2921 
171 40 20.2778 
172 40 22.5158 
173 40 20.4552 
174 40 22.6922 
175 40 20.5989 
176 40 22.8335 
177 40 20.7109 
178 40 22.9402 
179 40 20.796 
180 40 23.0257 
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181 40 20.8658 
182 40 23.0944 
183 40 20.9203 
184 40 23.1462 
185 40 20.9608 
186 40 23.1863 
187 40 20.9938 
188 40 23.2192 
189 40 21.0203 
190 40 23.2449 
191 40 21.0401 
192 40 23.2635 
193 40 21.0552 
194 40 23.2788 
195 40 21.0678 
196 40 23.2913 
197 40 21.0778 
198 40 23.301 
199 40 21.0853 
200 40 23.3079 
201 40 21.0906 
202 40 23.3133 
203 40 21.0952 
204 40 23.3179 
205 40 21.0989 
206 40 23.3216 
207 40 21.1019 
208 40 23.3245 
209 40 21.1041 
210 40 23.3265 
211 40 21.1055 
212 40 23.3279 
213 40 21.1067 
214 40 23.3291 
215 40 21.1077 
216 40 23.3301 
217 40 21.1086 
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218 40 23.331 
219 40 21.1093 
220 40 23.3316 
221 40 21.1098 
222 40 23.3321 
223 40 21.1102 
224 40 23.3324 
225 40 21.1104 
226 40 23.3326 
227 40 21.1105 
228 40 23.3328 
229 40 21.1106 
230 40 23.3329 
231 40 21.1108 
232 40 23.333 
233 40 21.1109 
234 40 23.3331 
235 40 21.1109 
236 40 23.3332 
237 40 21.111 
238 40 23.3333 
239 40 21.1111 
240 40 23.3333 
241 40 21.1111 
242 40 23.3333 
243 40 21.1111 
244 40 23.3334 
245 40 21.1111 
246 40 23.3334 
247 40 21.1111 
248 40 23.3334 
249 40 21.1111 
250 40 23.3334 
251 40 21.1111 
252 40 23.3334 
253 40 21.1111 
254 40 23.3333 
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255 40 21.1111 
256 40 23.3333 
257 40 21.1111 
258 40 23.3333 
259 40 21.1111 
260 40 23.3333 
261 40 21.1111 
262 40 23.3333 
263 40 21.1111 
264 40 23.3333 
265 40 21.1111 
266 40 23.3333 
267 40 21.1111 
268 40 23.3333 
269 40 21.1111 
270 40 23.3333 
271 40 21.1111 
272 40 23.3333 
273 40 21.1111 
274 40 23.3333 
275 40 21.1111 
276 40 23.3333 
277 40 21.1111 
278 40 23.3333 
279 40 21.1111 
280 40 23.3333 
281 40 21.1111 
282 40 23.3333 
283 40 21.1111 
284 40 23.3333 
285 40 21.1111 
286 40 23.3333 
287 40 21.1111 
288 40 23.3333 
289 40 21.1111 
290 40 23.3333 
291 40 21.1111 
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292 40 23.3333 
293 40 21.1111 
294 40 23.3333 
295 40 21.1111 
296 40 23.3333 
297 40 21.1111 
298 40 23.3333 
299 40 21.1111 
300 40 23.3333 
 
  342 
 
Table D-4: Test Data with Random Noise 
Time (min) U (mU/min) y (mU/L) 
0 20 0.9501 
1 20 1.4876 
2 20 2.9778 
3 20 3.8454 
4 20 5.1274 
5 20 5.7759 
6 20 6.1601 
7 20 6.3341 
8 20 7.6801 
9 20 7.7845 
10 20 8.3826 
11 20 8.9378 
12 20 9.4043 
13 20 9.5179 
14 20 9.2217 
15 20 9.6854 
16 20 10.4226 
17 20 10.5897 
18 20 10.2471 
19 20 10.8741 
20 20 10.1676 
21 20 10.5777 
22 20 11.1386 
23 20 10.424 
24 20 10.633 
25 20 10.7683 
26 20 10.8269 
27 20 11.2862 
28 20 11.0035 
29 20 10.9741 
30 20 10.8296 
31 20 11.5953 
32 20 11.3231 
33 20 11.8363 
34 20 11.3945 
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35 20 11.3685 
36 20 11.8148 
37 20 11.5098 
38 20 11.2016 
39 20 11.684 
40 20 11.8616 
41 20 11.0535 
42 20 11.7242 
43 20 11.43 
44 20 11.8891 
45 20 11.5664 
46 20 11.7786 
47 20 11.5031 
48 20 11.3832 
49 20 11.2721 
50 20 11.2791 
51 20 11.7707 
52 20 11.3939 
53 20 11.6351 
54 20 11.2465 
55 20 11.7954 
56 20 11.4776 
57 20 11.9607 
58 20 11.9556 
59 20 11.6964 
60 20 11.6003 
61 20 12.0044 
62 20 11.927 
63 20 11.751 
64 20 11.9247 
65 20 11.7676 
66 20 11.4498 
67 20 11.398 
68 20 11.4498 
69 20 11.643 
70 20 11.8363 
71 20 11.4187 
72 20 11.9481 
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73 20 11.6778 
74 20 11.4803 
75 20 11.8128 
76 20 11.6568 
77 20 11.5552 
78 20 11.805 
79 20 11.7319 
80 20 11.9055 
81 20 12.0676 
82 20 11.6334 
83 20 11.991 
84 20 11.2838 
85 20 12.0907 
86 20 11.3824 
87 20 11.3633 
88 20 11.9867 
89 20 11.8483 
90 20 11.2475 
91 20 11.1228 
92 20 12.0049 
93 20 11.3102 
94 20 11.4098 
95 20 11.7725 
96 20 11.3955 
97 20 11.5803 
98 20 11.1759 
99 20 12.0994 
100 20 11.6939 
101 20 11.5346 
102 20 11.6266 
103 20 11.4451 
104 20 11.544 
105 20 11.3371 
106 20 11.6909 
107 20 11.8715 
108 20 11.641 
109 20 11.7517 
110 20 11.3202 
  345 
111 20 11.4909 
112 20 11.8945 
113 20 11.792 
114 20 11.5722 
115 20 11.6789 
116 20 11.9053 
117 20 11.1703 
118 20 11.714 
119 20 11.1614 
120 20 11.5265 
121 20 11.4161 
122 20 11.9855 
123 20 11.1261 
124 20 11.8791 
125 20 12.082 
126 20 12.1012 
127 20 11.9 
128 20 11.5498 
129 20 11.6094 
130 20 11.3251 
131 20 11.7546 
132 20 11.4311 
133 20 12.0712 
134 20 11.8377 
135 20 11.5231 
136 20 11.8557 
137 20 11.3791 
138 20 11.551 
139 20 12.0445 
140 20 11.7944 
141 20 11.3237 
142 20 11.9503 
143 20 11.7399 
144 20 11.2449 
145 20 11.3182 
146 20 11.7183 
147 20 11.741 
148 20 11.4816 
  346 
149 20 11.6863 
150 20 11.5522 
151 40 12.435 
152 40 13.5304 
153 40 14.8045 
154 40 15.3794 
155 40 16.5282 
156 40 17.5152 
157 40 17.5373 
158 40 18.0199 
159 40 19.0794 
160 40 19.5009 
161 40 19.2855 
162 40 19.6238 
163 40 20.0955 
164 40 20.7534 
165 40 20.4593 
166 40 20.9787 
167 40 21.426 
168 40 21.6729 
169 40 21.7933 
170 40 21.3146 
171 40 21.7994 
172 40 21.8855 
173 40 21.885 
174 40 21.7652 
175 40 22.3587 
176 40 22.4454 
177 40 22.5285 
178 40 22.3262 
179 40 22.4454 
180 40 22.0503 
181 40 22.4147 
182 40 22.7106 
183 40 22.9143 
184 40 22.3171 
185 40 22.3187 
186 40 22.9478 
  347 
187 40 22.3311 
188 40 22.9184 
189 40 23.035 
190 40 22.3699 
191 40 22.3868 
192 40 22.2055 
193 40 22.2418 
194 40 22.8111 
195 40 22.3675 
196 40 23.0261 
197 40 22.3611 
198 40 22.3622 
199 40 23.1893 
200 40 22.6378 
201 40 22.5407 
202 40 22.5174 
203 40 22.5705 
204 40 22.6008 
205 40 22.8009 
206 40 22.3308 
207 40 22.2507 
208 40 22.6724 
209 40 23.0847 
210 40 23.1499 
211 40 22.4808 
212 40 22.3773 
213 40 23.0905 
214 40 22.456 
215 40 22.8645 
216 40 23.186 
217 40 22.8845 
218 40 23.0903 
219 40 22.2302 
220 40 22.3576 
221 40 23.0396 
222 40 22.6512 
223 40 23.1116 
224 40 22.9563 
  348 
225 40 22.9088 
226 40 22.5676 
227 40 22.3876 
228 40 22.3773 
229 40 22.4129 
230 40 22.6442 
231 40 23.0778 
232 40 22.7122 
233 40 23.0379 
234 40 22.6828 
235 40 22.6794 
236 40 22.6728 
237 40 22.6343 
238 40 23.1238 
239 40 22.2278 
240 40 22.5196 
241 40 22.2714 
242 40 22.9154 
243 40 22.8724 
244 40 23.2052 
245 40 22.7749 
246 40 22.6223 
247 40 22.421 
248 40 22.8475 
249 40 22.9556 
250 40 22.5981 
251 40 22.2321 
252 40 22.6421 
253 40 22.9759 
254 40 23.0161 
255 40 23.1422 
256 40 23.067 
257 40 22.59 
258 40 22.843 
259 40 22.9535 
260 40 22.4161 
261 40 23.127 
262 40 22.7914 
  349 
263 40 22.854 
264 40 22.4566 
265 40 22.771 
266 40 23.1538 
267 40 22.5574 
268 40 22.8777 
269 40 22.6141 
270 40 22.8495 
271 40 22.9213 
272 40 22.6194 
273 40 22.6358 
274 40 22.8774 
275 40 23.0598 
276 40 22.5938 
277 40 22.6475 
278 40 22.8169 
279 40 22.788 
280 40 22.9388 
281 40 22.7335 
282 40 22.9986 
283 40 22.7116 
284 40 22.4081 
285 40 22.9229 
286 40 23.2049 
287 40 23.0289 
288 40 22.9258 
289 40 22.7072 
290 40 22.3368 
291 40 22.8871 
292 40 22.5876 
293 40 22.3623 
294 40 22.789 
295 40 23.0452 
296 40 22.8962 
297 40 23.2217 
298 40 23.1839 
299 40 22.2811 
300 40 22.5825 
  350 
Table D-5: Two-Compartment Test Data with Stiff Solver 
Time (min) U (mU/min) y (mU/L) 
0 20 0 
1 20 2.9367 
2 20 5.2088 
3 20 6.9742 
4 20 8.3524 
5 20 9.4356 
6 20 10.2923 
7 20 10.9751 
8 20 11.5246 
9 20 11.9716 
10 20 12.3404 
11 20 12.648 
12 20 12.9072 
13 20 13.131 
14 20 13.324 
15 20 13.4955 
16 20 13.6473 
17 20 13.7854 
18 20 13.9107 
19 20 14.0266 
20 20 14.1344 
21 20 14.2347 
22 20 14.3296 
23 20 14.4192 
24 20 14.5039 
25 20 14.5849 
26 20 14.6623 
27 20 14.736 
28 20 14.8066 
29 20 14.8746 
30 20 14.94 
31 20 15.0027 
32 20 15.0628 
33 20 15.1207 
34 20 15.1766 
  351 
35 20 15.2305 
36 20 15.2823 
37 20 15.332 
38 20 15.3801 
39 20 15.4264 
40 20 15.4711 
41 20 15.5142 
42 20 15.5556 
43 20 15.5955 
44 20 15.6341 
45 20 15.6713 
46 20 15.7071 
47 20 15.7415 
48 20 15.7748 
49 20 15.8069 
50 20 15.8378 
51 20 15.8676 
52 20 15.8963 
53 20 15.924 
54 20 15.9507 
55 20 15.9765 
56 20 16.0014 
57 20 16.0252 
58 20 16.0482 
59 20 16.0705 
60 20 16.092 
61 20 16.1128 
62 20 16.1328 
63 20 16.152 
64 20 16.1705 
65 20 16.1883 
66 20 16.2055 
67 20 16.2221 
68 20 16.2382 
69 20 16.2537 
70 20 16.2686 
71 20 16.283 
72 20 16.2968 
  352 
73 20 16.31 
74 20 16.3228 
75 20 16.3352 
76 20 16.3472 
77 20 16.3588 
78 20 16.37 
79 20 16.3807 
80 20 16.391 
81 20 16.401 
82 20 16.4105 
83 20 16.4197 
84 20 16.4286 
85 20 16.4372 
86 20 16.4455 
87 20 16.4535 
88 20 16.4612 
89 20 16.4686 
90 20 16.4758 
91 20 16.4826 
92 20 16.4892 
93 20 16.4956 
94 20 16.5018 
95 20 16.5078 
96 20 16.5135 
97 20 16.5191 
98 20 16.5244 
99 20 16.5295 
100 20 16.5344 
101 20 16.5392 
102 20 16.5438 
103 20 16.5482 
104 20 16.5525 
105 20 16.5566 
106 20 16.5606 
107 20 16.5644 
108 20 16.5681 
109 20 16.5716 
110 20 16.5751 
  353 
111 20 16.5784 
112 20 16.5816 
113 20 16.5846 
114 20 16.5876 
115 20 16.5905 
116 20 16.5932 
117 20 16.5958 
118 20 16.5984 
119 20 16.6008 
120 20 16.6032 
121 20 16.6055 
122 20 16.6077 
123 20 16.6099 
124 20 16.6119 
125 20 16.6139 
126 20 16.6158 
127 20 16.6176 
128 20 16.6194 
129 20 16.6211 
130 20 16.6227 
131 20 16.6243 
132 20 16.6258 
133 20 16.6273 
134 20 16.6287 
135 20 16.6301 
136 20 16.6314 
137 20 16.6327 
138 20 16.6339 
139 20 16.6351 
140 20 16.6362 
141 20 16.6373 
142 20 16.6384 
143 20 16.6394 
144 20 16.6404 
145 20 16.6413 
146 20 16.6422 
147 20 16.6431 
148 20 16.644 
  354 
149 20 16.6448 
150 20 16.6297 
151 40 19.6076 
152 40 21.8752 
153 40 23.6371 
154 40 25.0135 
155 40 26.0948 
156 40 26.9508 
157 40 27.6328 
158 40 28.1814 
159 40 28.6282 
160 40 28.9973 
161 40 29.3038 
162 40 29.5637 
163 40 29.7868 
164 40 29.9807 
165 40 30.1516 
166 40 30.3044 
167 40 30.4419 
168 40 30.5682 
169 40 30.6838 
170 40 30.7919 
171 40 30.8929 
172 40 30.9876 
173 40 31.0776 
174 40 31.1629 
175 40 31.2438 
176 40 31.3214 
177 40 31.3956 
178 40 31.4667 
179 40 31.5346 
180 40 31.6 
181 40 31.6631 
182 40 31.7236 
183 40 31.7817 
184 40 31.8377 
185 40 31.8917 
186 40 31.9437 
  355 
187 40 31.9937 
188 40 32.0418 
189 40 32.0883 
190 40 32.1332 
191 40 32.1765 
192 40 32.2181 
193 40 32.2582 
194 40 32.2968 
195 40 32.3341 
196 40 32.3701 
197 40 32.4047 
198 40 32.438 
199 40 32.4702 
200 40 32.5013 
201 40 32.5314 
202 40 32.5602 
203 40 32.588 
204 40 32.6147 
205 40 32.6406 
206 40 32.6656 
207 40 32.6897 
208 40 32.7129 
209 40 32.7353 
210 40 32.7567 
211 40 32.7774 
212 40 32.7974 
213 40 32.8167 
214 40 32.8354 
215 40 32.8534 
216 40 32.8707 
217 40 32.8874 
218 40 32.9034 
219 40 32.9188 
220 40 32.9337 
221 40 32.9482 
222 40 32.9621 
223 40 32.9755 
224 40 32.9884 
  356 
225 40 33.0007 
226 40 33.0126 
227 40 33.0242 
228 40 33.0354 
229 40 33.0461 
230 40 33.0565 
231 40 33.0666 
232 40 33.0762 
233 40 33.0854 
234 40 33.0943 
235 40 33.1029 
236 40 33.1112 
237 40 33.1192 
238 40 33.127 
239 40 33.1345 
240 40 33.1417 
241 40 33.1486 
242 40 33.1552 
243 40 33.1616 
244 40 33.1678 
245 40 33.1737 
246 40 33.1795 
247 40 33.1851 
248 40 33.1904 
249 40 33.1956 
250 40 33.2006 
251 40 33.2054 
252 40 33.2099 
253 40 33.2144 
254 40 33.2187 
255 40 33.2228 
256 40 33.2268 
257 40 33.2307 
258 40 33.2344 
259 40 33.2379 
260 40 33.2414 
261 40 33.2447 
262 40 33.2479 
  357 
263 40 33.2509 
264 40 33.2539 
265 40 33.2568 
266 40 33.2596 
267 40 33.2622 
268 40 33.2648 
269 40 33.2672 
270 40 33.2696 
271 40 33.2719 
272 40 33.2741 
273 40 33.2763 
274 40 33.2783 
275 40 33.2803 
276 40 33.2822 
277 40 33.2841 
278 40 33.2858 
279 40 33.2875 
280 40 33.2892 
281 40 33.2908 
282 40 33.2923 
283 40 33.2938 
284 40 33.2952 
285 40 33.2966 
286 40 33.2979 
287 40 33.2992 
288 40 33.3004 
289 40 33.3016 
290 40 33.3028 
291 40 33.3039 
292 40 33.3049 
293 40 33.306 
294 40 33.3069 
295 40 33.3079 
296 40 33.3088 
297 40 33.3097 
298 40 33.3105 
299 40 33.3114 
300 40 33.3122 
  358 
Table D-6: Two-Compartment Test Data with Nonstiff Solver 
Time (min) U (mU/min) y (mU/L) 
0 20 0 
1 20 2.9367 
2 20 5.2085 
3 20 6.9733 
4 20 8.3509 
5 20 9.4328 
6 20 10.2884 
7 20 10.9709 
8 20 11.5204 
9 20 11.9672 
10 20 12.3359 
11 20 12.6433 
12 20 12.9029 
13 20 13.1263 
14 20 13.3206 
15 20 13.4912 
16 20 13.6435 
17 20 13.7821 
18 20 13.9087 
19 20 14.0247 
20 20 14.1318 
21 20 14.2321 
22 20 14.3275 
23 20 14.418 
24 20 14.5037 
25 20 14.5845 
26 20 14.6611 
27 20 14.7341 
28 20 14.8045 
29 20 14.8728 
30 20 14.9385 
31 20 15.0014 
32 20 15.0618 
33 20 15.1197 
34 20 15.1753 
35 20 15.2289 
36 20 15.2808 
37 20 15.3308 
  359 
38 20 15.3791 
39 20 15.4255 
40 20 15.4702 
41 20 15.5132 
42 20 15.5545 
43 20 15.5943 
44 20 15.6328 
45 20 15.6699 
46 20 15.7058 
47 20 15.7405 
48 20 15.7739 
49 20 15.8061 
50 20 15.8371 
51 20 15.8669 
52 20 15.8956 
53 20 15.9232 
54 20 15.9497 
55 20 15.9752 
56 20 15.9999 
57 20 16.0237 
58 20 16.0468 
59 20 16.0692 
60 20 16.0908 
61 20 16.1115 
62 20 16.1315 
63 20 16.1507 
64 20 16.1692 
65 20 16.1871 
66 20 16.2043 
67 20 16.2209 
68 20 16.2369 
69 20 16.2524 
70 20 16.2673 
71 20 16.2816 
72 20 16.2954 
73 20 16.3088 
74 20 16.3216 
75 20 16.334 
76 20 16.3459 
77 20 16.3575 
  360 
78 20 16.3686 
79 20 16.3793 
80 20 16.3896 
81 20 16.3996 
82 20 16.4092 
83 20 16.4184 
84 20 16.4273 
85 20 16.4359 
86 20 16.4442 
87 20 16.4522 
88 20 16.4599 
89 20 16.4673 
90 20 16.4745 
91 20 16.4814 
92 20 16.4881 
93 20 16.4945 
94 20 16.5007 
95 20 16.5066 
96 20 16.5124 
97 20 16.5179 
98 20 16.5232 
99 20 16.5284 
100 20 16.5333 
101 20 16.5381 
102 20 16.5427 
103 20 16.5472 
104 20 16.5515 
105 20 16.5556 
106 20 16.5596 
107 20 16.5635 
108 20 16.5672 
109 20 16.5707 
110 20 16.5742 
111 20 16.5775 
112 20 16.5807 
113 20 16.5838 
114 20 16.5868 
115 20 16.5896 
116 20 16.5924 
117 20 16.5951 
  361 
118 20 16.5976 
119 20 16.6001 
120 20 16.6025 
121 20 16.6048 
122 20 16.607 
123 20 16.6092 
124 20 16.6112 
125 20 16.6132 
126 20 16.6152 
127 20 16.617 
128 20 16.6188 
129 20 16.6205 
130 20 16.6222 
131 20 16.6238 
132 20 16.6253 
133 20 16.6268 
134 20 16.6282 
135 20 16.6296 
136 20 16.6309 
137 20 16.6322 
138 20 16.6335 
139 20 16.6346 
140 20 16.6358 
141 20 16.6369 
142 20 16.638 
143 20 16.639 
144 20 16.64 
145 20 16.6409 
146 20 16.6419 
147 20 16.6428 
148 20 16.6436 
149 20 16.6445 
150 20 16.6428 
151 40 19.5506 
152 40 21.8304 
153 40 23.6014 
154 40 24.9839 
155 40 26.0697 
156 40 26.9283 
157 40 27.6134 
  362 
158 40 28.1646 
159 40 28.6136 
160 40 28.9836 
161 40 29.2918 
162 40 29.5529 
163 40 29.7773 
164 40 29.9718 
165 40 30.1431 
166 40 30.297 
167 40 30.4361 
168 40 30.5625 
169 40 30.6784 
170 40 30.7864 
171 40 30.8886 
172 40 30.9852 
173 40 31.0758 
174 40 31.1608 
175 40 31.2409 
176 40 31.3171 
177 40 31.391 
178 40 31.4627 
179 40 31.5315 
180 40 31.5974 
181 40 31.6605 
182 40 31.7209 
183 40 31.7789 
184 40 31.8348 
185 40 31.8889 
186 40 31.9412 
187 40 31.9915 
188 40 32.04 
189 40 32.0865 
190 40 32.1313 
191 40 32.1744 
192 40 32.2159 
193 40 32.2559 
194 40 32.2946 
195 40 32.3321 
196 40 32.3683 
197 40 32.4032 
  363 
198 40 32.4368 
199 40 32.4691 
200 40 32.5002 
201 40 32.53 
202 40 32.5586 
203 40 32.5862 
204 40 32.6127 
205 40 32.6384 
206 40 32.6632 
207 40 32.6873 
208 40 32.7107 
209 40 32.7331 
210 40 32.7548 
211 40 32.7756 
212 40 32.7957 
213 40 32.8149 
214 40 32.8335 
215 40 32.8515 
216 40 32.8688 
217 40 32.8855 
218 40 32.9016 
219 40 32.9171 
220 40 32.9321 
221 40 32.9465 
222 40 32.9604 
223 40 32.9738 
224 40 32.9867 
225 40 32.9991 
226 40 33.0112 
227 40 33.0227 
228 40 33.0339 
229 40 33.0447 
230 40 33.055 
231 40 33.065 
232 40 33.0746 
233 40 33.0839 
234 40 33.0929 
235 40 33.1015 
236 40 33.1098 
237 40 33.1179 
  364 
238 40 33.1256 
239 40 33.1331 
240 40 33.1403 
241 40 33.1472 
242 40 33.1539 
243 40 33.1604 
244 40 33.1666 
245 40 33.1725 
246 40 33.1783 
247 40 33.1838 
248 40 33.1892 
249 40 33.1944 
250 40 33.1994 
251 40 33.2042 
252 40 33.2088 
253 40 33.2133 
254 40 33.2176 
255 40 33.2218 
256 40 33.2258 
257 40 33.2296 
258 40 33.2334 
259 40 33.237 
260 40 33.2404 
261 40 33.2438 
262 40 33.247 
263 40 33.2501 
264 40 33.2531 
265 40 33.256 
266 40 33.2587 
267 40 33.2614 
268 40 33.264 
269 40 33.2665 
270 40 33.2689 
271 40 33.2712 
272 40 33.2734 
273 40 33.2756 
274 40 33.2777 
275 40 33.2797 
276 40 33.2816 
277 40 33.2834 
  365 
278 40 33.2852 
279 40 33.287 
280 40 33.2886 
281 40 33.2902 
282 40 33.2918 
283 40 33.2933 
284 40 33.2947 
285 40 33.2961 
286 40 33.2974 
287 40 33.2987 
288 40 33.3 
289 40 33.3012 
290 40 33.3023 
291 40 33.3034 
292 40 33.3045 
293 40 33.3055 
294 40 33.3065 
295 40 33.3075 
296 40 33.3084 
297 40 33.3093 
298 40 33.3102 
299 40 33.311 
300 40 33.3118 
  366 
APPENDIX E 




% Created by Terry Farmer, 7/26/06 
  
% Purpose- To use parameter estimation to determination the optimal 





% First, get parameters 
A01 = .2; %min^-1 
A12 = 0.4; %min^-1 
A13 = 0.04; %min^-1 
A21 = .1; %min^-1 
A31 = .02; %min^-1 
V = 4; %L 
global tdata yode1 
  
tdata = [0:1:300]; 
y0 = 0; %mU/L 
x20 = 0; %mU 




yode1 = xode1(:,1); 
 
%Initial Guess for parameters 
    P01 = [.2;.4;.04;.1;.02;2]; 
LB = [0;0;0;0;0;.001]; % Lower Bounds 













  367 
ypost1 = Xpost1(:,1); 
S11 = Xpost1(:,4); 
S12 = Xpost1(:,5); 
S13 = Xpost1(:,6); 
S14 = Xpost1(:,7); 
S15 = Xpost1(:,8); 
S16 = Xpost1(:,9); 
 
% Confidence Interval Calculations 
S = [S11 S12 S13 S14 S15 S16]; % Sensitivity Matrix 
H = 2*S'*S; 
np = length(P); % Number of parameters 
nd = length(tdata); % Number of data points 
s2 = (1/(nd-np))*postsse; % Sample variance 
b = 2*s2*np*finv(.95,np,nd-np); 
  
Htild = inv(H); 
P 
  
% Size of confidence interval 
L1 = sqrt(b*Htild(1,1)); 
L2 = sqrt(b*Htild(2,2)); 
L3 = sqrt(b*Htild(3,3)); 
L4 = sqrt(b*Htild(4,4)); 
L5 = sqrt(b*Htild(5,5)); 
L6 = sqrt(b*Htild(6,6)); 
 
% Percent size of confidence interval (relative to average parameter 
value) 
P1 = 100*L1/P(1) 
P2 = 100*L2/P(2) 
P3 = 100*L3/P(3) 
P4 = 100*L4/P(4) 
P5 = 100*L5/P(5) 
P6 = 100*L6/P(6) 
  
% Confidence window 
C1 = [P(1)-L1 P(1)+L1] 
C2 = [P(2)-L2 P(2)+L2] 
C3 = [P(3)-L3 P(3)+L3] 
C4 = [P(4)-L4 P(4)+L4] 
C5 = [P(5)-L5 P(5)+L5] 
C6 = [P(6)-L6 P(6)+L6] 
  368 
function [res,grad,hess] = resid(X) 
  
% Written by Terry Farmer, 7/27/06 
% Purpose: To produce y, based on a determined model.  Also produce 
% gradient and hessian for y with respect to each model parameter. To 
be 
% used with fmincon to determine optimal parameter values, given data. 
  
global yode1 tdata 
 
% Differential Equation 
A01 = X(1); 
A12 = X(2); 
A13 = X(3); 
A21 = X(4); 
A31 = X(5); 




% Get Initial Values 
y0 = 0; 
x20 = 0; 
x30 = 0; 
  




ymodel = y(:,1); 
S = y(:,4:9); 
% Now get quantities for optimization 
% First, calculate objective function 
res = sum((yode1 - ymodel).^2); 
grad = (-2*S'*(yode1-ymodel))'; 
hess = 2*S'*S; 
  
  
     
  369 
function Xdot = state(t,X,A01,A12,A13,A21,A31,V) 
  
% Written by Terry Farmer 6/21/06 
% Purpose- To solve ODE's from Joseph's 3 compartment model, along with 
sensitivities 
 
y = X(1); 
x2 = X(2); 
x3 = X(3); 
S11 = X(4); 
S12 = X(5); 
S13 = X(6); 
S14 = X(7); 
S15 = X(8); 
S16 = X(9); 
S21 = X(10); 
S22 = X(11); 
S23 = X(12); 
S24 = X(13); 
S25 = X(14); 
S26 = X(15); 
S31 = X(16); 
S32 = X(17); 
S33 = X(18); 
S34 = X(19); 
S35 = X(20); 
S36 = X(21); 
  
  
if t <=150 
U = 20; 
else 
    U = 40; 
end 
  
xdot = -(A01+A21+A31)*y + (A13/V)*x3 + (A12/V)*x2 +U/V; % Actual ode 
for dependent variable 
x2dot = A21*y*V - A12*x2; 
x3dot = A31*y*V - A13*x3; 
  
S = [S11 S12 S13 S14 S15 S16;S21 S22 S23 S24 S25 S26; S31 S32 S33 S34 
S35 S36]; 
  
% Create fx matrix 
f1x1 = -(A01+A21+A31); 
f1x2 = (A12/V); 
f1x3 = (A13/V); 
f2x1 = A21*V; 
f2x2 = -A12; 
f2x3 = 0; 
f3x1 = A31*V; 
f3x2 = 0; 
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f3x3 = -A13; 
  
fx = [f1x1 f1x2 f1x3; f2x1 f2x2 f2x3; f3x1 f3x2 f3x3]; 
  
% Create ftheta matrix 
f1th1 = -y; 
f1th2 = x2/V; 
f1th3 = x3/V; 
f1th4 = -y; 
f1th5 = -y; 
f1th6 = -(1/V^2)*(A12*x2 + A13*x3 + U); 
f2th1 = 0; 
f2th2 = -x2; 
f2th3 = 0; 
f2th4 = V*y; 
f2th5 = 0; 
f2th6 = A21*y; 
f3th1 = 0; 
f3th2 = 0; 
f3th3 = -x3; 
f3th4 = 0; 
f3th5 = V*y; 
f3th6 = A31*y; 
  
fth = [f1th1 f1th2 f1th3 f1th4 f1th5 f1th6; f2th1 f2th2 f2th3 f2th4 
f2th5 f2th6;f3th1 f3th2 f3th3 f3th4 f3th5 f3th6]; 
  
% Get Sdot 
Sdot = fx*S + fth; 
  
% Get components 
S11dot = Sdot(1,1); 
S12dot = Sdot(1,2); 
S13dot = Sdot(1,3); 
S14dot = Sdot(1,4); 
S15dot = Sdot(1,5); 
S16dot = Sdot(1,6); 
S21dot = Sdot(2,1); 
S22dot = Sdot(2,2); 
S23dot = Sdot(2,3); 
S24dot = Sdot(2,4); 
S25dot = Sdot(2,5); 
S26dot = Sdot(2,6); 
S31dot = Sdot(3,1); 
S32dot = Sdot(3,2); 
S33dot = Sdot(3,3); 
S34dot = Sdot(3,4); 
S35dot = Sdot(3,5); 
S36dot = Sdot(3,6); 
  




    S25dot;S26dot;S31dot;S32dot;S33dot;S34dot;S35dot;S36dot]; 
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APPENDIX F 
HOVORKA MEAL MODEL DERIVATION 
 
Hovorka and co-authors [3] assumed that oral ingestion of glucose is described by 
two compartments in series.  Each compartment has a kinetic elimination rate of the 
inverse of the time to maximum absorption, tmaxG.  For the first compartment, assume 
there is no glucose flow.  In this way, the first compartment is modeled as a semi-batch 
reactor, in which there is only outflow, and the initial loading of the reactor is accounted 
for in the initial conditions.  This is shown in Equation (F.1) with the initial condition 





dm 11 −=      (F.1) 
( ) mealmm =01      (F.2) 
 
The variable m1 represents the mass of glucose in the first compartment.  This is a simple 











texpmm1     (F.3) 
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 The second compartment will have the outlet of the first compartment as its input, 
and the absorption of the glucose into the blood as its output.  Both are described by the 



























This is also a simple linear ODE, which can be solved by determining and 
integrating factor.  Bringing m2 to the left side of the equation, and multiplying both sides 






















2     (F.5) 
 
Initially, there is no glucose in the second compartment, so m2(0) is zero.  













2     (F.6) 
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K can be shown to be zero by using the initial condition.  By isolating m2 and 
noting that the absorption rate is simply the kinetic elimination of glucose from the 




















==     (F.7) 
 
This is the glucose absorption rate expression used in the Hovorka model. 
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APPENDIX G 
 SORENSEN DIABETIC MODEL INITIALIZATION ITERATIONS 
 
%Program Solver.m 
%I.  Documentation 
  
% Created for Sorensen Model Solution 




%Tasks:  Uses ODE45 to solve the Sorensen model for glucose, insulin, 
and 
%glucagon.  The model 
%dependent variables are given by an output vector x, which is 
determined 
%by inputing the models and the initial x conditions, x_ss, into the 




% Description of inputs needed for the program 
%   x0 vector consisting of initial steady state conditions for the 
%   model.  Used as initial values vector for ODE45 
%   tf, the duration of time for which the model will be solved 
%   
  
% Description of outputs returned by the program 
%   x, the vector of G's, I's and Tau. 
%   t, all time values at the model was evaluated 
%   Plots graphing various outputs as functions of time. 
  
  
%II.  Variable declaration/initialization 
clc                         %  Clears the command window 
clear all                   %  Deletes all variables from memory 
close all                   %  Closes all open figure windows 
  




VGBV = 3.5; % dL 
VBI = 4.5; % dL 
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VGH= 13.8; % dL 
VGL = 25.1; % dL 
VGG = 11.2; % dL 
VGK = 6.6; % dL 
VGPV = 10.4; % dL 
VPI = 63; % dL 
VIB = 0.265; %L 
VIH = 0.985; %L 
VIG = 0.945; %L 
VIL = 1.14; %L 
VIK = 0.505; %L 
VIPV = 0.735; %L 
VIPI = 0.1*VPI; %L 
VTau = VIB + VIH + VIPV + VIK + VIL +(VIPI); %L 
  
%Flow Rates 
QGB = 5.9; % dL/min 
QGH = 43.7; % dL/min 
QGA = 2.5; % dL/min 
QGL = 12.6; % dL/min 
QGG = 10.1; % dL/min 
QGK = 10.1; % dL/min 
QGP = 15.1; % dL/min 
QIB = 0.45; %L/min 
QIH = 3.12; %L/min 
QIA = 0.18; %L/min 
QIK = 0.72; %L/min 
QIP = 1.05; %L/min 
QIG = 0.72; %L/min 
QIL = 0.90; %L/min 
  
%Times 
TB = 2.1; % min Transcapillary diffusion time constant 
TGP = 5.0; % min Transcapillary diffusion time constant 
TIP = 20; %min Transcapillary diffusion time constant 
  
%Source and Sink Terms 
rBGU = 70; % mg/min (constant) 
rRBCU = 10; % mg/min (constant) 
rGGU = 20; % mg/min (constant) 
rBPGU = 35; % mg/min 
rBHGP = 155; % mg/min  
rBHGU = 20; % mg/min 
TI = 25; % min 
TT = 65; % min 
FLIC = 0.40; %fractional clearance 
FKIC = 0.3; %fractional clearance 
FPIC = 0.15; %fractional clearance 
rMTauC = .910; % L/min 
  
% Basal values for diabetic model 
GLb = 101.0; % mg/dL 
GPIb = 86.81; 
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GHb = 91.89; 
ILb = 21.43; % mU/L 
IPIb = 5.304;  
IHb = 15.15;  
  
  
% Initializations for diabetic model 
% Initial values of glucose and insulin conc. 
rIVIb     = 20; % mU/min 
IHi      = rIVIb/(QIH - QIL*(1-FLIC) - QIK*(1-FKIC) - QIP*(1-FPIC) - 
QIB); % mU/L 
IPVi     = IHi * (1-FPIC); % mU/L 
IBi      = IHi; 
IGi      = IHi; 
IKi      = IHi*(1-FKIC); 
ILi      = IHi*(1-FLIC); 
IPIi     = IPVi - (QIP*(TIP/VIPI))*(IHi - IPVi); 
  
% Determine Glucose and glucose concentrations 
% Iterate to find arterial glucose concentration 
j = 1; 
GHi = GHb; % Initial guess for GH is GH basal. 
  
while j < 1000 
  
%Initialize Glucagon Model 
     
MGPTauR = (1+2.095*tanh(4.18*(1-.6191))) - 2.095 * tanh( 4.18 * 
((GHi/GHb) - 0.6191 )); 
MIPTauR = (1+.61016*tanh(1.0571*(1-.46981))) - 0.61016 * tanh( 1.0571 * 
((IHi/IHb) - 0.46981)); 
TauNi = MIPTauR * MGPTauR; 
  
GBVi = GHi - rBGU/QGB; 
GGi = GHi - rGGU/QGG; 
  
MIPGU = (1-6.51623*tanh(.33827*-4.82113)) + 6.51623 * tanh ((0.33827 * 
((IPIi/IPIb) - 5.82113))); 
GPVi = GHi/(1 + ((VPI*MIPGU*rBPGU)/((QGP*VPI*GPIb) + 
(TGP*QGP*MIPGU*rBPGU)))); 
  
%Iterate to find Kidney glucose concentration 
GKi = GHb; % Initial guess is GHb 
k = 1; 
while k < 1000 
if GKi < 460 
    rKGE = 71 + 71 * tanh ( 0.11 * (GKi - 460)); % mg/min if GK <= 460 
mg/dL 
else 
    rKGE = -330 + 0.872 * GKi; % mg/min if GK >= 460 mg/dL 
end 
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GKc = GKi; 
GKi = GHi - (rKGE / QGK); 
if (abs(GKi - GKc))<1.0e-18 
    k = 1000; 
else  




% Iterate to find liver glucose concentration. 
GLi = GLb; % Initial liver glucose concentration guess 
i = 1; 
while i < 1000 
% rHGP calculation 
MIinfHGP = (1+1.138*tanh(1.669*(1-.8885))) - 1.138 *tanh ((1.669 * 
((ILi/ILb) - 0.8885))); 
MIHGPi = MIinfHGP; 
MTau0HGP = (1/(tanh(.388)))*tanh (0.388 * TauNi); 
f2i = (MTau0HGP - 1)/2; 
MTauHGP = MTau0HGP - f2i; 
MGHGP = (1+1.406*tanh(.6199*(1-.4969))) - 1.406 * tanh (0.6199 * 
((GLi/GLb) - 0.4969)); 
rHGP = MIHGPi * MTauHGP * MGHGP * rBHGP; 
% rHGU calculation 
MIinfHGU = (1/(tanh(.549))) * tanh (0.549 * (ILi/ILb)); 
MIHGUi = MIinfHGU; 
MGHGU = (1-5.6589*tanh(2.4375*(-0.48))) + 5.6589 * tanh (2.4375 * 
((GLi/GLb) - 1.48)); 
rHGU = MIHGUi * MGHGU * rBHGU; 
GLc = GLi; 
GLi = (1/QGL)*(QGA*GHi + QGG*GGi + rHGP - rHGU) ;%Checking liver 
glucose 
if (abs(GLi - GLc))<1.0e-18 
    i = 1000; 
else  




GHc = GHi; 
GHi = (1/QGH)*(QGB*GBVi + QGL*GLi +QGK*GKi +QGP*GPVi - rRBCU); 
%Checking arterial glucose 
if (abs(GHi - GHc)) < 1.0e-18 
    j = 1000; 





GPIi = GPVi /(1 + ((MIPGU*rBPGU*TGP)/(VPI*GPIb))); 
GBIi = GBVi - (TB*(rBGU/VBI)); 
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x0 = [GBVi; GBIi; GHi; GGi; GLi; GKi; GPVi; GPIi; MIHGPi; f2i;  
    MIHGUi; IBi; IHi; IGi; ILi; IKi; IPVi; IPIi; TauNi];   % Initial 
conditions are the results of the iterations 
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APPENDIX H 
DERIVATION OF MICHAELIS-MENTEN KINETICS 
 
The Michaelis-Menten equation is routinely used to describe kinetics involving an 
enzyme.  Its derivation begins by assuming the enzyme catalyzed reaction proceeds by 
the following mechanism [5]: 
 











  (H.1) 
 
The second step in the reaction, in which the complex dissociates to form the product, is 
first order in the complex.  The Michaelis-Menten equation makes the quasi-steady state 
assumption with respect to the complex, assuming that complex formation and 
dissociation are occurring at the same rate.  It is also assumed that there is a total 
maximum enzyme concentration, and that the complex concentration is less than or equal 
to this concentration.  Complex formation is assumed to be first order in the 
concentration of available enzyme, which is simply the total enzyme minus the 
complexes formed, and first order in the substrate concentration.  Complex formation is 
also considered reversible, meaning that the complex may dissociate back to the substrate 
and the enzyme.  The reverse reaction is first order in complex concentration.  All of this 
is combined to show the following steady state relation: 
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( ) ( )211 kkESSESEk Total +=− −      (H.2) 
 
where subscript 1 represents complex formation, -1 represents the complex reverse 
reaction, and 2 represents product formation.  For ease of derivation, the rate constants 












21     (H.3) 
 
The complex concentration, ES, is then isolated, and the product formation rate is written 







== 220     (H.4) 
 
The rate v0 represents the initial reaction rate, which is often measured in enzymatic 
reactions that can reach equilibrium fairly quickly.  The parameter Vmax is defined as the 








=0      (H.5) 
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APPENDIX I 
DERIVATION OF DONNAN RATIO EQUATION 
 
The purpose of this derivation is to use the concept of equilibrium with respect to 
swellable hydrogel polymer network to determine the Donnan ratio, K, of the system, for 
a particular set of conditions.  Given the Donnan ratio and the concentrations of ionic 
species in the external solution, the gel concentrations of the various species can be 
determined. 
At equilibrium, the following ideal assumptions are made [6].  First, only 
hydrogen ions are interacting with the amine groups on the polymer chain.  Second, at 
equilibrium, the gel is assumed to be electrically neutral.  Third, because of the first 
assumption, any interactions between ions and the gel surface are neglected.  Fourth, the 
electric potential is assumed to be uniformly distributed throughout the gel, meaning that 
spatial considerations are neglected as well.  Finally, the amine groups are assumed to not 
interact with each other. 
Because the gel is considered electrically neutral, the total charge is zero.  This is 




aaHii znzn0     (I.1) 
 
This says that the total charge is equal to the total charge associated with each species 
including the amine groups in the gel network.  The variable naH represents the number of 
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protonated amine groups in the network.  The number of moles of each species is best 
represented by the concentration of each species and the volume at which that 
concentration exists.  The mobile species exist in the gel solvent, while the amine groups 
are present on the polymer itself.  Neglecting volume effects of the mobile ionic species, 
it can be assumed that the volume of each species is simply the solvent volume, Vs. as 
shown by Equation (I.2). 
 
( )10 ++= ∑ aHp
i
iis cVzcV      (I.2) 
 
In order to relate this equation to known quantities, a few definitions will be given.  First, 
the concentration of ionic species i in the gel, ci, is related to concentration of the species 







=       (I.3) 
 
where c’i is the concentration in the external environment.  Next, the two volumes used in 
(I.2) can be simplified when expressed as volume fractions of the total gel volume: 
 
ϕgp VV =       (I.4) 
( )ϕ−= 1gs VV       (I.5) 
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where Vg is the total gel volume and φ is the polymer volume fraction.  Finally, While the 
concentration of protonated amine groups cannot be determine experimentally, it can be 
calculated if the original amine loading, the amine pKg, and the system pH are known by 





ccK =       (I.6) 
 
Solving for caH results in (I.6): 
 




ccc =       (I.7) 
 
where ca represents the amine concentration that has not been protonated.  Based on the 
functional group loading, this term can be found to eliminate an unknown term: 
 
    σ=+ aaH cc       (I.8) 
 
in which σ is the functional group density of the polymer, and (I.8) is simply a mass 
balance of the functional groups.  Using (I.8) to eliminate ca in (I.7) and noting that the 
gel hydrogen ion concentration is related to the external hydrogen ion concentration 
through Donnan equilibrium results in the following equation in terms of only external 
environment variables: 





c σ      (I.9) 
 
Substituting (I.4), (I.5), and (I.9) into (I.2), and using the definition of pKg and pH, the 
final equation for Donnan equilibrium is given in (I.10). 
 









σϕϕ    (I.10) 
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APPENDIX J 
MATLAB SOURCE CODE FOR IMPLICIT CLOSED-LOOP CONTROL 
 




% Device gives the insulin output from the injectible polymer 
% nanoparticles.  Given the material parameters, the function 
determines 
% the insulin output of the system. 
  
% Written by Terry Farmer, 6/14/06 
 
  
G = x(1); % glucose concentration in medium (mmol/L) 
X = x(2); % Proportional to bound insulin (remote compartment) (min^-1) 
I = x(3); % Insulin Level 
Gd = x(4);  % Glucose concentration in device (mmol/L) 
GA = x(5);  % gluconic acid concentration  (mmol/L) 
Id = x(6);  % insulin concentration in device (mU/L) 
XL = x(7); % crosslinking ratio 
  
  
% Get parameter values for model equations 
Ks = 6.187e-1; % Glucose concentration at 50% of max rate (mmol/L) 
Cn = 14.4; 
L = 1.54; % Angstroms 
rI = 16; % Insulin radius (Angstroms) 
rG = 4.2; % Glucose radius (Angstroms) 
rGA = .012; % Gluconic acid radius; Either taken as same as glucose or 
as hydrogen ion (Angstroms) 
  
% Equations 
pH0 = 7.4; % Initial pH guess 
Qmax = 40*exp(-49.8*(XL-0.005)); 
if XL >0.02 
    Qmin = 2; 
else 
    Qmin = 3; 
end 
  
A = 0.5*(Qmax+Qmin); 
B = Qmax-A; 
dPH = 1; 
Iter = 0; 
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% Use iteration to determine pH and swelling 
  
while abs(dPH) > 1.0e-6 & Iter < 1001 
q = A + B * tanh(-10*(pH0-pKg)); 
phi = 1/q;  
% First get necessary model parameters 
pH = 7.4; % Blood pH 
pK = 6.33; % pK of bicarbonate buffer 
phi0 = 1/q; % Initial volume fraction 
  
% Assume bicarbonate buffer conditions 
H1 = 3.98e-8; % mol/L 
Na1 = 142/1000; % mol/L Sodium concentration 
K1 = 4.2/1000; % mol/L Potassium concentration 
Ca1 = 1.2/1000; % mol/L Calcium concentration 
Cl1 = 108/1000; % mol/L Chloride ion concentration 
HCO3 = 25/1000; % bicarbonate concentration (mol/L) 
CO2 = 1.224/1000; % carbon dioxide concentration (mol/L) 
  
% use fsolve to find donnan ratio for cationic gel 
options = optimset('Display','off'); 
lambda = fsolve(@don,10,options,q,sigma,pKg);  
  
pH1 = pH - log10(lambda); % Device pH without gluconic acid 
  
% Determine device concentrations of buffer molecules 
H = lambda*H1; % Device H concentration (mol/L) 
Na = lambda*Na1; % Device Na concentration (mol/L) 
HCO3 = HCO31*(lambda^(-1)); % Device HCO3 concentration (mol/L) 
  
buffer = HCO3 + CO2; % buffer concentration 
  
% Given gluconic acid concentration, determine pH 
  
pH2 = pK + log10(((10^(pH1-pK))-((GA*.001/buffer)*(1+(10^(pH1-
pK)))))/(1+((GA*.001/buffer)*(1+(10^(pH1-pK)))))); 
dPH = pH2 - pH0; 
pH0 = pH2; 
Iter = Iter + 1; 
end 
  
R = Rcoll*(q^(1/3)); 
mesh = (Cn^.5)*(q^(1/3))*((XL*2)^(-.5))*(L); % Mesh size for 
diffusivity (Angstroms) 
DI = DI0*(1 - (rI/mesh))*exp(-1/(q-1)); % Initial insulin diffusivity 
(Cm^2/s) 
DG = DG0*(1 - (rG/mesh))*exp(-1/(q-1)); % Initial glucose diffusivity 
(cm^2/s) 
DGA = DG;% Initial gluconic acid diffusivity (cm^2/s) 
V = 12*1000; % Volume of tank (cm^3) 
  
if t < tmeal 
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    D = 0; 
else 
D = 1.157*exp(-0.05*(t - tmeal)); 
end 
D = 0; 
% Bergman model parameters 
P1 = 0.00001; % min^-1 
P2 = 0.025; %min ^-1 
P3 = .000013; %L/(mU*min^2) 
n = 5/54; % min^-1 
  
U = (4*pi*Ng*DI*60*(Id-I)*(R^2/(thick)))/1000; 
  
Gdot = real(-4*pi*Ng*DG*60*(R^2/(thick*V))*(G-Gd) - P1*(G-G_b) - G*X + 
D); 
Xdot = (-P2*X + P3*(I - I_b)); 
Idot = (U/(V/1000)) - n*I; 
Gddot = (3*60*DG*(G - Gd)/(R*thick) - (Vmax*Gd)/(Ks+Gd)); 
GAdot = ((Vmax*Gd/(Ks+Gd)) - (3*60*DGA/(R*thick))*GA); 
Iddot = (-3*DI*60*(Id - I)/(R*thick)); 
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function char = don(lambda,q,sigma,pKg); 
  
  
% Function don determines the value of the nonlinear Donnan equilibrium 
to use in a solver program to solve for the Donnan ratio.  The equation 
is set to zero, and given other parameters, is solved for lambda. 
  
% Written by Terry Farmer, 10/11/06 
 
% First get necessary model parameters 
pH = 7.4; % Blood pH 
phi0 = 1/q; % Initial volume fraction 
  
% Assume phosphate buffer conditions 
H1 = 3.98e-8; % mol/L 
Na1 = 142/1000; % mol/L Sodium concentration 
K1 = 4.2/1000; % mol/L Potassium concentration 
Ca1 = 1.2/1000; % mol/L Calcium concentration 
Cl1 = 108/1000; % mol/L Chloride ion concentration 
HCO3 = 25/1000; % bicarbonate concentration (mol/L) 
  
  
char = (1 - phi0)*((-1*(lambda^(-1))*(HCO3+Cl1)... 
    +(lambda*(H1+Na1+K1))+((lambda^2)*2*Ca1))) + ((sigma*phi0)/(1 + 
(lambda^(-1))*(10^(pH-pKg)))); 
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% Program Solver 
% Written by Terry Farmer, 6/29/06 
  
% Purpose: To simulate the response of injected hydrogels that release 
% insulin in response to a change in plasma glucose levels.  The model 
uses 
% the Bergman minimal model to simulate the diabetic patient, and the 




% Get parameter values for model equations 
% System design parameters 
Cenz = 1; % glucose oxidase concentration (uM) 
Ng = 3.54e7; % Number of injected particles 
xx = .004; % Crosslinking ratio 
DI0 = (1.41e-13); % Initial insulin diffusivity (Cm^2/s) 
DG0 = (6.9e-12);% Initial glucose diffusivity (cm^2/s) 
sigma = 4; % Charged group density (mol/L) 
pKg = 7.1; % pK of functional group 
kd = 0.001; %min^-1 (Degradation rate constant) 
Id_b = 1e8; % mU/L (Insulin Loading) 
thickness = 0.1; % Fraction of collapsed gel size  
% Simulation Time 
t0 = 0; % minutes 
tmeal = 60; % minutes 
tfinal = 400; % minutes 
  
% Characteristic values 
Vmax = 860*60*Cenz*(1e-3); % Maximum oxidation rate (mmol/L*min) 
Ks = (6.187e-7)*1000*1000; % Glucose concentration at 50% of max rate 
(mmol/L) 
Cn = 14.4; 
L = 1.54; % Angstroms 
rI = 16; % Insulin radius (Angstroms) 
rG = 2.5; % Glucose radius (Angstroms) 
rGA = 2.5; % Gluconic acid radius; Either taken as same as glucose or 
as hydrogen ion (Angstroms) 
DGA0 = DG0; % Initial gluconic acid diffusivity (cm^2/s) 
  
  
% Getting initial values 
G_b = 4.5; % Basal glucose (mmol/L) 
X_b = 0; % Basal proportional term (min^-1) 
I_b = 15; % Basal insulin level (mU/L) 
  
% Guess pH 
pHb = 7.4; 
dPH = 1; 
Iter = 0; 
 
 
  391 
Qmax = 40*exp(-49.8*(xx-0.005)); % From curve fitting 
Rcoll = (4.5/(Qmax^(1/3)))*(1e-6)*100; % Maximum collapsed particle 
size (cm) 
thick = thickness*Rcoll; % assumes 10% thickness 
  
if xx >0.02 
    Qmin = 2; 
else 
    Qmin = 3; 
end 
A = (Qmax + Qmin)/2; 
B = Qmax - A;  
C = -10; 
while abs(dPH) > 1.0e-6 & Iter < 1001 
         
Q_b = A + B * tanh(C*(pHb-pKg)); 
phi = 1/Q_b;  
% First get necessary model parameters 
pH = 7.4; % Blood pH 
pK = 6.33; % pK of phosphate buffer 
phib = 1/Q_b; % Initial volume fraction 
  
% Assume bicarbonate buffer conditions 
H1 = 3.98e-8; % mol/L 
Na1 = 142/1000; % mol/L Sodium concentration 
K1 = 4.2/1000; % mol/L Potassium concentration 
Ca1 = 1.2/1000; % mol/L Calcium concentration 
Cl1 = 108/1000; % mol/L Chloride ion concentration 
HCO3 = 25/1000; % bicarbonate concentration (mol/L) 
CO2 = 1.224/1000; % carbon dioxide concentration (mol/L) (PC02 = 40 mm 
Hg; K = 0.03 mmol/L/mm Hg 
  
% use fsolve to find donnan ratio for cationic gel 
options = optimset('Display','off'); 
lambda = fsolve(@don,10,options,Q_b,sigma,pKg);  
  
pH1 = pH - log10(lambda); % Device pH without gluconic acid 
  
% Determine device concentrations of buffer molecules 
H = lambda*H1; % Device H concentration (mol/L) 
Na = lambda*Na1; % Device Na concentration (mol/L) 
HCO3 = HCO31*(lambda^(-1)); % Device HCO3 concentration (mol/L) 
  
buffer = HCO3 + CO2; 
  
% Swelling based parameters to find GA_b (for pH calculation) 
mesh = (Cn^.5)*(Q_b^(1/3))*((xx*2)^(-.5))*(L); % Mesh size for 
diffusivity 
DI_b = (DI0)*(1 - (rI/mesh))*exp(-1/(Q_b-1)); % Initial insulin 
diffusivity (Cm^2/s) 
DG_b = (DG0)*(1 - (rG/mesh))*exp(-1/(Q_b-1)); % Initial glucose 
diffusivity (cm^2/s) 
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DGA_b = DG_b; % Initial gluconic acid diffusivity (cm^2/s) 
R_b = Rcoll*(Q_b^(1/3)); % Initial particle radius 
  
  
% Now solve for initial device concentrations 
% Gd_b is determined via a quadratic equation 
Aqd = 1; 
Bqd = (((Vmax*(R_b*thick))/(3*DG_b*60)) + Ks - G_b); 
Cqd = -Ks*G_b; 
  
y1 = (-Bqd + sqrt((Bqd^2) - 4*Aqd*Cqd))/(2*Aqd); % Solution 1 to 
quadratic 
y2 =(-Bqd - sqrt((Bqd^2) - 4*Aqd*Cqd))/(2*Aqd); % Solution 2 to 
quadratic 
  
% Now get Gd_b 
if y1 < 0 
    Gd_b = y2; 
else 
    Gd_b = y1; 
end 
  
% Now solve for GA_b 
GA_b = ((R_b*thick)*Vmax*Gd_b)/(3*60*DGA_b*(Ks+Gd_b)); 
% Given gluconic acid concentration, determine pH 
  
pH2 = pK + log10(((10^(pH1-pK))-((GA_b*.001/buffer)*(1+(10^(pH1-
pK)))))/(1+((GA_b*.001/buffer)*(1+(10^(pH1-pK)))))); 
dPH = pH2 - pHb; 
pHb = pH2; 
Iter = Iter + 1; 
end 
  
% Create Initial vector 




% Create sensitivity matrix 
np = 15; % number of adjustable parameters in model\ 
if(0) 
S0 = zeros(length(x0),np); 
% Convert matrix to column vector, with sequentially 
for i = 1:length(x0) 
    for j = 1:np 
        Sp0(np*(i-1)+j,1) = S0(i,j); 
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xnew0 = [x0;Sp0]; 
end 
% Simulation 




% Extract values 
G = x(:,1); 
XC = x(:,2); 
I = x(:,3); 
Gd = x(:,4); 
GA = x(:,5); 
Id = x(:,6); 
X = x(:,7); 
  




% First get necessary model parameters 
pH = 7.4; % Blood pH 
pK = 6.33; % pK of phosphate buffer 
  
% Assume bicarbonate buffer conditions 
H1 = 3.98e-8; % mol/L 
Na1 = 142/1000; % mol/L Sodium concentration 
K1 = 4.2/1000; % mol/L Potassium concentration 
Ca1 = 1.2/1000; % mol/L Calcium concentration 
Cl1 = 108/1000; % mol/L Chloride ion concentration 
CO2 = 1.224/1000; % CO2 concentration (mol/L) 
HCO31 = 25/1000; % bicarbonate concentration (mol/L) 
  
% Matrix Pre-allocation 
pH0 = zeros(1,length(t)); 
A = pH0; 
B = A; 
q = B;  
lambda = q; 
pH1 = pH0; 
pH2 = pH1; 
H = pH1; 
Na = pH1; 
buffer = pH1; 
HCO3 = pH1; 
  
  
for i = 1:length(GA) 
    % Equations 
    Qmax(i) = 40*exp(-49.8*(X(i)-0.005)); 
    if X(i) > 0.02 
        Qmin(i) = 2; 
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    else 
        Qmin(i) = 3; 
    end 
     
A(i) = 0.5*(Qmin(i)+Qmax(i)); 
B(i) = Qmax(i) - A(i); 
pH0(i) = 7.4; % Initial pH guess 
  
dPH(i) = 1; 
Iter = 0; 
% Use iteration to determine pH and swelling 
while abs(dPH(i)) > 1.0e-6 & Iter < 1001 
% Parameters for pH evaluation 
  
q(i) = A(i) + (B(i) * tanh((-10*(pH0(i) -pKg)))); 
  
% use fsolve to find donnan ratio for cationic gel 
options = optimset('Display','off'); 
lambda(i)= fsolve(@don,1,options,q(i),sigma,pKg);  
  
pH1(i) = pH - log10(lambda(i)); % Device pH without gluconic acid 
  
% Determine device concentrations of buffer molecules 
H(i) = lambda(i)*H1; % Device H concentration (mol/L) 
Na(i) = lambda(i)*Na1; % Device Na concentration (mol/L) 
HCO3(i) = HCO31*(lambda(i)^(-1)); % Device HCO3 concentration (mol/L) 
  
buffer(i)= HCO3(i) + CO2; 
  
% Given gluconic acid concentration, determine pH 
  
pH2(i) = pK + log10(((10^(pH1(i)-pK))-
((GA(i)*.001/buffer(i))*(1+(10^(pH1(i)-
pK)))))/(1+((GA(i)*.001/buffer(i))*(1+(10^(pH1(i)-pK)))))); 
dPH(i) = pH2(i) - pH0(i); 
pH0(i) = pH2(i); 
Iter = Iter + 1; 
end 
  
R(i) = Rcoll*(q(i)^(1/3)); % Vector of R's 
mesh(i) = (Cn^.5)*((X(i)*2)^(-.5))*(q(i)^(1/3))*(L); 
DI(i) = DI0*(1 - (rI/mesh(i)))*exp(-1/(q(i)-1)); % Vector of 
Diffusivities 
U(i) = (4*60*pi*R(i)^2*Ng*DI(i)*(Id(i)-I(i))/(thick*1000)); 
Idot(i) = -3*60*DI(i)*(Id(i)-I(i))/(R(i)*thick); 
end 
 
% Fraction of Insulin released 
fr = (Id_b-Id)/(Id_b); 
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